Global Regulatory Monitor Regulatory News, Week 4 · 2026/10
Period 2026-10-19 ~ 2026-10-26Published 2026-10-26Collected 276 · 136 cardsEvidence A 41 · B 95 · C 0
34 cards in this issue cover Korean regulator documents. Company and institution names, and quoted source text, are shown in Korean exactly as they appear on the official record.
This week's key points
FDA issued a Warning Letter to Baxter over cephalosporin cross-contamination and aseptic process validation failures at its Round Lake site.
Health Canada announced a Type I recall of Dantrium Intravenous (dantrolene sodium for injection) for particulate contamination.
MFDS imposed a 3-month import suspension on a ciclesonide nasal spray after the importer released a batch before quality test approval.
43 of 86 FDA 483 observation at sites in United States
Country and category from the findings database
About AI-generated content
Summaries, translations, implications, check items, and in-depth analysis are written by generative AI; figures, quotations, links, and machine-extracted tables are provided as in the source. This is reference material — check the official source before making decisions.
[FDA 483 observation · FDA]WuXi Biologics Ireland Limited — Bag leaks and OOS retest procedure gaps
FDA🧬 Biologics483
FDA issued a 483 with four observations to WuXi Biologics Ireland Limited, a biologic drug substance manufacturer, after an inspection ending 12/16/2025. Observations cover recurring process bag leaks, high invalid assay rates, a logbook vs SAP record discrepancy, and an OOS investigation SOP allowing original results to be invalidated without a root cause.
Published 2026-10-22 · Inspection date 12/16/2025 · Drug Substance Manufacturer · FEI 3026506583
Key facts · Basis: official index plus supporting sources
Observation 1: multiple bag leak deviations in 2024 and 2025; 2025 bag defect rates of 0.45% to 5.88%; corrective change control PR 218330 pending approval
Observation 4: WX-SOP-10217 allows retest results to invalidate the original analysis when no root cause is found
Insight · Editorial insight
An SOP clause letting retests invalidate original OOS results without an identified root cause signals that FDA tied this directly to the reliability of batch release decisions. Recurring bag leak rates in a biologic drug substance process, with the corrective change control still awaiting approval, also suggest scrutiny of how effectively deviations are addressed.
Check points
Whether OOS SOPs permit retesting and invalidation without a root cause
Trending of single-use bag leak deviations and status of corrective change controls
Invalid assay rate trends per method and verification of training effectiveness
Observation detail · 4 observations · From the source
Observation 1
(4) equipment utilized in the mw drug substance manufacturing process is deficient.
Specifically, Multiple deviations of bag leaks have been identified in 2024 and 2025 involving various bag siZes gm 0) etc.) of mw bags. The calculated bag defect rates range from 0.45% to 5.88% for 2025. These bags perform critical functions throughout the manufacturing process, including oH) @) etc. Change control PR 218330 was initiated on Dec 1, 2025, proposing to implement a@ (4) bags as a corrective measure. However, this change control is currently under board review and pending approval. The effectiveness of this proposed change control in reducing the bag leakage rate is currently unclear.
Observation 2
Laboratory controls are inadequate to ensure reliable analytical testing of critical quality and safety attributes.
Specifically, Critical analytical methods showed high invalid assay rates froma@ to current: m@ fora @@ ALaboratory Investigation Report (LIR) has been initiated, and operator training was identified as the main root cause. While some methods have shown improvement following enhanced training programs O@ invalid rates for the following critical analytical methods remain high in @@ for o@ @@ |!n addition, invalid rates are also high fotg@ iNey
Observation 3
10903 New Hampshire Avenue; White Oak Building 51, Room 2269 12/08/2025-12/16/2025 Silver Spring, MD 20993 Email: OPMABLA [email protected] 3026506583 SUED Brendan McGrath, VP of Manufacturing and Ireland Site Lead Wuxi Biologics Ireland Limited Dundalk Science and Technology Park CITY, STATE, ZIP CODE, COUNTRY TYPE ESTABLISHMENT INSPECTED Mullagharlin, Dundalk, County Louth, A91 X56F, Ireland Drug Substance Manufacturer Written documents are inadequate to ensure proper documentation of manufacturing operations.
Specifically, During walk-through of the manufacturing area for o@ @) step, it was observed that the logbook reflected a completed gw cycles while the SAP system showedg@ cycles. This discrepancy between physical records and SAP system represents inadequate documentation practices.
Observation 4
Laboratory investigation procedures for Out of Specification (OOS) results are inadequate.
Specifically, In WX-SOP-10217: Laboratory Investigation Report Procedure, Section 5.5.9.1, states: "If no root cause is identified through phase 1 and 2 investigations, upon consultation with QA, the investigation may progress to retesting.". Section 5.5.9.5 specifies: "If all results meet specification, are within system suitability and sample acceptance criteria the re-testing can be reported and the original analysis invalidated.". This SOP allows retesting and subsequently invalidate the original results if no root cause has been identified, which is inappropriate. When no clear laboratory error has been identified, the initial results may constitute valid analytical findings that should be reported and considered in the batch release decisions. SEE
At an inspection ending 04/18/2024, FDA cited CSL Behring GmbH (FEI 3003098680) for not adequately establishing corrective and preventive action procedures. The single observation concerns incomplete documentation and implementation of procedures for analyzing complaints to identify quality problems.
Published 2026-10-20 · Inspection date 04/18/2024 · Biologics & Medical Device Manufacturer · FEI 3003098680
Key facts · Basis: official index plus supporting sources
One observation: CAPA procedures for complaint analysis not adequately established
Trend analysis records for December 2023 to February 2024 lacked evaluation of identified Alert Limit deviations
Insight · Editorial insight
Identifying Alert Limit deviations in complaint data without recording an evaluation signals a weak link between trending and CAPA initiation. It is worth noting that having a procedure clause (Section 4.7) is not enough if the justification for whether further action is needed is not actually documented.
Check points
Written procedure for monthly complaint trend analysis and its evaluation criteria
Documented evaluation and follow-up decision when Alert Limits are exceeded
Justification records on whether additional actions are required after trending
Observation detail · 1 observation · From the source
Inspectors: Joshua J Silvestri
Observation 1
Procedures for corrective and preventive action have not been adequately established.
Specifically, you have not fully documented and implemented written procedures for analysis of complaints to identify existing and potential quality problems. For example, A. You have not fully implemented Section 4.7 of your Complaints Management procedure requiring that you document the justification as to whether or not additional actions are required following your analysis to determine if there is a trend in the compliant data. B.You do not have written procedures defining your monthly complaint data trend analysis and evaluation. Further, your records of trend analysis for complaint data in December 2023, January 2024, and February 2024 do not list an evaluation covering Alert Limit deviations which were identified during these reviews.
[FDA 483 observation · FDA]FinVector Oy — Unverified supplier COAs and MOI validation
FDA🧬 Biologics483
FDA issued a Form 483 with five observations to FinVector Oy, a viral vector manufacturer in Finland, after an inspection ending 05/28/2024. Key issues are unverified supplier COAs for the Adstiladrin primary container vial and for components and excipients, and no validation of combinations of multiplicity of infection (MOI) and duration of infection (DOI), both critical process parameters.
Published 2026-10-20 · Inspection date 05/28/2024 · Biologics/Viral Vector · FEI 3010227150
Key facts · Basis: official index plus supporting sources
Facility: FinVector Oy, FEI 3010227150
Observations: container COA verification, reserve sample inspection, cleaning schedules, process validation, component COA verification
Process: MOI target is 163 VP/Cell, but other values within the range are not prohibited
Insight · Editorial insight
MOI and DOI were each designated critical process parameters, yet combinations within their ranges, including extremes, were never validated. For biologics processes that allow an operating range, the validation basis for parameter combinations, not just individual ranges, appears to be open to review.
Check points
Validation basis for combinations of critical process parameters, including extremes
Periodic verification of primary container and component supplier COAs
Procedure for annual visual inspection of reserve samples
Observation detail · 5 observations · OCR reading of the scanned original
The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.
Observation 1
Establishment of the reliability of the container and closure supplier's report of analyses is deficient in that the test results are not appropriately validated at appropriate intervals.
The quality control unit lacks responsibility to approve all procedures or specifications impacting on the identity, strength, quality and purity of drug products.
Specifically, your quality control unit has not established a procedure that governs the performance of visual inspection on reserve samples from representative sample lots at least once a year for evidence of deterioration.
Observation 3
Written procedures for cleaning and maintenance fail to include maintenance and cleaning schedules.
Observation 4
Your firm has not adequately validated your adherent (b) (4) regarding cell infection in that certain combinations of critical parameters have not been assessed.
Failure to check the reliability of Certificate of Analysis (COA) at Regular Intervals.
Specifically, your firm has not established the reliability of suppliers COA through appropriate validation of the supplier’s test result at appropriate intervals for the following components/excipients: pecification Number Material Name (b) (4) (b) (4) (b) (4) (b) (4) ” (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4)
[FDA 483 observation · FDA]CMC lCOS Biologics, Inc. — Missed preventive maintenance and late deviations
FDA🧬 Biologics483
FDA issued a Form 483 to CMC lCOS Biologics, Inc., a US biologics manufacturer, after an inspection ending 04/18/2016. Three legible observations (2 to 4) cover a deviation investigation without impact assessment on earlier batches, 15 of 47 required weekly preventive maintenance tasks missed and 8 late, and critical deviations formally opened past the required window.
Published 2026-10-20 · Inspection date 04/18/2016 · Biologics Manufactuter · FEI 3000209996
Key facts · Basis: official index plus supporting sources
Preventive maintenance: of 47 weekly tasks, 8 late, 15 missed, 2 not scheduled
Insight · Editorial insight
This is a 2016 record, but missed preventive maintenance on critical equipment was cited with exact counts. Formal deviation documentation opened late became a separate observation even though the client was notified and investigations started on time, suggesting that deviation initiation deadlines at contract manufacturers may draw scrutiny.
Check points
Monitoring of preventive maintenance adherence on critical equipment
Impact assessment on earlier batches when a deviation occurs
Timely formal documentation of critical deviations
Observation detail · 3 observations · OCR reading of the scanned original
The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.
Observation 2
Deviations during production have not been thoroughly investigated.
Specifically, a. (b) (4) documented in deviation DEV-1498 did not trigger impact assessment on previous batches manufactured (b) (4) The impact on product quality of (BD) (4) hat might have been damaged | . Add Contirwation Page
Observation 3
Preventative maintenance ofcritical equipment is not performed per written procedures.
Specifically, a. Preventative maintenance for (b} (4) was not performed as scheduled. Daily tasks are not documented, Between June 7, 2015 and April 21, 2016, of 47 required weekly PM activities, eight that were late, 15 were missed, and two were not scheduled. Over the ten month period, only one ofthree quarterly j Maintenance activities was performed, due on August 31, 2015, completed on April 19, 2016, Semi-annual }preventative maintenance performance was two months overdue,
Observation 4
Failure to follow standard operating procedure for deviation management, Specifically, a.
Critical deviations DEV-1484, DEV-1632, and DEV-2081 were initiated, respectively, 1, 5, and 2, days past the yoy 4 * . ® : . (DY (4) window as required by the deviation management procedure, GMP-0263, Rev 16. In all cases, the client was notified and initial investigations started within (0) (4) but the official documentation of the deviations were not initiated within the (8) (4) window. Wie - : ee ee tae Peete Tree 1
[FDA 483 observation · FDA]Lonza Biologics, Inc. — CASGEVY process state of control not shown
FDA🧬 Biologics483
FDA issued a Form 483 with three observations to Lonza Biologics, Inc., a US manufacturer, after an inspection ending 04/16/2026. The core finding is that the firm had not shown its CASGEVY manufacturing process was in a state of control: APS runs were repeated after a trend of aseptic lapses, healthy donor and commercial batches were rejected, and CAPAs for particulate and environmental monitoring deviations were behind schedule.
Published 2026-10-20 · Inspection date 04/16/2026 · Drug Manufacturer · FEI 3001451441
Key facts · Basis: official index plus supporting sources
Facility: Lonza Biologics, Inc., FEI 3001451441
Observations: process state of control, sterile contamination prevention procedures, warehousing
A 483 from the 06/06/2025 inspection of the same FEI (Lonza Portsmouth) is also in this issue
Insight · Editorial insight
The same site was cited for CASGEVY aseptic processing failures in 2025, and the 2026 inspection found repeated APS runs, rejected batches and delayed CAPAs, raising the state of control itself. Inspections soon after commercial launch may look at aseptic behavior trends and CAPA progress, not just APS results.
Check points
Reasons for repeated APS runs and records of aseptic behavior trends
CAPA progress for particulate trend deviations
Vial counts recorded per final product storage unit
Observation detail · 3 observations · OCR reading of the scanned original
The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.
Observation 1
Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Procedures describing the warehousing of drug products are not followed.
Specifically, a review of the use log form (_ (Db) (4) _ ) for (b) (4) of CASGEVY final drug product vials in’ (b) (4) revealed that your firm failed to capture the number of vials transferred to this unit for Batch Nos. (b) (4) . Additionally, the’ (1b) (4) __ inventory list for CASGEVY final drug product vials (1B) (4) — units only reports the final product batch number and not the actual number of vials placed in the (0) units.
[FDA 483 observation · FDA]GlaxoSmithKline Biologicals Kft. — Vaccine deviations not assessed for worst case
FDA🧬 Biologics483
FDA issued a Form 483 with two observations to GlaxoSmithKline Biologicals Kft., a licensed biological drug manufacturer in Hungary, after an inspection ending 01/31/2025. Particulate contamination and temperature excursion deviations were not expanded to worst-case conditions before the batches were released for further manufacture of INFANRIX and BOOSTRIX, and a procedure created as a corrective action had no risk assessment behind it.
Published 2026-10-20 · Inspection date 01/31/2025 · Licensed Biological Drug Manufacturer · FEI 3008322822
Key facts · Basis: official index plus supporting sources
Observations: deviation investigations without worst-case assessment, component acceptance procedures
Products: batches used in further manufacture of INFANRIX and BOOSTRIX
Insight · Editorial insight
Batches were released while deviation investigations had not assessed worst-case conditions, and the procedure written as the corrective action allowed use without a risk assessment. Where an upstream deviation feeds several finished products, the basis for the corrective action itself may come under review.
Check points
Worst-case risk analysis in deviation investigations
Impact assessment across all affected items after temperature excursions
Risk assessment behind procedures introduced as corrective actions
Observation detail · 2 observations · OCR reading of the scanned original
The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.
Observation 1
Discrepancy and failure investigations related to manufacturing were not expanded to assess worst case conditions.
Specifically, a) Deviation 201042740 initiated on 09JAN2024, pertaining to particulate contamination of was not adequately investigated. Your (b) (4) identified an within a (b) (4) sent for analysis during the deviation investigation. However, you failed to perform an adequate risk analysis that included worst case conditions to support the utilization of during manufacturing of (6)i(4)i ll lll | lll batch “This batch was released and distributed for further manufacture of final drug products INFANRIX (lots (BY (4) 9) and BOOSTRIX (lot(6))). b) Deviation 201079963 was initiated on 25JUL2024 pertaining to a (b) (4) 7) This batch was identified as out of controlled temperature fol) hrs with the warmest temperature reachin ). You failed to evaluate product impact for all 17 and failed to adequately investigate and justify your viability testing sample was representative of worst-case conditions. This was released for further manufacture of and (6) 4) batches ad
Observation 2
Procedures for the acceptance and rejection of components and materials utilized within drug substance manufacturing are not adequate.
Procedure LSOP 9000087267 (ver. 01 — approved 20MAR2024), titled “FILT.UF (B)(4) Pi was implemented as a corrective action in response to deviation 201042740 and requires visual inspection of the prior to use within manufacturing. The procedure allows for the acceptance and use o containing ,” however, no risk assessment or study was conducted to assess the impact of utilizing with (b) (4) ” within your process.
[FDA 483 observation · FDA]GlaxoSmithKline Biologicals SA — Non-validated filling recipes in use
FDA🧬 Biologics483
FDA issued six observations to GlaxoSmithKline Biologicals SA, a vaccine manufacturer, at the close of an inspection ending 02/27/2026. Key issues are non-validated filling formats/recipes, mismatches with batch records, APS design and environmental monitoring gaps.
Published 2026-10-20 · Inspection date 02/27/2026 · Vaccine Manufacturer · FEI 3003973577
Key facts · Basis: official index plus supporting sources
Firm: GlaxoSmithKline Biologicals SA, FEI 3003973577
Six observations covering recipe accuracy checks, fill-volume recipes differing from batch records, APS worst-case design, unevaluated events and environmental monitoring
Example: SHINGRIX Batch No. ASFLA026A was made and released using a recipe different from the batch record
Insight · Editorial insight
Electronic recipes that control critical parameters such as fill volume were used without validation or change control, and actual settings did not match batch records, which points to a systemic gap in computerized system control rather than a one-off error. Combined with APS design and post-shutdown and post-excursion monitoring findings, the overall sterility assurance basis of the aseptic filling operation may come under scrutiny.
Check points
Validation and change control of electronic filling formats/recipes
Match between master batch record recipe/fill volume and actual operating settings
Environmental monitoring before restart after shutdowns and action-limit excursions
Observation detail · 6 observations · From the source
Observation 1
Input to and output from the computer and related systems of formulas are not checked for accuracy.
Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Specifically, A. The Master Batch Record, MBR, No. (b) (4) and executed production batch, (4) records for SHINGRIX® specify the use of format/recipe (b) (4) with a target fill volume of () However, actual manufacturing operations utilized format/recipe (b) (4) witha target fill volume of(b) (4), representing a (5) (4) deviation from the specified fill volume. Your firm failed to follow the batch record specifications during manufacturing for (b) (4) lots of SHINGRIX® PFS- Pre-Filled Syringe drug products, of which (b) (4)have been released since March 16, 2024. The actual fill volume and format/recipe used in production did not match the fill volume and format/recipe documented in the batch record. For example, your firm manufactured and released SHINGRIX® Batch No. ASFLA026A, release date September 1, 2025, on filling line using format/recipe IIMA with a fill volume of (Bb) (4). However, the MBR and production batch record reflect the use of format/recipe (1) (4) with a target fill volume of (b) (4) B. Filling parameters are modified and adjusted during production and process control in the (b)Oy the operator as needed. Your firm has not established procedures governing operator c
Observation 3
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.
Specifically, A.Your current APS (Aseptic Process Simulation) design does not challenge or represent worst-case conditions for routine commercial fill volumes and container sizes. Commercial products, such as Boostrix, Engerix, Havrix, Twinrix, Fluarix, FluLaval, Infanrix, Kinrix, Pediarix, Rotarix, Shinerix. Svnflorix. Penmenvy, Arexvy, and Hiberix are filled at volumes ranging from (b) (4) (b) (4) syringe containers, (b) (4) syringe containers, and (b) (4) (b) (4) vial containers. However, your APS program uses only the (b) (4) syringe container filled to a target volume of (b) (4) for filling line" and vial container filled to a target volumeo or (b) (4) | container filledto a target vol f b) (4 f filling line (1) (4) . B.Your LSOP 9000002087, version 17, “Validation of Aseptic Operations — Aseptic Process Simulation (APS)”, section 6.2.5.2 requires justification and validation of the (b) (4) (b) (4) media fill volumes for each container and validation of incubation conditions. Section 6.2.5.4 requires development and justification of a container (6) (4) _ ; otherwise, all container sizes must be (b) (4) during (b) (4) APS requalification. Section 6.2.5.4 further requires that w
Observation 4
Deviations from written production and process control procedures are not justified.
Specifically, your firm failed to evaluate unexpected events during drug product manufacturing to determine whether they constitute deviations from established procedures. There is no documentation demonstrating that your firm assessed these events or provided justification for why they were not classified and investigated as deviations. For example, your firm manufactured SHINGRIX® Lot No. ASFLAO18A on (b) (4) , During the manufacturing process, the operator detected a failure of the (b) (4) ), which monitors the Grade o filling line. This event was documented in the batch record as defect code (b) (4) However, your firm failed to evaluate whether this PEMS failure constituted a deviation from established procedures or requirements.
Observation 5
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
Specifically, A.Inadequate Environmental Monitoring Following Planned and Unplanned Shutdowns ol Your |, (b) (4) and (b) (4) units are classified as Grade (ISO “) during operations and declassified during shutdown. These Grade "” areas are used for
Observation 6
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
[FDA 483 observation · FDA]CoreRX Inc. — Unvalidated hold times in non-continuous process
FDA🧬 Biologics483
In an inspection of CoreRX Inc. (inspection date 03/20/2025), FDA observed unvalidated hold times for a non-continuous process, a weakly supported no-impact conclusion for a power outage deviation, no product impact assessment for missing environmental monitoring samples, and equipment cleaning and facility maintenance deficiencies.
Published 2026-10-20 · Inspection date 03/20/2025 · Biologic Drug Manufacturer · FEI 3007209985
Key facts · Basis: official index plus supporting sources
Investigation: missing EM samples (INC-24-00034) were concluded as no product impact without an impact assessment, and batches from that period were released
Insight · Editorial insight
Citing both a batch resumed after a power outage without validated hold times and investigations concluding no impact without an assessment signals that FDA scrutinizes the basis of deviation conclusions. Sites running non-continuous processes that can be interrupted may want to check that hold-time validation and deviation impact assessments are linked.
Check points
Validation basis for material hold times during process interruptions
Documentation of product impact assessments in deviation investigations
Availability of equipment cleaning instructions and cleaning logs
Observation detail · 6 observations · From the source
Inspectors: Peng Zhou · Thai D Truong
Observation 1
Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Specifically, A. Your multiple materials such as 0541 PIP Me% For example, the Ib/141 'process is not required to run continuously and is allowed to be completed over 51(41 until the OM 18)141 15141 . The are held process is finished. (0141 and other or for 51+0 (WI before resuming was paused on Ibif41 , the materials were placed on hold from on (.1(.) 81141 at batch were held on . Due to a power outage, the with other - Your process for batch resumed on , and was completed on, batch lwas released to your - Ifor further! OM) . Palforzi a _Ito the U.S market. Your firm has not established an appropriate hold time or validated the non -continuous
Observation 2
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically, A. Incident No. INC-24-00219, was initiated on July 8, 2024, for a site wide unplanned power outage that occurred on July 3, 2024. During this outage, manufacturing of Palforzia 20mg batch number was interrupted during the batch was placed on hold for the 111(4) ow) ( process. The and completed on. process for Palforzia I Additionally, experienced a temperature excursion due to the outage Your investigation concluded that there was no product impact; however, no product impact in the Palforzia batch was released to your client for further
Observation 3
Written procedures are not established and followed for the cleaning and maintenance of equipment, including ,used in the manufacture, jof a drug product.
Specifically, A. On March 12, 2025, multiple dissembled equipment parts of the , including the om fb1 were observed to have visible (EE of a B. You failed to establish cleaning instructions and documentation logs for the connecting to the used in the of excessive during the production of finished drug product. C. On March 12, 2025, equipment including: RE4I (1 of the was used in multiple location on surfaces of production PIRO
Observation 4
The responsibilities and procedures applicable to the quality control unit are not in writing.
Specifically, you fail to establish a procedure to adequately address the control of documents in your manufacturing suite when not in use. The following blank documents and records were observed in the common support area of the manufacturing suites during the walkthrough on March 12 2025 i. - 1-0147 "Line Clerance Form for - Manufacturing Operations" ii. Attachment 3 of SOP -0342 " Operation, Maintenance, and Calibration of the MN System, including Page 29-44 iii. Attachment 2 of SOP -0368" - Cleaning of MN for the 00I ", Major Cleaning of - (Page 1-3)
Observation 5
Buildings used in the manufacture, in a clean and sanitary condition.
of drug products are not maintained Specifically, during our inspection walkthrough on March 12 2025, we observed the following deficiency: A. Multiple cracks on the oxo on the - - , used for the of 0.5mg, 10mg, and 20mg of finished drug product Palforzia B. A hole on the MM 0841 ofthel were observed in production suite - for the manufacturing and no work order having been initiated for repair. ! of the C. Paint peeling off the - inside production suite - , which is used for the used for the manufacturing of 20mg and 100mg of finished thug product Palforzia.
Observation 6
Written procedures are not followed for the storage of components and dnig product Specifically, MO) MWD A.
On March 18' 2025, we observed that material was placed in the incorrect location in the including: Material Name and Batch !Location Assigned iniLocation observed in Number e 00.1 11310) Microcrystalline Powder
At a vaccine manufacturing site of GlaxoSmithKline Vaccines Srl (inspection date 01/26/2024), FDA observed inadequate CAPA for release-test invalid rates repeatedly exceeding thresholds, no deviation cluster analysis or CAPA effectiveness checks, expired operator training qualifications, late reporting of serious adverse events, and unlocked QC laptops.
Published 2026-10-20 · Inspection date 01/26/2024 · Vaccine Manufacturer · FEI 3006738517
Key facts · Basis: official index plus supporting sources
Deviations: over 5500 reported from January 2021 to December 2023, with no master CAPA or effectiveness checks for similar clusters
Insight · Editorial insight
Not treating over 5500 deviations as possible recurrences and not opening CAPAs for repeatedly exceeded invalid test rates signals that a quality system focused on closing individual events can be judged a failure of trend management. Sites with high deviation or invalid test volumes may want to check whether recurrence definitions, cluster analysis and CAPA effectiveness checks actually work.
Check points
Recurrence definition and cluster analysis of deviations by topic and root cause
CAPA initiation when QC invalid test rates exceed trending thresholds
Retraining before critical operator qualifications expire
Observation detail · 5 observations · From the source
Inspectors: Roger F Zabinski
Observation 1
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically, the following was observed: a) Covering the time period of January 2021, to the present, invalid test rates for release testing assays pertaining to Menveo and Bexsero drug substance (DS) and drug product (DP) batches were observed to routinely exceed the firm’s QC trending investigation threshold of) x. ia Within 2023, multiple assays were observed to have invalid rates exceeding _,,, - During review of 2023 data, it was observed that CAPAs were only opened or Menveo (DS & DP) and Bexsero (DS) zm assay (3 CAPAs and Menveo (DS) and Bexsero(DS)) sw ~=—S—S—s=é<C«s~*«‘«C:*«CSWLCSSay (1 CAPA). Innvaalid rates werre observed as high as}. for'~ and we assay. It was observed that no CAPAs were initiated to implement corrective action and prevent future occurrence ofran trending excursions for the following assays observed at over|~ _ invalid rate during| | analysis (this list is not all inclusive). * Menveo (DS & DP) - on conjugated bulks (b)(4)
Observation 2
The responsibilities and procedures applicable to the quality control unit are not fully followed.
specifically, the following was observed: a) The firm reported over 5500 deviations between January 2021 through December 2023. For 2023, root causes were classified as; “ method,|- |machine, and | manpower (human error). The firm does not assign most deviations as recurrences due to a reported limited definition in| - The firm has not performed analysis of the deviations per related topics, similar root cause, manufacturing production unit, or product to determine if there are clusters of similar deviations that may be recurrences and if there may need to be a general or master deviation or master CAPA to address these similar events. A review of the deviations revealed clusters of deviations under similar topics: | - for equipment;|. _|for HEPA and other filter failures; . —_|for water, wm Sw for training; [- | interventions (including maintenance | gy interventions). The firm has not established CAPA effectiveness checks to determine if corrections to similar events are correcting the issues. b) Deviation UE 201022310, opened on 19 September 2023, was for a failed HEPA filter leak test
Observation 3
Employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions.
Specifically, a) Critical cGMP training and operator qualifications are sometimes lapsed to be expired. The training qualifications are not always managed effectively to prevent gaps or lapses in training for operators who perform critical functions including aseptic operations and visual inspections and to ensure retraining is planned in a timely manner. Expired operator qualifications were
Observation 4
Not all adverse drug experiences that are both serious and unexpected have been reported to FDA within 15 calendar days of initial receipt of the information.
Specifically, a. The firm's pharmacovigilance reporting of adverse drug events in year 2023 listed the following number of events were reported to the agency later than the required time. Vaccine Number of events reported Number of Days Late ate to agency in 2023 1 to 122 The firm reported that some of the events for Shingrix were due to a common social media information event, but this was not defined. No explanation was given to why other adverse events were reported late or to the extent of number of days. b. The following additional vaccine adverse events were reported to the agency later than the 30- day requirement. Number of events reported (Number of Days Late ate to agency in 2023
Observation 5
Established laboratory control mechanisms are not followed.
Specifically, the following was observed: e While observing QC release testing pertaining to the Menveo Full Liquid (DP) Quantitative determination of se on bos assay for batches | we | ww on 01/18/2024, it was observed that testing analyst = |did not lock|~ _|laptop workstation utilized to record the assay within|- _|on multiple occasions when leaving ~ |workbench while conducting the assay. This activity does not follow firm procedure QC LSOP 9000054316 v10 “Good practices for computerized lab system” part 4.2 stating) - e While observing QC release testing pertaining to Bexsero (DS) Quantitative Determinations of wo inae aa on 01/19/2024, it was observed that testing analyst |= | did not lock!~ _|laptop workstation utilized to record the assay within|-_| when leaving '~_|workbench while conducting the assay. This activity does not follow firm procedure QC LSOP 9000054316 v10 “Good practices for computerized lab system” part 4.2 stating)=
FDA's inspection of Diagast, a blood grouping reagent maker (inspection date 04/19/2024), produced six observations, including unfiled MDRs for false positive and false negative complaints, an unsubmitted biological deviation report, and inadequate risk analysis and storage temperature procedures.
Published 2026-10-19 · Inspection date 04/19/2024 · Biologics IVD Manufacturer · FEI 3006261638
Key facts · Basis: official index plus supporting sources
Observations: 6 (MDR reporting, biological deviation reporting, risk analysis, storage temperature control, MDR procedure, in-process test records)
Insight · Editorial insight
Rh mistype and other false result complaints for blood grouping reagents were not reported as MDRs, and the MDR procedure lacked a malfunction definition and documented justification for non-reporting, signaling gaps in both complaint handling and regulatory reporting. The discarded first pH reading also suggests that retention of in-process raw data may be scrutinized from a data integrity angle.
Check points
MDR and deviation reportability assessment of complaints, with non-reporting rationale
Storage temperature excursion criteria and nonconformance handling
Retention of in-process test raw data, including repeat measurements
Observation detail · 6 observations · From the source
Inspectors: Creighton T Tuzon · Richard T Riggie · Elias N Paz Alonzo
Observation 1
An MDR report was not submitted within 30 days of receiving or otherwise becoming aware of information that reasonably suggests that a marketed device has malfunctioned and would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.
Specifically, You received multiple customer complaints that reasonably suggest MDR reportable events where a device malfunction likely occurred. For example, at least two (2) False Positive Customer Complaints (Cases: 2021-01270852, 2022- 01583216) ofan Rh mistype, and an Rh C mistype (Case 2022-01867083). Also, there were multiple False Negative results for which various antigens were mistyped. For example, an anti-E (Rh3) provided a false negative (Customer Complaint # WO000283663).
Observation 2
Failure to submit a biological deviation report.
Specifically, A. Customer complaint numbers, 1. WO-00333475, received on 11/8/2022, stated that unopened vials, Ref. 210532 Anti-Fyb
Procedures for the control of storage areas and stock rooms have not been adequately established.
Specifically, You have not defined proper temperature excursion procedures and what is an acceptable and unacceptable departure from acceptable storage temperatures. Your (6/4) located at Site % used to store blood grouping reagents and reagent red blood cells had a temperature excursion (B)(4)) degrees Celsius on September 5, 2023 and January 1, 2024. You did not initiate a non-conformance or document any action(s) taken due to the temperature being out of an acceptable range for more than (6)(4) ' Your procedure "Use/Verification of Temperature Loggers, Alarm Probes and Thermobuttons" does not establish the (6)(4) out-of-range acceptability. Currently, you have no procedure that defines when action or documentation should be initiated when the temperature of the (6)(4) deviates from its defined acceptable range.
Observation 5
The written MDR procedure does not include documentation and recordkeeping requirements for all information that was evaluated to determine if an event was reportable.
Observation 6
In-process inspections, tests, or other verification activities and approvals were not documented.
Specifically, On 04/12/2024, your firm formulated a batch offpy4yy of Anti-D Blood Grouping Reagent (Catalog No. (649); Lot 734000) to be processed into )@ kits @@cassettes ofml) of finished Anti-D BGR for automated systems for the U.S. market. During an in-process formulation quality control check for pH, your firm’s formulation technician §@%) measured the pH twice, discarding the paper record of the first pH measurement into biohazardous waste without retaining the pH measurement paper record and
FDA issued a 483 with 9 observations on Sipuleucel-T manufacturing to biological drug manufacturer Dendreon Pharmaceuticals LLC after an inspection ending 03/25/2026. It cited inadequate nonconformance and OOS investigations (a repeat observation), aseptic contamination-control gaps such as missed hand sanitization, unreliable electronic batch records, and reprocessing without quality unit approval.
Published 2026-10-19 · Inspection date 03/25/2026 · Biological Drug Manufacturer · FEI 3008821247
Key facts · Basis: official index plus supporting sources
Observation 1 (repeat): weak investigations, including a final product bag lot that failed visual inspection but was approved for use by SQA
Observation 3: operators entered and exited the biological safety cabinet without sanitizing hands
Insight · Editorial insight
A repeat observation on investigations alongside findings on aseptic practice, environmental monitoring and reprocessing approval points to concerns about overall quality unit oversight rather than isolated lapses. A sterility result changed without justification with a new CoA issued, and electronic batch records that may not identify who performed each step, are also worth noting from a data integrity standpoint.
Check points
Final product impact assessment, conclusions and follow-up in nonconformance and OOS investigations
Level of detail in hand and material sanitization steps for biological safety cabinet entry
Quality unit approval of reprocessing and a written reprocessing procedure
Observation detail · 9 observations · From the source
Inspectors: Sony Mathews · Esther A Ofori · Lizaida Perez · Emily B Camire
Observation 1
Written records of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications do not always include the conclusions and follow-up.
Although your firm's Quality Unit approved a written procedure, SOP-11058.33, entitled “Nonconformance Reporting," effective August 9, 2025, which defines the nonconformance management process, investigation, assessment of impact, determination of root cause, implementation of corrections, identification of corrective actions, documentation, and reporting of process nonconformities, your firm failed to thoroughly investigate the following: a) Non-conformance NC-2025-0053, initiated on May 23, 2025, investigated the visual inspection failure of final product bags with lot number (b) (4) the final product bags from this lot did not meet the required visual inspection criteria: (b) (4) units contained embedded particulates on the product (b) (4) surface, and | (B) (4) units contained embedded particulates on the (b) (4) product (b) (4) surface. Despite these findings, the lot was approved for use by Supplier Quality Assurance (SQA). This lot was subsequently used in the manufacturing of __ final product batches of Sipuleucel-T and remains the current lot in use for finished product. a ; . 4 4 b) For critical material, (b) (4) , Lot # (b) (4) were rejected during the ex packaging opera
Observation 2
Laboratory records do not include the initials or signature of a second person showing that the original records have been reviewed for accuracy.
Your firm's test method, (b) (4) entitled (b) (4) effective June 29, 2022, for Sipuleucel-T release lacks adequate independent verification of microbial contamination results. The procedure _reauires () (4) (b) (4) entitled “(b) (4) ” effective March 10, 2026, no microscopic examinationof(b) (4) by QC reviewers. On March 19, 2026, this was confirmed when an analyst performed (b) (4) for batches (b) (4) and (b) (4) , and a (b) (4) analyst stated reviewers verify only (b) (4) . This test is used for product release before final sterility testing is completed.
Observation 3
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in processing and packing.
Control procedures are not established which validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
Specifically, since February 2024, your firm has manufactured (b) (4) and (b) (4) in house. A comparison study was conducted to demonstrate the comparability between your in-house manufacturing process and the prior contract manufacturer’s process. Your current manufacturing process significantly differs from the contract manufacturer’s process in the following parameters: 1. Lot Size ll. Mixing Conditions Ill. Hold times IV. Elimination of (DB) (4) step a V. Filling Environment ISO “to ISO # VI. Method of (8) (4) sterilization VII. Different() (4) Composition The manufacturing validation and comparability study did not fully address the impact of the changes above. Your firm did not ensure the reproducibility and effectiveness of the manufacture of the (b) (4) solutions, (b) (4) . Your (b) (4) are a critical component in your Sipuleucel-T manufacturing process as they are used to (b) (4) the target cells. Since February 2024, your firm has manufactured approximately (b) (4) of (b) (4) and approximately
Observation 7
Drug product (b) (4) are (b) (4) so as to alter the safety, identity, strength, quality, and purity of the drug beyond the official or established requirements.
Specifically, since February 2024, your firm started using (b) (4) for the in-house manufacturing of (b) (4) instead of (B) (4) (b) (4) which were used by the CMO’s formulation. However, your stability study with (b) (4) in the (B) (4) position does not evaluate potential leachable, extractables, and seal integrity or if the formulation degrades when in direct, long-term contact with the (b) (4) or over time.
Observation 8
Employees engaged in the manufacture, processing and packing of a drug product lack the experience required to perform their assigned functions.
Your firm's quality unit approved written procedure, SOP-10046.20, entitled "General Visual Inspection," effective June 13, 2025, outlines the training and qualification requirements for personnel performing visual inspections. The quality unit failed to provide documents and demonstrate visual inspection test kits or library of defective samples as part of visual inspection training for employees performing 100% visual inspection. Furthermore, your firm relies on visual inspection to ensure the following materials do not contain particulates and are acceptable for use in manufacturing of your Sipuleucel-T drug product: 1;(b) (4 3: 4.
Observation 9
Reprocessing was performed without the review and approval of the quality control unit.
Specifically, employees engaging in the manufacturing operation of your (b) (4) determines whether ashould be reprocessed during packaging operations. Reprocessing can occur because of (b) (4) , (b) (4) , or incorrect color () (4), Furthermore, your firm does not have a written procedure for reprocess or rework. For example: a) (b) (4) Lot # (b) (4) had (b) (4) reprocessed inline during the packaging operation. b) (b) (4) Lot # (b) (4) had (b) (4) reprocessed inline during the packaging operation. c) (b) (4) Lot # (b) (4) had (b) (4) reprocessed inline during the packaging operation. = There is no quality unit oversight for approval of reprocessing of the ae
[FDA 483 observation · FDA]Shimoga Chemicals — Unreported HPLC injections and data integrity
FDA483
FDA issued a Form 483 with 10 observations to API manufacturer Shimoga Chemicals (inspection date 01/23/2026), led by unreported HPLC sample injections before or after official results, one of which yielded an out-of-specification assay, plus data integrity gaps in cleaning and batch records.
Published 2026-10-23 · Inspection date 01/23/2026 · API Manufacturer · FEI 3033881432
Key facts · Basis: official index plus supporting sources
Key observation: unreported Related Substances and Assay HPLC injections were left out of laboratory batch records; recalculation showed an OOS assay for one batch
Other observations: inadequate process validation, no cleaning validation, missing stability raw data, rusted and taped equipment
Insight · Editorial insight
Unrecorded injections preceding official results, including an OOS result for a batch shipped to the American market, point toward selective reporting of test data. Alongside cleaning, batch record and stability data gaps, it shows why audit trail review of chromatography data at API suppliers deserves attention.
Check points
Reconciliation of chromatography audit trails against reported results
Cleaning procedures and cleaning validation basis at API suppliers
Retention of raw data behind stability results
Observation detail · 10 observations · From the source
Inspectors: Rachael A Moss · Arsen Karapetyan
Observation 1
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assure that components and raw materials conform to appropriate standards of identity.
Specifically, A.Laboratory control procedures are not followed: -During review of electronic data for m@ USP API, we observed multiple unreported sample injections prior to or after the official reported sample injections for Related Substances and Assay by HPLC testing that were not documented in laboratory batch records. API batches involved ; - o@ included batch numbers . Batches oe were approved by QA and shipped to the U.S. market. -During the current inspection we requested your firm to perform calculations for all unreported Related Substances and Assay injections, where at least one batch, @@ revealed an unreported injection with an OOS result. Specifically, on 12/20/2024, your analyst injected a blank and single injection for sample @@ , with calculations during the current inspection resulting in OOS for assay, with calculated result as@@ % versus specification ofm@ %. The official reported result documented in your laboratory batch records for m@ was performed on 12/22/2024, with reported result asy@ %. This batch was shipped to the U.S. Market.
Observation 2
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Specifically, Your firm has failed to establish adequate process validation and production control procedures. Your process validation for @@ USP API and key starting materials does not accurately reflect actual manufacturing, making production non-replicable. A.Your firm’s process validation does not clearly identify the batch records used, their execution sequence, or how records are@m@ during the manufacture ofm@ USP API anda@ 0) , a key starting material. For example, each m@ USP API batch produced following m@ manufacture was o@ a practice not addressed in the process validation documentation. In addition, production occurs through the m@ @) execution of@ batch records—manufacture of oe oe however, this approach was not addressed in the process validation.
Observation 3
Batch production and control records do not include complete information relating to the production and control of each batch.
Specifically, A.Your firm fails to maintain accurate and consistent cleaning logs and batch records, demonstrating significant data integrity deficiencies in the documentation ofy@ 001 cleaning and 0) ofme USP API @@ batches form@ Review of the following batch
Observation 4
Procedures for the cleaning and maintenance of equipment and its release for use in the manufacture of intermediates and API are deficient regarding sufficient detail of the methods, equipment, and materials used in the cleaning and maintenance operation, and the methods of disassembly and reassembly of equipment as necessary to assure proper cleaning and maintenance.
Specifically, A.Your firm has not performed cleaning validation studies to address microbiological and residue contamination for processes where such contamination could be of concern during manufacture of 0) Equipment used in the manufacture ofw@ USP API includes Cleaning procedures for equipment used to manufacture o@ USP API for the U.S. market lack adequate detail and do not reflect actual practices. Your firm's cleaning procedures and batch records do not specify cleaning methods or techniques, materials used, contact times, acceptance criteria, or verification requirements. For example, while the cleaning SOPs for the m@ indicate that mw water/solvent is used for cleaning, the firm stated that they use onlym@ water for all equipment cleaning, without differentiation by product, batch, or stage of manufacture. The firm confirmed that the specific type of solvent is not documented in any procedure and that operators determine which solvents to use based on memory. An undocumented exception to the use ofm@ water for cleaning was identified for equipment »@ 1, which is cleaned with@ during processing. Per your firm's Production in Charge, during Step® of production for batches O@
Observation 5
Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength, quality and purity at the time of use.
Specifically, A.Stability study reports provided during the inspection in support of»@ USP API do not adequately support the statedw@ shelf life/expiry date. During our review of your completed long-term 2015 stability study reports and recorded results, we observed that your firm did not have supporting raw test data, both electronic and physical laboratory batch records, for stated results for the long-terme@ stability study. Furthermore, the current ongoing long-term
Observation 6
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
The accuracy, sensitivity, specificity and reproducibility of test methods have not been established and documented.
Specifically, Your firm has not established or documented method verification studies for the USP compendial assay and residual solvent test methods used for m@ USP API. The methods lack
Observation 8
Buildings used in the holding of active pharmaceutical ingredient do not have the suitable construction to facilitate cleaning, maintenance, and proper operations.
Specifically, During our walkthrough of the production area on January 19, 2026, we observed multiple deficiencies withe @ equipment and surrounding areas where m@ API is manufactured. Equipment and piping located on and above m@ where product material is H@ showed visible rust. M@ identified as clean or in operation had missing or removed bolts scattered around or placed on top of theq@ .-Am@ and hose assembly used to transfer product from the m@ 0 to theme was held together with tape and metal wiring. Plastic tarps positioned below the m@ to catch material during m@ operations were visibly soiled. These conditions demonstrate inadequate equipment maintenance and cleaning practices that present a risk of contamination to the API.
Observation 9
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Observation 10
Failure to ensure training is regularly conducted by qualified individuals and covers, at a minimum, the particular operations that each employee performs and CGMP as they relate to the employee’s functions.
Specifically, Your firm failed to ensure that personnel involved in drug manufacture operations were adequately trained. Per your firm's QA Executive, induction and@@ _training were not consistently performed, as outlined in your training procedure. For example, operators performing »@ operations for 0) USP API batchese@ lacked documented training for the
FDA issued a single-observation Form 483 to Catalent Massachusetts, LLC (inspection date 04/07/2026), citing in-process bulk powder sampling that did not follow the firm's sampling procedure and tests run under administrator credentials on a laboratory instrument.
Published 2026-10-23 · Inspection date 04/07/2026 · Manufacturer · FEI 3011696115
Key facts · Basis: official index plus supporting sources
Observation 1-A: bulk powder in the IBC was not sampled from sufficient locations as required by 'BOS-SOP-0249, Aseptic Sampling Technique'
Observation 1-B: tests on instrument Asset ID: Sys-0084 were run with administrator credentials despite 'SOP-BST-000043, DIA Data Integrity and Security' prohibiting generic accounts
Insight · Editorial insight
Operators cited the right procedure section yet sampled from only one point, signaling that in-process sample representativeness depends on floor practice rather than the written SOP. Administrator-credential testing despite individual accounts being available is a reminder to review instrument-level access control and record attributability together.
Check points
Alignment of in-process sampling locations and methods with the SOP
History of administrator or shared account use on test instruments
User attribution of instrument printouts and batch record signatures
Observation detail · 1 observation · From the source
Inspectors: Armen H Youssoufian · Ogechi C Nna
Observation 1
Written production and process control procedures are not followed in the execution of production and process control functions.
Specifically, A. Your firm failed to follow written procedure, ‘BOS-SOP-0249, Aseptic Sampling Technique’ which states for(b) (4) samples using (b) (4) the samples are to be taken from sufficient locations to obtain(b) (4) . In addition, the procedure states to (b) (4) . On 04/02/2026, we observed a Manufacturing Associate, and a Manufacturing Supervisor obtain (b) (4) for (b) (4) Bulk Powder batch # (b) (4) During discussion of the sampling technique, the operators referred to section 8.4 of the procedure on obtaining (b) (4) using (b) (4) however we observed the operator only obtain (b) (4) _ from the (b) (4) , into the IBC (Intermediate Bulk Container). Your firm failed to provide adequate justification for not following your procedure on taking a work-in progress / in-process (b) (4) of(b) (4) Bulk Powder batch # (b) (4) at sufficient locations to obtain (b) (4) of the bulk powder within the IBC. B. Your firm failed to follow your written procedure ‘SOP-BST-000043, DIA Data Integrity and Security’, which states the use of generic accounts is prohibited. During review of previous (b) (4) tests performed on the (b) (4) instrument, Asset ID: Sys-0084, multiple instances of a manuf
[FDA 483 observation · FDA]Frontage Laboratories, Inc. — OOS investigations and lab data integrity gaps
FDA483
FDA issued a Form 483 with four observations to contract testing laboratory Frontage Laboratories, Inc. after an inspection (inspection date 04/14/2026). Observations covered OOS investigations without root cause, modifiable and deletable instrument electronic data, missed data backups, and weak controls in a microbial limits test procedure.
Published 2026-10-23 · Inspection date 04/14/2026 · Contract Testing Laboratory · FEI 3006799640
Key facts · Basis: official index plus supporting sources
OOS: an assay OOS of 112.5% was retested at 96.0% and 102.1% with no root cause or justification for the variability, and no CAPA
Data integrity: original data files could be renamed or deleted via Windows File Explorer, and UV-VIS backups had not run since March 30, 2026
Insight · Editorial insight
Closing an OOS by retesting without a root cause, alongside original data that could be altered or deleted, signals broad concern over the reliability of test results. Sponsors that outsource testing to this laboratory may want to revisit its OOS investigation quality and instrument data access controls.
Check points
Root cause and retest justification in the contract lab's OOS investigations
Controls on modifying or deleting original instrument electronic data
Execution of instrument data backups and actions on backup failures
Observation detail · 4 observations · From the source
Inspectors: Junho Pak
Observation 1
Written records of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications do not always include the conclusions and follow-up.
Laboratory records do not include a complete record of all data secured in the course of each test, including all charts and spectra from laboratory instrumentation, properly identified to show the.
Specifically, generated electronic data from your (b) (4) laboratory instruments are not controlled to ensure security and integrity. For example, A.Original electronic data stored on the (b) (4) of the (b) (4) instrument was able to be modified and deleted with the Windows File Explorer. During the data integrity demonstrations on the instrument computer, analytical data file names for previously analyzed samples were able to be modified with the Windows File Explorer. Additionally, the demonstrations revealed original data files could be deleted from the instrument file folders by the manager level users. Deleted files were recovered in the system Recycle Bin and restored. As per the site management, the instrument software ‘(b) (4) ” was identified as 21 CFR Part-11 Compliant. Bb) (4) Analyzer instrument (b) (4) was not configured to maintain security and integrity of the generated electronic data. Electronic data on the instrument computer was not restricted to prevent modifications and the
Observation 3
Failure to maintain a backup file of data entered into the computer or related system.
Specifically (b) (4) system backup of electronic data from the (b) (4) UV-VIS Spectrophotometer was not executed for paces and the firm’s IT group failed to take corrective actions for the identified data backup failures, as defined in the written procedure. According to the system logs, the last successful (6) (4) data backup was executed on March 30, 2026. At time of the facility walkthrough on April 8, 2026, the instrument computer was observed to have been powered off, in contrary to the label on the instrument, “DO NOT TURN OFF THIS COMPUTER”.
Observation 4
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
Specifically, the(b) (4) Microbial Limits/Bioburden testing procedure do not contain sufficient control to ensure (b) (4) have reached the required (b) (4) , prior to use. There are no defined methods to identify the (b) (4) of the (b) (4) and insufficient controls to ensure sufficient (b) (4) . Exceeding the (b) (4) requirements could destroy/attenuate the microorganisms on test, resulting in reduced or false negative test results.
[FDA 483 observation · FDA]PReye LLC — Sterile repackaging in an unclassified office
FDA483
FDA issued a Form 483 with four observations to repackager/relabeler PReye LLC after an inspection (inspection date 03/19/2026). It cited repackaging of sterile drug products in an unclassified office without environmental monitoring, receipt without identity testing, and the absence of a quality control unit.
Published 2026-10-23 · Inspection date 03/19/2026 · Repackager/Relabeler · FEI 3031057987
Key facts · Basis: official index plus supporting sources
Sterile repackaging: done in an unclassified office under an unqualified laminar airflow hood, with no environmental, surface or personnel monitoring
Quality system: sterile products from a compounding pharmacy repackaged without identity testing or COA review, and no vendor qualification or procedures for deviations, change control and other processes
Insight · Editorial insight
Repackaging sterile products in an office without demonstrated ISO 5 conditions signals that the basis for sterility assurance is missing altogether. Because products from an outside compounding pharmacy were distributed without identity testing or COA review, gaps in supplier and quality agreement oversight are also worth noting.
Environmental and personnel monitoring in aseptic areas
Identity testing and COA review for received drug products
Observation detail · 4 observations · From the source
Inspectors: Brittny C Cargo
Observation 1
Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of drug products.
Specifically, A.Your firm repackages sterile (b) (4) drug product(b) (4) , in an unclassified office environment using a (6) (4) laminar airflow hood. The area lacks appropriate cleanroom classifications (e.g., ISO 5 conditions), and your firm has not demonstrated that aseptic conditions are maintained during processing. Further, the laminar airflow hood used during repackaging has not been qualified, certified, or routinely maintained. Your firm has no documentation demonstrating that the hood provides adequate HEPA filtration or unidirectional airflow. B.Your firm does not perform viable or non-viable environmental monitoring, surface sampling, or personnel monitoring in areas where sterile drug products are repackaged. Your firm lacks data to demonstrate control of the aseptic processing environment. These conditions create a significant risk of contamination of drug products intended to be sterile.
Observation 2
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.
Observation 3
The identity of each component of a drug product is not verified by conducting at least one test to verify the identity, using specific identity tests if they exist.
Specifically, Your firm receives sterile drug product, (b) (4) , from a compounding pharmacy and repackages them without performing identity testing. Your firm also fails to obtain or review Certificate of Analysis (COAs) to verify the identity, strength, quality, and purity of the received drug products.
Observation 4
There is no quality control unit.
Specifically, Your firm has not been effective in carrying out its duties of ensuring drug product purported to be sterile are manufactured in accordance with current good manufacturing practices (CGMP) to ensure safety, efficacy, purity, and overall quality at your firm. This is evident by the following deficiencies: A. Failure to qualify the following vendors
[FDA 483 observation · FDA]SURETEC INNOVATIONS LLC — Ineffective QC unit and release before testing
FDA483
FDA issued a Form 483 with four observations to manufacturer SURETEC INNOVATIONS LLC after an inspection (inspection date 03/05/2026). It cited an ineffective quality control unit, shipment before testing and quality approval were complete, unvalidated test methods, and no potency testing of the finished product.
Published 2026-10-23 · Inspection date 03/05/2026 · Manufacturer · FEI 3030456591
Key facts · Basis: official index plus supporting sources
Release control: finished product shipped on 09/03/2025, while testing and quality review and approval were completed on 09/10/2025
Lab and quality system: one QC manager both tested and approved batch release, micro and potency methods were not validated, and twelve total plate count OOS results were not investigated
Insight · Editorial insight
Shipping product before testing ended, with one person both testing and approving release, signals that independent quality release decisions are not functioning. Continued use of a material despite uninvestigated repeat total plate count OOS results also suggests microbial control was not feeding into release decisions.
Check points
Controls that block shipment before testing and quality approval
Investigation of repeat OOS results and fitness-for-use decisions
Observation detail · 4 observations · From the source
Inspectors: Jeffrey T Prosterman
Observation 1
There is no quality control unit.
Specifically, Your quality control unit has not been effectively carrying out its duties to ensure that drug products are manufactured in accordance with current good manufacturing practices (CGMP). Since January 2025 your firm has released and distributed about batches of (b) (4) , under the following conditions: a. The Quality Control Manager performs and approves all laboratory tests without independent review. The testing and batch release approval executed by the same individual, which represents a lack of segregation of duties in the quality control process. b. Your firm has not qualified or validated its manufacturing equipment, including the (b) (4) system, the blending tank for finished product bulk blend, and the storage tank for product storage and transfer to packaging. c.The labels for the product (b) (4) are not reviewed by Quality Control. There is no inventory of drug labels used in production. Drug labels are used and returned without any type of accountability, documentation or record keeping. There is no oversight for potential discrepancies.
Observation 2
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Observation 3
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
Observation 4
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
Specifically, a. Potency is not performed on the finished product (b) (4) . Potency is performed on the bulk blend before it is transferred into the (b) (4), packaged and distributed. b. Raw materials used in the manufacture of finished product are not tested for identification, and the active ingredient, (b) (4) , is not tested for potency.
[FDA 483 observation · FDA]AstraZeneca AB — Weak foreign particle investigations and CAPA
FDA483
FDA's inspection of AstraZeneca AB (FEI 3003342394), ending 04/10/2026, found that a tablet foreign-particle investigation was closed without confirming the source and was not followed by CAPA or preventive maintenance updates. The Form 483 lists two observations.
Published 2026-10-23 · Inspection date 04/10/2026 · Drug Manufacturer · FEI 3003342394
Key facts · Basis: official index plus supporting sources
Observation 1: QE-239020 foreign-particle investigation closed without determining the source; no CAPA despite a process issue recurring four times
Observation 2: a worn tablet press was named as the cause, but the preventive maintenance program was not updated
Insight · Editorial insight
Closing an investigation without identifying the particle source, and treating an issue seen four times in one batch as minor, suggests that deviation investigations were not reliably linked to CAPA. The finding that the worn tablet press was not addressed in preventive maintenance makes it worth checking whether investigation conclusions actually flow into equipment management.
Check points
Closure criteria for deviations where the contaminant source is unconfirmed
Criteria for opening CAPA on recurring process issues
Whether equipment-related root causes update the preventive maintenance program
Observation detail · 2 observations · From the source
Observation 1
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Specifically, Your firm's CAPA system is not always adequate to ensure deviations have appropriate measures implemented to prevent recurrence. During the manufacturing ofm@ mg tablets, Batch m@ o@ ,QTY:@@ tablets, EXP: m@ , manufactured from m@ through OX) , IN-process appearance testing revealed four tablets containing foreign particulate matter. This was from the inspection ofm@ tablets. Laboratory analysis identified the contaminant as@@ _ _. Quality Event QE-239020 was initiated 16NOV2025, and your investigation attributed the defect to a worn tablet press. However, the preventative maintenance program was not updated to address the equipment wear condition that caused this deviation.
[FDA 483 observation · FDA]GH Genhelix, S.A. — OOS handling and electronic data integrity gaps
FDA483
FDA's inspection of drug substance maker GH Genhelix, S.A. (FEI 3016809519), ending 01/25/2022, produced nine observations, including OOS results invalidated without scientific justification and inadequate review of electronic raw data.
Published 2026-10-23 · Inspection date 01/25/2022 · Drug Substance Manufacturer · FEI 3016809519
Key facts · Basis: official index plus supporting sources
OOS: OOS-20-012 at the 12-month stability time point was invalidated by retesting a backup sample without scientific justification
Data integrity: interrupted injections showing "Data Incomplete" were not reviewed, and there was no procedure to review electronic data on R&D equipment
Insight · Editorial insight
Invalidating an OOS confirmed in the original sample by testing a backup container, while being unaware that interrupted-injection data were retrievable, points to weaknesses in both result handling and data integrity. The observations also cover all master and working cell bank vials stored in one room and unclear antifoam instructions for the production bioreactor, suggesting issues across the quality system and process control.
Check points
Scientific justification required to retest or invalidate OOS results
Scope of review over all electronic raw data, including interrupted injections
Whether cell bank vials are stored in separate locations
Observation detail · 9 observations · From the source
Inspectors: Arsen Karapetyan
Observation 1
Equipment used in the manufacture and processing of a drug substance shall be suitably located to facilitate operations for its intended use.
Specifically, During the inspection, 4) 4)batch @ a for batch § failed to meet the well-controlled critical process parameter (WC-CPP) 9, 4) ofw@ due to the firm not havingo@ units in order to perform the unit operation. The firm opened up deviation 22-016 to investigate the root cause. The deviation investigation is ongoing and the impact on product quality is being assessed.
Observation 2
Material Management is inadequate.
Specifically, the supplier of critical process equipment ®@ that are needed to performo@® essential unit operations, did not deliver the promised number of gy _in your purchase order in December 2021 and missed several agreed upon delivery dates in January 2022 resulting in deviation 22-016.
Observation 3
Written records of investigations into unexplained discrepancies do not always include conclusions and follow-up which are adequately justified.
Observation 4
The responsibilities and procedures applicable to the quality control are not in writing and fully followed.
Specifically, A. Investigations do not always include complete data derived from all tests necessary to assure compliance with established specifications and standards. During review of laboratory data, we observed multiple sequences where interrupted sample injections were injected and showed that the sample did not run, instead showing “Data Incomplete”. Your firm was not aware that data from these injections are retrievable. Samples injected were not documented to be performed, in order to determine whether the samples injected had any discrepancies or appeared to be out of trend. This discrepancy in your firm’s ability to retrieve, review and investigate all electronic raw data is a gap in your Data Integrity system. B. QC Review of chromatographic and non-chromatographic electronic raw data generated by analysts in the QC laboratory is not adequate. QC technicians responsible for electronic data review do no perform a comprehensive review of all potential electronic data generated for all test items in your stand alone and network softwares. C. Your firm has identified Research and Development laboratory stand alone equipment as back-up testing equipment for QC analysts. There
Observation 5
Drug Substance filling is inadequate.
Specifically, we observed drug substance bottles filled at a rate which caused splashing and extensive 4 ») 4) The nature of the®® have not been characterized to date.
Observation 6
havens cleaning is inadequate.
Specifically, a discoloration in the Oa _was observed during the walk through of the downstream operations. The nature of the discoloration is unknown at this time.
Observation 7
Cell Bank Storage is inadequate.
Specifically, all master cell bank and working cell bank vials are located in a single location, room wwe in the manufacturing building.
Observation 8
a) The instructions to add antifoam in the production bioreactor are unclear and open to operator interpretation.
Anti-foam addition has varied gq) across batches in 2021. b) The instructions to sequentially add g) 4 during ow oa are unclear and not specified in the batch record.
Observation 9
Class D area cleaning is inadequate.
Specifically, ag)4 area used to movew@ between®@® in the manufacturing facility had debris on the floor. 4.
[FDA 483 observation · FDA]VitaCare Labs Inc. — Repeat cleaning and validation deficiencies
FDA483
FDA's inspection of contract OTC drug manufacturer VitaCare Labs Inc. (FEI 3008920776), ending 05/16/2025, produced six observations covering process and cleaning validation, equipment cleaning and maintenance, and skipped stability testing, many of them repeats from the 2018 inspection.
Published 2026-10-23 · Inspection date 05/16/2025 · Contract OTC Drug Manufacturer · FEI 3008920776
Key facts · Basis: official index plus supporting sources
Repeat observations: process validation, equipment cleaning, batch records, stability and testing issues recurred from the 10/22/2018-10/26/2018 inspection
Stability: required annual ongoing stability testing omitted for every marketed OTC product since 2023, contrary to VC-SOP-Q-303.2
Insight · Editorial insight
The recurrence of 2018 findings in process validation, equipment cleaning and stability testing suggests that the earlier corrective actions did not take hold. Dead legs, corrosion and leaks on non-dedicated equipment, together with cleaning validation that does not address worst-case conditions, make cross-contamination control at this multi-product contract site worth watching.
Check points
Effectiveness checks on CAPA for prior inspection findings
Rationale for worst-case selection in cleaning validation of non-dedicated equipment
Whether annual ongoing stability testing is performed as the SOP requires
Observation detail · 6 observations · From the source
Inspectors: Hung H Do
Observation 1
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Specifically, This is a REPEAT OBSERVATION from the inspection conducted 10/22/2018 to 10/26/2018. Unqualified and Undefined: When Process Validation Fails to Deliver During a regulatory compliance review of your validation program on 05/13/2025, your Quality Unit provided several process validation (PV) reports for the following OTC m@ drug products: oO While reviewing the reports, several critical quality failures demonstrate the inadequate of your validation program for OTC m@ drugs. Issues identified include
Observation 2
Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent malfunctions and contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically, This is a REPEAT OBSERVATION from the inspection conducted 10/22/2018 to 10/26/2018. Your firm neglected to adequately clean and maintain non-dedicated equipment used for manufacturing over-the-counter a@ drug products. Elevated Risk of Cross-Contamination On 05/12/2025, I conducted an extensive inspection ofyour @@ tank 11 and@w filler m@ equipment previously used by your Production Manager during the cleaning validation of lot m@ for oe on 03/27/2025. Since then, your Production Manager confirmed that these equipment have not been used to make any commercial products. Given the current state of
Observation 3
Batch production and control records do not include complete information relating to the production and control of each batch.
The written stability testing program is not followed.
Specifically, This is a REPEAT VERBAL OBSERVATION from the inspection conducted 10/22/2018 to 10/26/2018. Customer Satisfaction Over Compliance: Stability Testing Vanished Your firm’s stability program (VC-SOP-Q-303.2) states that once long-term data confirms a product’s shelf life, one lot each year is selected for continuous stability testing. Despite this requirement, your Quality Unit prioritized customer satisfaction over fulfilling regulatory compliance, which led to the omission of the required stability testing for every marketed OTC m@ product since 2023. Examples of the commercial batches were reviewed with your quality unit to identify which timepoints your contract laboratory had last completed. OC)
Observation 5
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assure that components conform to appropriate standards of identity, strength, quality and purity.
Observation 6
Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.
Specifically, Your investigations into elevated microbial counts for the »@ samples lacked sufficient root
FDA issued a Form 483 with 3 observations to J Sterling Industries, LLC after an inspection ending 01/08/2026. Cleanroom environmental specifications and monitoring were inadequate, CAPA initiation, root cause investigation and effectiveness checks did not follow procedures, and equipment maintenance schedules and installation did not match manufacturer requirements.
Published 2026-10-23 · Inspection date 01/08/2026 · Manufacturer · FEI 3008879776
Key facts · Basis: official index plus supporting sources
5 of 11 CAPAs reviewed had effectiveness plans without measurable pass/fail criteria
Insight · Editorial insight
Viable contaminant limits lacked justification, and an excursion was not assessed for a product family in the same cleanroom with tighter bioburden limits, which signals environmental limits that are not tied to product requirements. Together with a recurring nonconformance scored as a first occurrence to avoid a CAPA, it is worth checking alert and action limits in shared cleanrooms and how risk scores are assigned.
Check points
Justification of cleanroom microbial limits against the strictest product requirement
Procedural compliance of monitoring locations, including work surfaces and airlocks
Use of recurrence history in risk scoring and measurable CAPA effectiveness criteria
Observation detail · 3 observations · From the source
Inspectors: Suyang Qin
Observation 1
Procedures to control environmental conditions have not been adequately established.
Specifically, e Cleanroom specifications have not been adequately established. For example, e Specification for maximum surface viable or airborne viable contaminants are not adequately established. Per Bioburden Monitoring of Kalamazoo Cleanroom CR006K- WI Rev 01 08/17/2024 page 9 section 8.4.6, a limit ofMMMMMJ CFU is not to be exceeded. However, your firm does not have an adequate justification for the upper limit of CFU. Per Quality Inspection Requirements MN Prod Family QIR ev D 01/07/2025 page 15, each product has a pre-sterilization bioburden alert t ofal CFU and action limit ofWicru. The(b) (4) _ product family is manufactured within the cleanroom. e Specification for minimum positive pressure has not been established in| ontrolled
Observation 2
Procedures for corrective and preventive action have not been adequately established.
Specifically, e Corrective and preventive actions are not initiated in accordance with established procedures. Per 13 Corrective and Preventive Actions Rev 19 08/14/2025, page 4, section 2.2, review of nonconformance records can result in a decision of corrective action required; when the nonconformance evaluation indicates a recurring or systemic issue, a new CAPA will be initiated and linked to the nonconformance. Per 12 Control of Non-conforming product Rev 27 11/07/2025 page 3 section 3.2, a risk assessment to determine the need for generating a corrective action is performed b , then a Corrective Action 1s required.
Observation 3
Schedules for the adjustment, cleaning, and other maintenance ofequipment have not been adequately established.
Specifically, e The preventive maintenance for the equipment is not adequately established. Per Total Preventive Maintenance Form 1154 Rev A 08/16/2023 the sealer has (b) (4) maintenance tasks related to mspections for damage to equipment and equipment cleaning and(b) (4) maintenance tasks of inspections for damage to electrical cables and power adaptors. However, per Owner’s Manual pages 35 — 36, maintenance activities should include checks for the filter /regulator system and draining ofPD water and as well as periodic checks for tightness of screws, nuts and bolts to the sealing chamber, tools, and platens. Your firm does not have adequate rationale for why these preventive maintenance activities were not established in the preventive maintenance schedule for the equipment. e The 2) equipment was not installed in accordance with manufacturer requirements. Per tallation Qualificationi Rev A 06/15/2023 page 1, the equipment is installed with electrical requirements established as(b) (4) VAC, iheBPhase, Ml Amp.
[FDA 483 observation · FDA]Compass Health Brands Corp. — Receiving inspection not per AQL sampling plan
FDA483
During a 02/27/2026 inspection of Compass Health Brands Corp. (manufacturer, repacker/relabeler), FDA issued one observation that activities to ensure purchased product meets specified purchasing requirements were not adequately established and implemented.
Published 2026-10-23 · Inspection date 02/27/2026 · Manufacturer, repacker/relabeler · FEI 3005182235
Key facts · Basis: official index plus supporting sources
Observation: incoming inspections not consistently performed per the AQL sampling plan in procedures #SP-28-01 and #WI-SP-28-01
The observation points to a gap between a documented AQL sampling plan and the sample sizes actually used at receiving inspection. When sampling does not follow the plan, the basis for accepting purchased product is weakened.
Check points
Whether actual receiving sample sizes match the AQL sampling plan
Clarity of procedures on which sampling plan applies to each item
Observation detail · 1 observation · From the source
Inspectors: Laureen M Geniusz
Observation 1
The inspection or other activities necessary for ensuring that purchased product meets specified purchasing requirements were not adequately established and implemented.
Specifically, incoming inspections are not consistently performed in accordance with the established AQL sampling plan, as described in procedures #SP-28-01, "Receiving Inspection", and #WI-SP-28-01, "Inspection and AQL Sampling Plan". For example, * Hydratherm Deluxe: Sampling Plan: a Sample size : were (b)4) sampled (out ofra * O2 Concentrators: Sampling Plan: »« Sample size = aw Sse sampled (out of fois)
[FDA 483 observation · FDA]Sterigenics UK Limited — Chamber nitrogen flow change not validated
FDA483
During a 09/25/2025 inspection of UK contract sterilizer Sterigenics UK Limited, FDA issued three observations covering process validation of a sterilization chamber nitrogen change, CAPA documentation, and management review procedures.
Published 2026-10-23 · Inspection date 09/25/2025 · Contract Sterilizer · FEI 3002807091
Key facts · Basis: official index plus supporting sources
Observation 1: under change request CR.24.S0.027, a Chamber 5 nitrogen flow result of 47.2 mB/min failed and no work was done to rectify it
Observations 2-3: no record that CAPA CA-8134 corrective action 1 was implemented; required managers absent from the 9/27/2024 management review
Insight · Editorial insight
Leaving a failing result unaddressed after a nitrogen system change suggests change control and validation were not linked for a sterilization process that cannot be fully verified by later testing. Combined with an unevidenced CAPA action on aeration room temperature and an incomplete management review, the findings point to loose follow-through across the quality system.
Check points
Handling and re-evaluation of failing validation results after sterilizer changes
Objective evidence that CAPA corrective actions were completed
Whether required attendees are present at management reviews
Observation detail · 3 observations · From the source
Inspectors: Frank J Marciniak
Observation 1
A process whose results cannot be fully verified by subsequent inspection and test has not been adequately validated according to established procedures.
Specifically, change request CR.24.S0.027 was opened to change the nitrogen line and regulator to a PSV and reduce the nitrogen pressure from ~——SSS_—sin thee sterilization chambers. The Chamber 4 CR.24.80.027, Chamber 5 Nitrogen Flow Control document, Section 6.1, Chamber 5 Nitrogen Flow, states " - The calculated pressure change was 47.2 mB/min. which wasa failing result. No work was done to rectify the nitrogen flowrate.
Observation 2
Corrective and preventive action activities and/or results have not been adequately documented.
Specifical corrective action CA-8134, opened due to|- | customer loads impacted as a result of the temperature within the aeration room falling below the minimum temperature for more than 30 minutes. Two root causes have been identified as part of the CAPA Investigation. They are “Equipment” due to the failure of the Air Handling
Observation 3
Procedures for management review have not been adequately established.
Specifically, the Management Review Procedure, STG-WI-1470, Section B, Facility Management Review Meeting states under 2.a, For facility/laboratory management review, facility/laboratory managers/supervisors must be present. The management review conducted 9/27/2024, covering the period from 1/1/2024 through 6/1/2024 only had four people present, the Production Manager, General Manager, EHS Manager, and Laboratory Manager. The QA Manager, Customer Service Manager, and Maintenance Managers were not present.
In an inspection ending 03/06/2026, FDA issued Helios Cardio Inc. a Form 483 with one observation that it did not adequately evaluate and control the contract manufacturer of its CardiaMend device. Accepting the supplier's own internal audit report in place of an audit was not adequately justified.
Published 2026-10-23 · Inspection date 03/06/2026 · Manufactuer · FEI 3020856782
Key facts · Basis: official index plus supporting sources
Observations: one (outsourced processes not adequately monitored and controlled)
Procedure cited: SOP004 "Supplier Management" Section 5.2.9 and Attachment 1
Insight · Editorial insight
The finding that a supplier's self-written internal audit report was accepted as a substitute for an audit, without evaluating performance against the Quality Agreement, signals that paperwork alone may not demonstrate control over contract manufacturing. Because the gap was measured against the firm's own SOP requirements for initial evaluation of a major supplier, firms that rely heavily on contract manufacturers may want to look at how they justify and document audit substitutions.
Check points
Documented justification when a supplier's own audit report replaces an audit
Review of contract manufacturer performance against the Quality Agreement
Execution of SOP-required steps in initial evaluation of major suppliers
Observation detail · 1 observation · From the source
Inspectors: James P Finn
Observation 1
Outsourced processes that affect product conformity to requirements were not adequately monitored and controlled.
Specifically, your firm did not conduct an adequate evaluation of your contract manufacturer for the CardiaMend device to ensure control. The acceptance of the supplier's own internal audit report as a substitute for an audit was not adequately justified, and did not evaluate critical controls such as performance against your established Quality Agreement. Your procedure, SOP004 "Supplier Management," Section 5.2.9 and Attachment 1 requires an ((D) (4) (6) (4)as part of the Initial Evaluation for a Major supplier.
[FDA 483 observation · FDA]Granules Pharmaceuticals Inc. — Stability OOS and unknown impurity not resolved
FDA483
In an inspection ending 04/03/2026, FDA issued Granules Pharmaceuticals Inc. a Form 483 with four observations. They cover recurring stability failures with an uncharacterized unknown impurity, failure to follow the stability program, missing batch record pages and checklists, and poorly maintained HVAC equipment serving storage areas.
Published 2026-10-23 · Inspection date 04/03/2026 · Drug Manufacturer · FEI 3011585184
Key facts · Basis: official index plus supporting sources
Observation 1: a capsule lot showed assay degradation to 89.8% and 88.7% plus unknown impurity OOS; investigations remain incomplete
Observations 2-4: stability testing outside windows, lost batch record pages and pre-start-up checklists, AHU pipe leaks leading to rejection of stored materials
Insight · Editorial insight
Leaving investigations open on recurring stability OOS results without characterizing or toxicologically qualifying the impurity signals that the shelf-life basis of marketed product may be in question. Combined with missed stability testing windows and lost batch records, the findings read more like a weakness in how testing and documentation systems are executed than isolated events.
Check points
Status of structural characterization and toxicological qualification of unknown impurities behind recurring stability OOS
Adherence to stability sample pull and testing windows
Controls preventing loss of issued batch record pages and pre-start-up checklists
Observation detail · 4 observations · From the source
Inspectors: David A Oluwo · Ofuje D Daniyan
Observation 1
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
[FDA 483 observation · FDA]Conroe Welding Supply, Inc — No quality unit and unapproved batch release
FDA483
In an inspection ending 04/03/2026, FDA issued medical gas repacker Conroe Welding Supply, Inc a Form 483 with five observations. The core findings are that the firm effectively had no quality unit or quality management system and released and distributed batches without a documented release approval.
Published 2026-10-23 · Inspection date 04/03/2026 · Medical Gas Repacker · FEI 1625647
Key facts · Basis: official index plus supporting sources
Observation 1: no QA personnel designated; filler, tester and release approver were the same person; no SOPs for training or annual product review
Observations 2-5: source bulk lot numbers not recorded, batches released with blank approver signature, no testing of incoming bulk, no equipment performance program
Insight · Editorial insight
Having one person fill, test and approve release, and distributing lots without an approval signature, signals that independent quality verification was not functioning. The lack of testing on incoming bulk medical gas and unrecorded source lot numbers also weaken the basis for tracing the quality of distributed product.
Check points
Segregation of filling, testing and release approval duties
Quality unit review and signed approval before release
Testing of incoming bulk medical gas and recording of source lot numbers
Observation detail · 5 observations · From the source
Batch production records do not include documentation that each significant step in the packaging of the medical gas was performed.
Specifically, Source bulk() (4) lot numbers were not recorded on batch records dated (b) (4) (lots(b) (4) (lots (b) (4) ), and (b) (4) (lots (b) (4) ). These lots were distributed to customers.
Observation 3
The quality unit failed to review and approve manufacturing production and control records, including those for packaging and labeling, to determine compliance with all established, approved written procedures before batches were released or distributed.
Specifically, The product release approver signature line was blank on batch records dated (b) (4) (lots (b) (4) ), and the batches were released without any documented approval. These lots were distributed to customers.
Observation 4
Your firm failed to perform required tests on bulk medical(b) (4) USP received for production.
Specifically, No testing was performed on any bulk lot of medical (6) (4) USP received from your supplier. Your firm has not established and maintained a program to ensure the reliability of the supplier's capabilities through appropriate assessment and testing procedures.
Observation 5
Your firm failed to establish a written program designed to ensure proper performance of automatic, mechanical, and electronic equipment used to produce medical (b) (4) Specifically, The new (b) (4) equipment (Db) (4) Pumping System) used for production and the (DB) (4) used for testing lack a written program to ensure proper performance and maintenance.
Your firm uses this equipment to fill and test medical () (4)gas distributed to customers. Tenothy HVo » 4 Bae Sigted: 04 022026 11:02:21
[FDA 483 observation · FDA]GOJO Industries LLC — Sampling plan and returned product controls
FDA483
FDA's inspection of GOJO Industries LLC, ending 04/09/2026, resulted in three observations: sampling plans for bulk and in-process material lacking scientific justification, returned drug products restocked without testing or storage-condition review, and inadequate dispensing room cleaning procedures.
Published 2026-10-23 · Inspection date 04/09/2026 · Manufactuer · FEI 1519176
Key facts · Basis: official index plus supporting sources
Obs. 1: bulk tanks sampled at limited locations, and in-process sampling frequency does not consider batch size, without scientific justification
Obs. 2-3: returned products released back to inventory without testing or storage verification; white powder residue seen in a dispensing bay
Insight · Editorial insight
Fixed sampling locations and frequencies that ignore batch size appear unable to represent content uniformity, signaling that investigators expect a scientific basis for sampling plans. Restocking returns without verifying storage conditions and lacking cleaning instructions between API dispensing activities are also worth reviewing together as return-handling and cross-contamination controls.
Check points
Scientific basis for sampling plans reflecting batch size and tank location
Storage-condition verification and testing before restocking returns
Cleaning and documentation requirements at product changeover in multi-product dispensing rooms
Observation detail · 3 observations · From the source
Inspectors: Anna M Spiros
Observation 1
Laboratory controls do not include the establishment of scientifically sound and appropriate sampling plans designed to assure that in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity.
Drug products are not stored under appropriate conditions of temperature, humidity and light so that their identity, strength, quality, and purity are not affected.
Equipment and utensils are not cleaned at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically, your firm’s procedure for cleaning the dispensing rooms is inadequate. This procedure, WIS-OPM-1029, Dispensing and Mix General Housekeeping and Sanitation, 1/31/2025, revision 11, does not require documentation when dispensing activities occur where multiple APIs and excipients are portioned out for manufacturing drug product purposes, i.e. (b) (4) and (b) (4) (b) (4) Additionally, your firm’s procedure, does not provide cleaning instructions to ensure no cross contamination among products, such as when an API is dispensed on the same day that another API or excipient is dispensed. The current procedure only requires cleaning to be performed (b) (4) . On 01/06/2026 dispensing bay __ was observed with remains of apparent white powder residue on the walls, floor, and on the dust snorkel which sits above the product being weighed out. This practice could lead to cross contamination of drug products.
[FDA 483 observation · FDA]Lantheus Medical Imaging, Inc. — Release of lots exceeding visual inspection limits
FDA483
FDA's inspection of Lantheus Medical Imaging, Inc., ending 04/09/2026, resulted in seven observations, including release of a lot whose visual inspection defect rates exceeded action levels, failure to evaluate CMO rejects, unjustified raw material sampling, administrator access on particulate counters, and weak labeling access control.
Published 2026-10-23 · Inspection date 04/09/2026 · Manufacturer · FEI 1216602
Key facts · Basis: official index plus supporting sources
Obs. 1-2: a lot exceeding action levels in all defect categories was released, and CMO-removed rejects were not evaluated against the firm's own limits
Obs. 6: manufacturing operators hold administrator privileges, including data deletion and date/time modification, on particulate counters used for environmental monitoring
Insight · Editorial insight
Releasing a lot over action levels because defects were removed and tightened AQL was passed appears to be cited for not investigating the high defect rate itself as a process signal. Differing CMO and in-house visual inspection criteria that kept CMO-stage rejects out of the firm's assessment are a signal to revisit how defect data is shared under quality agreements.
Check points
Root cause investigation and other-lot impact criteria when visual inspection action levels are exceeded
Whether CMO visual inspection rejects are aggregated against in-house limits
User privilege segregation on environmental monitoring instruments
Observation detail · 7 observations · From the source
Inspectors: Daniel L Zheng · Lori M Newman
Observation 1
There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Observation 3
Component testing is deficient in that each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality.
Specifically, A.Your firm lacks scientific justification for your sampling specification for release testing of incoming raw material (b) (4) . Your firm samples in accordance with the (b) (4) raw material specification, which requires Identification (DB) (4) content) and Assay testing to be performed on (b) (4) of each received lot regardless of the size of the received lot. Your firm lacks data to demonstrate that(b) (4) would be representative of a lot, and your (b) (4) raw material specification fails to meet your procedural requirement on the number of containers necessary to be representative of a lot. Your firm uses (b) (4) as an excipient for production of all lots of drug product (b) (4). For example, for (b) (4) lot (b) (4), your firm received (b) (4) bottles of(b) (4) and sampled (b) (4) to : : (o) (4) . perform Identification and Assay testing. Your firm used (BD) (4) loi(b) (4) to manufacture (b) (4) lot(b) (4). expiry(b) (4) —_, which your quality unit released for distribution on 12/17/2025. Your firm received approximately ots of(b) (4) in 2024-2025.
Observation 4
Laboratory controls do not include the establishment of scientifically sound and appropriate sampling plans and test procedures designed to assure that components and drug product containers conform to appropriate standards of identity, strength, quality and purity.
Strict control is not exercised over labeling issued for use in drug product labeling operations.
Specifically, A. Cartons bearing lot numbers and expiry dates for drug product (1) (4) are staged in cages without locks in an unsecured area of the controlled room temperature (CRT) warehouse, designated Room (b) (4), for extended periods during the packaging process. For example, on 3/18/2026, I observed cartons bearing lot number (BD) (4) in an unlocked cage in an unsecured area of Room (Db) (4). Status documentation on the cage indicated that cartons had been moved to that location on 2/27/2026. Personnel from your operations, manufacturing, aa packaging, supply chain, facilities, engineering, validation, quality control, and metrology departments have access to warehouse (1) (4).
Observation 6
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
Specifically, manufacturing operators have access to administrator privileges, including data deletion and date/time modification, on your firm’s(D) (4) particulate counters. Your firm uses the particulate counters to perform nonviable particulate sampling in your environmental monitoring program.
Observation 7
Access to the storage area for labels and labeling materials is not limited to authorized personnel.
Specifically, A. Your firm stores vial labels for drug product (b) (4) in a badge-access cage, designated Room (6) (4) jocated in the rear of the controlled room temperature (CRT) warehouse. Personnel from your operations, manufacturing, kit packaging, supply chain, facilities, engineering, validation, quality control, and metrology departments have access to this label cage. B. Your firm stores product package inserts for drug product (1b) (4) in the (b) (4) CRT warehouse, designated Room (6) (4) and(b) A), outside of the label cage. Personnel from your operations, manufacturing, kit packaging, supply chain, facilities, engineering, validation, quality control, and metrology departments have access to this warehouse.
[FDA 483 observation · FDA]Kaysersberg Pharmaceuticals SAS — Aseptic EM gaps and OOS investigation failures
FDA483
FDA's inspection of Kaysersberg Pharmaceuticals SAS, ending 07/19/2016, resulted in eight observations, including no root cause for batches failing environmental viable air limits, acceptance of microbial OOS retest results, and no routine monitoring of Grade A aseptic filling areas.
Published 2026-10-23 · Inspection date 07/19/2016 · Drug Manufacturer · FEI 3002806288
Key facts · Basis: official index plus supporting sources
Obs. 1: two batches failing viable air limits were released to the US market without root cause or CAPA, and microbial OOS results were replaced by resampling without scientific basis
Obs. 2: viable air and particulate monitoring is not routinely performed in Grade A areas used for aseptic filling
Insight · Editorial insight
Procedures requiring two environmental failures before quarantine and allowing only passing retest values to be reported signal that the procedure design itself enabled OOS invalidation, not just individual decisions. The lack of routine Grade A checks on aseptic fillers and sanitization contact times that diverge from the disinfectant efficacy report are worth reviewing together as the basis for aseptic environmental control.
Check points
Batch quarantine and release criteria after environmental monitoring failures
Scientific basis required before accepting microbial OOS resample or retest results
Grade A viable and particulate monitoring schedule for each aseptic filling machine
Observation detail · 8 observations · From the source
Inspectors: Michael A Charles
Observation 1
Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.
Written procedures for cleaning and maintenance fail to include description in sufficient detail of methods, equipment and materials used and parameters relevant to the operation.
Routine calibration of mechanical equipment is not performed according to a written program designed to assure proper performance.
Calibration of O@ speeds (rpm) for processing tanks used to make) is not always conducted following a scheduled program, such as for theo # 3, C 40, and C 26 tanks.
Observation 6
Written production and process control procedures are not documented at the time of performance.
Although ®@ 9 times are documented during the manufacturing of , na) speeds for formulation, which are critical process parameters, are not recorded in batch records during production.
Observation 7
Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in- process material and the drug product.
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that in-process materials conform to appropriate standards of identity, strength, quality and purity.
FDA issued a 483 with four observations to API manufacturer ChemPacific Corporation after an inspection ending 04/07/2026, covering data integrity lapses such as undocumented HPLC injections and no manual integration procedure, no ongoing stability program, poor material storage and identification, and facility disrepair.
Published 2026-10-23 · Inspection date 04/07/2026 · API Manufacture · FEI 3003299802
Key facts · Basis: official index plus supporting sources
Firm: ChemPacific Corporation (FEI 3003299802), API manufacture
Observation 1: 35 undocumented HPLC sample injections on GMP materials between April 2023 and December 2024, no written procedure for manual integration, and batch record checker signatures not entered contemporaneously
Observations 2 to 4: released API batches not placed on stability, failed R&D intermediate stored in a freezer with GMP intermediates, and damaged ceiling with a water leak left unrepaired in a raw material quarantine room
Insight · Editorial insight
Injecting GMP samples under a non-GMP project name without records, a practice also seen on other lab instruments, is a data integrity signal that can call the completeness of the site's test data into question. Combined with the missing stability program and mixed storage of materials, the findings read as a broad quality system gap that customers sourcing this API may want to weigh in supplier qualification.
Check points
Reconciliation of full chromatography injection history against test records
Whether a procedure defines when and how manual integration is allowed
Whether released API batches are enrolled in ongoing stability testing
Observation detail · 4 observations · From the source
Inspectors: Yaharn Su
Observation 1
The firm failed to maintain adequate quality control systems, including data integrity controls and procedural oversight, Specifically, a.
Your firm failed to ensure that laboratory records include complete data derived from all tests conducted on GMP materials and failed to maintain adequate documentation of laboratory testing activities. Review ofHPLC sample injection testing data from instruments (b)(4) and) (b)(4) (software:| (b)(4) ) revealed that analysts performed 35 undocumented HPLC sample injections on GMP materials under the non-GMP testing project name "test" and the GMP testing project name (b)(4) between April 2023and December 2024. Both instruments are used for testing GMP and non-GMP samples. This practice is also performed on the firm’s other laboratory equipment: GC, IR/UV, and (b)(4) For example, analysts conducted sample testing without recording the activities in laboratory logbooks and analyst notebooks. The undocumented analyses fall into the following categories with the reasoning behind each injection
Observation 2
The firm failed to have an ongoing testing program designed to monitor the stability characteristics of active pharmaceutical ingredients.
Specifically, Your firm has not performed an ongoing stability testing program that is established to monitor the stability characteristics ofAPI (b)(4) to establish or verify retest dates. For example: Your firm manufactured (b)(4) batches ofAPI (b)(4) in (b)(4) (batches (b)(4) ). Although these batches have been tested and approved for release, they have not been placed on stability studies.
Observation 3
Materials are not handled and stored in a manner to prevent contamination and ensure proper identification.
Additionally, there is inadequate separation between materials of different statuses. Specifically, Your firm does not have material log-in records for your refrigerators and freezers used to store critical production materials. On March 30, 2026, during a facility walkthrough, it was observed that the firm stores intermediates in refrigerators (b)(4) and freezers (b)(4) but could not demonstrate adequate knowledge ofthe materials stored in specific units. For example, an unidentified bag of failed research and development intermediate IM-(6)(4) was found in Freezer /)(6)(4)), which is also used to store GMP intermediates for (b)(4) production. The firm was unable to explain the reason for storing this material in the freezer or the duration of storage. The presence ofthis unidentified, failed research and development material in the same storage unit as approved GMP intermediates creates a risk of cross-contamination or mix-up between rejected materials and materials intended for use in drug product manufacturing.
Observation 4
Buildings used in the manufacture, processing, packing, or holding of intermediates and API are not maintained in a good state of repair and kept in a clean condition.
Specifically, Your firm has not maintained facility ceilings in critical GMP areas in a good state of repair. For example, during a facility walkthrough on 03/30/2026, it was observed that Room (M4), designated as "GMP Raw Material (Quarantine)," had damaged and discolored ceiling tiles above the sampling area. The ceiling tiles showed discolored stain marks and a crack approximately two feet long. Your QA staff observed a water leak in this room
[FDA 483 observation · FDA]FRUEH VERPACKUNGSTECHNIK AG — No cleaning validation; weak QU oversight
FDA483
FDA issued six inspectional observations to Swiss packager FRUEH VERPACKUNGSTECHNIK AG after an inspection dated 03/24/2023. They include no cleaning validation or disinfectant efficacy studies and weak quality unit control over batch record issuance and electronic data review.
Published 2026-10-23 · Inspection date 03/24/2023 · Drug Product Packager, Medical Device Packager · FEI 3010363503
Key facts · Basis: official index plus supporting sources
Observations: six (cleaning validation, supplier bioburden requirements, batch records, quality unit, incoming lot identification, sterilization process validation)
Insight · Editorial insight
The finding that no cleaning validation or disinfectant efficacy studies existed for packaging equipment and rooms signals that FDA treats packaging as a cross-contamination control point. Batch record issuance and electronic data review gaps cited together suggest the quality unit's oversight system as a whole was in question.
Check points
Cleaning validation and disinfectant efficacy studies for packaging equipment and rooms
Page-level control of issued batch records and master batch record management
Bioburden requirements in component specifications and supplier certificates
Observation detail · 6 observations · From the source
Inspectors: Stephen D. Eich
Observation 1
Procedures for the cleaning and maintenance of equipment are deficient regarding the protection of clean equipment from contamination prior to use.
Specifically, your firm has not performed any cleaning validation studies to assess the effectiveness of your cleaning procedures for equipment and rooms used in the packaging operations for| wu woe drug products. Additionally, no disinfectant efficacy studies have been conducted to ensure the effectiveness of your disinfectants used during cleaning operations.
Observation 2
Requirements that must be met by suppliers have not been adequately established.
Specifically, = ws components off am -__\drug product are not adequately controlled for bioburden levels. Specifications for ii | ww do not include a bioburden requirement and incoming certificates of conformity do not certify that components meet a bioburden requirement.
Observation 3
The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing, processing, and packing.
Observation 4
The responsibilities and procedures applicable to the quality unit are not in writing and fully followed.
Specifically Supervisory oversight over quality/production unit operations and laboratory/production electronic system and data is deficient. For Example A. The Quality Unit lacks adequate control over the issuance of production batch records purported to be controlled under your batch issuance procedures. During the inspection, it was observed that copies ofofficial batch records for dru uctsPe | | tae ithout adequately controlling each page. For example, (b)(4) B. There are no requirements for the Quality Unit oversight of Master Batch Record storage and copying for use in manufacturing to ensure executed record instructions are accurate reproductions of the master records. Your firm does not maintain adequate master batch records for the above- mentioned drug products. During the inspection, we observed at least two recent deviations where incorrect batch record documents were issued and used by the production unit. C. Your firm does not have adequate Quality Unit oversight of visual inspection qualification test kits and the qualification process for operators performing vi i i ations during packaging of drug products wi For example, per = firm’s procedure, th (b)(4) SEE
Observation 5
Each lot in shipment received was not identified with a distinctive code for each container or grouping of containers for components, Specifically, The firm does not assign unique lot number for each lot in each shipment received for all drug components.
Currently, the firmusesthe[ws MEDICAL DEVICE
Observation 6
A process whose results cannot be fully verified by subsequent inspection and test has not been adequately validated.
[FDA 483 observation · FDA]Linde Gas & Equipment Inc. — Inadequate APR; no stability program
FDA483
FDA issued two inspectional observations to medical gas manufacturer and repackager Linde Gas & Equipment Inc. after an inspection dated 04/01/2026. Product-specific annual product reviews were inadequate and no stability testing program was established for USP grade Air and other products.
Published 2026-10-23 · Inspection date 04/01/2026 · Medical Gas Manufacturer and Repackager · FEI 2523408
Key facts · Basis: official index plus supporting sources
Observations: two (inadequate annual product reviews, no stability program for USP grade Air and others)
Insight · Editorial insight
The finding that the annual review procedure lacked requirements for evaluating batch records, test results and stability data, and that the 2023 - 2025 reviews omitted OOS investigations, process capability trends and change controls, signals that product-level trend evaluation was largely a formality. Lots released since 12/01/2025 without stability studies are a reminder that medical gases are held to drug stability expectations.
Check points
Product-specific evaluation of batch records, test results and stability data in annual reviews
Inclusion of OOS investigations, process capability trends and change controls in annual reviews
A written stability testing program for each medical gas product
Observation detail · 2 observations · From the source
Inspectors: Luxuly Abraham
Observation 1
he firm failed to conduct thorough and adequate annual product reviews.
Specifically, our document PD.OPS-0026, Revision 7, Internal Quality System Assessments and Product reviews, effective /2/2026, does not include specific requirements for conducting product-specific reviews ofmedical gases, including evaluation of batch records, testing results and stability data. Additionally, the 2023 - 2025 Quality Management reviews lacked Out-of-specification (OOS) investigations, process capability trends and change controls made during he review period for each specific product.
Observation 2
here is no written testing program designed to assess the stability characteristic of USP grade Air, (b) (4) and (b) (4) Specifically, ‘Your firm has not established a stability program, nor have you performed stability studies to assess the stability characteristics of USP grade Air: (b) (4) as well as (b) (4) .
[Guidance · FDA]Hazard Analysis and Risk-Based Preventive Controls for Human… — New human food preventive controls draft chapter
FDAGuidance
FDA announced in the Federal Register the availability of one more draft chapter of its multichapter draft guidance on hazard analysis and risk-based preventive controls for human food.
Published 2026-10-23 · Document no. 2026-21669 · Issuing authority FDA · Topic Hazard Analysis and Risk-Based Preventive Controls for Human Food; Draft Guidanc…
Original text and translation
The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of one additional draft chapter of a multichapter draft guidance for industry titled "Hazard Analysis and Risk-Based Preventive Controls for Human Food.
Key facts · Basis: official source record kept by the collector
Publication date: 2026-10-23
Nature: one additional draft chapter of a multichapter draft guidance
Insight · Editorial insight
The notice reads as part of FDA's chapter-by-chapter build-out of its preventive controls guidance for human food. The new chapter's specific topic needs to be confirmed against the source, and sites handling both food and drug products may want to compare its hazard analysis approach with their own quality risk management.
Check points
Topic and scope of the newly released draft chapter
Whether any site or product falls under human food rules
[FDA 483 observation · FDA]Unilab Chemicals and Pharmaceuticals Private Ltd. — Unverified supplier COAs and record-keeping lapses
FDA483
FDA issued a 483 with five observations to Indian API manufacturer Unilab Chemicals and Pharmaceuticals Private Ltd. after an inspection ending 02/27/2026. Findings cover unverified supplier COAs for non-USP solvents, uninvestigated equipment breakdowns, pre-filled and shredded quality records, and visible residue after cleaning, flagged as a repeat observation.
Published 2026-10-22 · Inspection date 02/27/2026 · API Manufacturer · FEI 3004985767
Key facts · Basis: official index plus supporting sources
Observations: five (supplier COA reliability, uninvestigated discrepancies, QC records, GMP training, equipment cleaning)
The cleaning residue finding is marked as a repeat observation
Insight · Editorial insight
Beyond unverified supplier COAs, the 483 cites pre-filled logbooks, signatures by people who did not do the work, and shredded GMP data, which puts overall record reliability in question. Residue after documented cleaning being a repeat observation suggests earlier corrections did not hold, so buyers of this firm's APIs may want to reassess supply risk.
Check points
Supplier qualification, quality agreements and COA verification for non-USP solvents and other materials
Deviation handling and batch impact assessment for equipment breakdowns
Controls against pre-filled logbooks and proxy signatures
Observation detail · 5 observations · From the source
Inspectors: Guerlain Ulysse
Observation 1
There is a failure to establish the reliability of the component supplier's report of analyses.
Specifically, A) There is no supplier qualification or quality agreement established for the following non-USP solvents used for manufacturing APIs: B) Certificate ofAnalysis (COA) test results provided by the supplier of non-USP solvents have not been validated. This includes the lack of verification for Identity test results, jg -—«Limit test results, wwLimit test results, Residue on Evaporation test results, pH test results, Solvent Acidity test results, Denaturant Level test results, and/or Impurity test results. In addition, the non-USP in-house test method used for Gas Chromatography (GC) purity testing has not been validated. According to the QA Manager, the test parameters for the in-house methods were solely determined based on the firm's laboratory capability.
Observation 2
There is a failure to thoroughly review any unexplained discrepancy whether or not the API batch has already been distributed.
A) According to the QA Manager, there have been no deviations or non-conformances reported since the previous 2019 inspection. However, the following equipment breakdowns recorded in the Breakdown Maintenance Record Logbook, Format No.: UNI/MAIN/006 and 2024-2025 CAPA logs did not include thorough investigation of the API equipment breakdown incident (e.g., during which stage in activities), root cause analysis and product quality impact details on distributed API batches: Machine/Equipment Breakdown Restart Date Root Cause Corrective Action No./Plant Location | Date ae Jan 06, 2025 Jan 06, 2025 | (yy New J) Fitting | Leakage Problem for Work Completed a em. oO Dec 01, 2024 Dec 01, 2024 an Vessel om New valve fitted in | | eae Valve Leakage Ayn
Observation 3
The responsibilities and procedures applicable to the quality control unit are not in writing or fully followed.
Specifically, The following deficiencies were observed during my inspectional walkthrough of the Quality Assurance (QA) area on February 23, 2026: A. 2025 Quality Control API test results (e.g. pH and Assay test results) were observed to be documented on loose uncontrolled template paper for commercial API batches. According to the Production Manager, this document template is no longer in use as of 2026 and all the remaining uncontrolled documents previously filled with similar GMP data have already been shredded. There is no record of which GMP documents have been previously shredded in 2025 and the , years prior. B. The Microbiology Department's Cleaning Record of Equipment Log No. F/MIC/008 was pre- dated with equipment cleaning (Frequency: g@ _) already completed on g ; which is & @ since the last equipment cleaning documented for completion on poe The logbook entry pre-dated for g4 also included Done By, Checked By, and Reviewed By signatures that were already filled in as ofa C. According to the QA Manager, the Done By signature in Cleaning Record of Equipments Logbook is not signed by the actual person doing the work (Production Worker) due to English language barrier. The
Observation 4
GMP training is not conducted with sufficient frequency to assure that employees remain familiar with cGMP requirements applicable to them.
Specifically, There is no documented GMP training (e.g. on Good Documentation Practices) and training on standard operating procedures applicable to the job functions of the Quality Control (QC) Lab Assistant, who is routinely involved with QC sampling activities and functions involving QC instrument cleaning and equipment upkeep. There is also a lack GMP and SOP training for the Production Worker responsible for routinely cleaning microbiology and QC laboratory equipment. Guerlain Ulysse
Observation 5
There is a failure to clean equipment and utensils to prevent contamination or carry-over of a material that would alter the quality of the API beyond the official or other established specifications.
Specifically, There are no standard operating procedures or established instructions to perform and document a visual inspection of equipment subsequent to cleaning operations. For example: During my walkthrough of the Bulk Drug (API) Manufacturing Area on February 23, 2026, I observed that thes, ofBi UNI)@ 06 had visible g)4) | residue product material all throughout the surfaces and gq gasket area. This is despite full equipment cleaning documented as already being completed on February 16, 2026. . ***This is a Repeat Observation***
[FDA 483 observation · FDA]Saptalis Pharmaceuticals LLC — No life-cycle control for filling transfer hoses
FDA483
FDA issued a 483 with one observation to US drug product manufacturer Saptalis Pharmaceuticals LLC after an inspection ending 03/06/2026. Transfer hoses that move bulk drug product to filling lines were cleaned and reused without a replacement interval or life-cycle management program.
Published 2026-10-22 · Inspection date 03/06/2026 · Drug Product Manufacturer · FEI 3012152381
Key facts · Basis: official index plus supporting sources
Observations: one (equipment design, cleaning and maintenance, transfer hoses)
Not done: hose leachable and material compatibility studies, and written limits on number or duration of uses
Insight · Editorial insight
Transfer hoses touch liquid product directly, so reusing them without leachable or compatibility data or use limits can generally be associated with leachable migration or cleaning carry-over. Although there is only one observation, it spans the filling of several solution and suspension products, which makes it a useful prompt to review life-cycle control of product-contact consumables.
Check points
Leachable and material compatibility assessment of product-contact hoses and tubing
Written limits on the maximum number of uses or duration of use for hoses
Replacement interval and life-cycle records for reused hoses
Observation detail · 1 observation · From the source
Inspectors: Emmanuel T Donyina · Alice S Tsao
Observation 1
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design, of adequate size and suitably located to facilitate operations for its intended use and cleaning and maintenance.
[FDA 483 observation · FDA]The Mentholatum Company — Weak OOS probes and specs widened after failures
FDA483
FDA issued a 483 with four observations to The Mentholatum Company after an inspection ending 03/23/2026. It cites inadequate OOS root-cause investigations and release on retest results, specification changes made to accommodate OOS results without rationale, unrecorded volumes in lab records, and annual product reviews that missed trends.
Published 2026-10-22 · Inspection date 03/23/2026 · Manufacturer · FEI 3000717606
Key facts · Basis: official index plus supporting sources
At least 25 OOS investigations in the last 3 years closed with only "possible" root causes
Insight · Editorial insight
Replacing OOS results with retests and widening specifications to fit failing results points to a 483 centered on the scientific basis for OOS invalidation and specification control. Repeated OOS results on the same tests that the annual product review did not flag suggest investigations, CAPA and annual review are not connected.
Check points
Justification for invalidating initial OOS results and releasing on retests
Change control and scientific rationale for specification changes made after OOS results
Whether annual product reviews trend OOS results and deviations and link them to CAPA
Observation detail · 4 observations · From the source
Inspectors: Lauren H Augustyniak
Observation 1
There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically, A.Your firm's OOS investigation practices do not conduct a thorough investigation to determine root causes, leading to repeated failures including out-of-specification results for active pharmaceutical ingredients and content uniformity. Currently you are releasing product despite specification failures based on retest results without proper investigation or justification to invalidate the initial OOS failures. Review of your OOS investigation log from the last 3 years revealed at least 25 investigations concluding with "possible" root causes without definitive determination. Examples include: 1.00S-946-QC concluding "possible root cause may have been sample preparation error" with no verification 2.00S-0019-QC concluding "Possible root cause may have been incorrect (b) (4) ” 3.00S-0022-QC concluding "Possible root cause may have been standard preparation". Additionally, at least 6 investigations (OOS-003 1-QC, OOS-0049-QC, OOS-0051-QC, OOS-0067-QC, OOS- 0069-QC, OOS-0107-QC) conclude "Possible root cause could be the age of the material" without assessing potential supplier or storage issues. B.Your OOS files from 2023-2026 revealed investigation root causes without
Observation 2
Laboratory records do not include the quantity of the sample.
Specifically, During live evaluation of raw material release testing of (b) (4) (Batch # (6) (4) _—+) performed on 3/19/2026, your analyst was observed performing method Q-1045, (b) (4) Assay determination by Gas Chromotography, Version 1.0, Effective Date: 5/18/2022. The analyst was observed: 1.Weighing USP Reference Standard material with weights recorded it Notebook Number 861, Page 51 (weight (b) (4) . weight (b) (4) ) 2.(b) (4) volumetric flask 3.Assuming (b) (4) volume without measuring or recording the actual volume added 4.Entering the unconfirmed concentration of(b) (4) _ into the GC software without written verification of calculations The test method requires to "accurately weigh standard known sample to (b) (4) _" which necessitates precise measurement and documentation of both weight and volume to calculate concentration. However, no written calculation was recorded to confirm the known standard solution concentration ((b) (4) __) prior to entry into the GC system. When questioned, the analyst stated: "J always add exactly (b) (4).” Additionally, historical data review of the analysts Laboratory notebook and raw data from the same method performed by the same analyst o
Observation 3
Determinations of conformance to appropriate written specifications for acceptance are deficient for drug products.
Specifically, Your firm changed batch release specifications in response to out-of-specification (OOS) results without providing adequate scientific rationale, and without following formal change control procedures. Review of the OOS log identified at least specification changes made in response to OOS results over 3 years (OOS-0002, OOS-0005-QC, OOS-0009-QC, OOS-0021-QC, OOS-0024-QC, OOS-0030-QC, OOS-0041-QC, OOS-0053-QC, OOS-0055-QC, OOS-0080-QC) allowing substandard batches to be released to the market. For example: A. OOS-0021-QC - (b) (4) , Lot (6) (4)- Deficiencies in OOS-0021-QC Investigation: Your firm explicitly states "”o root causefor the high (b) (4) values has been determined" yet proceeded to change the specification and release the batch. However, the specification was widened from (b) (4) % to (b) (4) % specifically to accommodate the 107.3% failing result. No scientific rationale was provided for why®% (b) (4) is acceptable when % was previously the upper limit, or what quality attributes are affected by higher (b) (4) levels. The investigation committed to "review ofstability data providing proofthat the (b) (4) analysis is stable throughout the expiry" yet the ba
Observation 4
Records are not maintained so that data therein can be reviewed at least annually to evaluate the quality standards of each drug product to determine the need for changes in specifications or manufacturing or control procedures.
[FDA 483 observation · FDA]Fougera Pharmaceuticals, LLC. — Weak controls on shared and campaign-use hoses
FDA483
FDA issued a one-observation Form 483 to Fougera Pharmaceuticals, LLC. after an inspection of its non-sterile manufacturing site ending 03/26/2026. Investigators found the firm lacked adequate data and procedures to support hoses that are not product-dedicated or are used across multi-day campaigns.
Published 2026-10-22 · Inspection date 03/26/2026 · Non- Sterile Manufacturer · FEI 2410271
Key facts · Basis: official index plus supporting sources
Observation: equipment and utensils not maintained at appropriate intervals to prevent contamination
Detail: manufacturing hoses are shared across multiple products; filling hoses are product-dedicated but used through campaign runs
Insight · Editorial insight
The observation signals that FDA expects data-backed cleaning effectiveness and use-duration limits even for simple components such as transfer hoses at non-sterile sites. Firms may want to confirm that shared and campaign-use hoses are explicitly covered by their cleaning validation and cross-contamination controls.
Check points
Cleaning validation data for hoses shared between products
Justification for maximum campaign use duration of hoses
Documented procedures for dedicated versus shared hose use
Observation detail · 1 observation · From the source
Inspectors: Syeda N Mahazabin · Divek R Jumani
Observation 1
Equipment and utensils are not maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically, Your firm failed to have adequate data and procedures to support the use of hoses that are not product dedicated or used in multi-day campaign during manufacturing and filling operations of your drug products: ||(b) (4) hoses used during manufacturing are not product-dedicated and are used interchangeably across multiple products. (b) (4) hoses used during filling operations are product-dedicated but are used during campaign runs lasting up to (b) (4) . ((b) (4) hoses used during filling operations are (6) (4) use but are used throughout campaign runs lasting up to (b) (4) .
[FDA 483 observation · FDA]Newton Laboratories, Inc. — Stability gap after container closure change
FDA483
FDA issued a three-observation Form 483 to Newton Laboratories, Inc. after inspecting its homeopathic drug manufacturing site, ending 03/26/2026. The firm placed no stability samples on study since a February 2021 cap change, did not investigate 194 leaking-bottle complaints, and had not qualified its container closure integrity.
Published 2026-10-22 · Inspection date 03/26/2026 · Homeopathic Drug Manufacturer · FEI 1051203
Key facts · Basis: official index plus supporting sources
Stability: no samples placed on stability since the February 2021 cap change (Change Control CCLN-2101-1), a five-year gap
Complaints: 194 leaking-bottle complaints in 2023-2025 across at least 15 batches, rising 140% from 37 to 89 between 2023 and 2024, with no investigation
Insight · Editorial insight
Rising leak complaints after a cap change with no stability data, handled only by replacing units, show change control, complaint handling and container integrity failing to connect. Firms may want to check that closure changes trigger renewed stability testing and container closure integrity assessment before approval.
Check points
Resumption of stability testing after container closure changes
Trend analysis of recurring complaints linked to root cause investigation
Container closure integrity qualification status
Observation detail · 3 observations · From the source
Inspectors: Martin M Kimani · John D Mcintosh
Observation 1
The written stability testing program is not followed.
Specifically, your firm has failed to establish and maintain an adequate stability testing program for all of your finished homeopathic drug products, as required by your Stability Standard Operating Procedure NLQA-057 “Stability Testing - Test-Sample Submission” rev 4 effective 5/15/2025, which requires submission of homeopathic drug products for (b) (4) and real time stability studies for(b) (4) =. The following identified issues state specific deficiencies: ‘1You have not placed any stability samples into the stability program since February 2021, following the implementation of Change Control CCLN-2101-1_(b) (4) Caps which changed the container closure system from a (b) (4) cap to a (6)(4) cap for your liquid formulations. This represents a five-year gap in stability testing for products with a modified container closure system. ‘|You have not generated any stability data for any of your pellet finished products intended for vulnerable populations, such as: (b) (4) (mfg #(6) (4) _, Lot #s (1) (4) ) (b) (4) (mfg #(b) (4) _, Lot #s(b) (4) ) o(b) (4) = (mfg # (6) (4), Lot #s (b) (4) ) ‘|Between February 2021 to March 2026, your firm manufactured a total of (b) (4) batches across y
Observation 2
Complaint procedures are deficient in that they do not include provisions that allow for the review and determination of an investigation by the quality control unit.
Specifically, your firm's complaint handling Standard Operating Procedures SOP NLQA-005 “Product-Customer Complaints” Rev 4 effective 04/01/2025 and SOP NLQA-006_ “Product Complaint Investigation” Rev 4 effective 04/01/2025 lacks sufficient detail regarding investigation requirements, root cause analysis procedures, trending analysis, and corrective and preventive action (CAPA) implementation for product quality complaints. For example, Between 2023 and 2025, the firm received 194 complaints regarding leaking bottles affecting at least 15 different batches, including but not limited to (b) (4) (Batch Record# (b) (4) ) and (b) (4) (Batch Record# (b) (4) ). Leaking/seal complaints increased from 37 in 2023 to 89 in 2024, representing a 140% increase, before decreasing to 68 in 2025. This trend was observable, yet the firm took no investigative action. The firm's response to the leaking bottle complaints consisted solely of replacing the affected product units for consumers without: investigating the underlying cause(s) of the container closure failures, evaluating the impact on affected batch(es) (b) (4) (Batch Record# (6) (4) ) and (b) (4) (Batch Record# (b) (4) ), assessing whether
Observation 3
Container closure systems do not provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product.
Specifically, your firm has not conducted container closure integrity qualification or validation studies to demonstrate that the (®)@) bottles with (6)(4) caps adequately protect against contamination, evaporation, or leakage throughout the product shelf life. This applies to all your manufactured homeopathic drugs, including but not limited to (b) (4) (Batch# (b) (4) ), (B) (4) (Batch Record# (b) (4) _), and (b) (4) (Batch Record# (b) (4) ). This deficiency is particularly concerning given the 194 leaking bottle complaints received between 2023 and 2025 (see Observation [2]) and the absence of stability data for products with this closure system since its implementation in February 2021 (see Observation [1]). Martin M Kimani
FDA issued a three-observation Form 483 to Veterinary Pharmacy Corporation, a veterinary compounding pharmacy, after an inspection ending 03/19/2026. Investigators cited widespread contamination and weak cross-contamination controls in the amoxicillin area, media fills that do not reflect real conditions, and deviation from a decree of injunction by releasing sterile injectable lots without endotoxin testing.
Published 2026-10-22 · Inspection date 03/19/2026 · Veterinary Compounding Pharmacy · FEI 3002726048
Key facts · Basis: official index plus supporting sources
Contamination: a pallet of used compounding equipment left in a non-classified amoxicillin storage room for about 1.5 to 2 years, amoxicillin powder covering production equipment, staff moving between areas without garbing changes
Sterile: sterile lots such as V20030526 released without endotoxin testing; media fills do not simulate container size, unit count or worst-case conditions
Insight · Editorial insight
Amoxicillin powder leaving the dedicated area uncleaned and staff moving without garbing changes suggest that beta-lactam cross-contamination controls were not functioning. Release of sterile injectables without lot-by-lot endotoxin testing by a firm under a decree of injunction signals that FDA applies strict sterile release expectations to veterinary compounders too.
Check points
Personnel and material flow and deactivation cleaning for beta-lactam areas
Lot-by-lot endotoxin testing of sterile injectables
Worst-case design of media fills, including container size, unit count and duration
Observation detail · 3 observations · From the source
Inspectors: Nicholas J Presto · Beatrix D Hippe · Vaishali J Patel
Observation 1
Contamination was observed in your production area and areas adjacent to production areas.
Specifically, A)A_ pallet of used compounding equipment was observed in the non-classified Amoxicillin storage room. Items on_ this pallet included, but were not limited to, used process (b)(4) which were coated with yellow residue, (b)(4) . All equipment on this pallet appeared to be coated with a layer of white powder. Your staff stated that this pallet of used equipment had been present in this location for approximately 1.5 to 2 years. This pallet is located immediately adjacent to the door leading to Amoxicillin Room(b)(4) where finished product compounding and packaging of Amoxicillin products takes place. B) Widespread and extensive damage was observed on the painted drywall walls in the Amoxicillin processing area. This damage included an approximately 6-inch long and 3-inch deep hole punched in a wall from the handle of an over-extended door, multiple scrapes in paint and drywall ranging from | to 6 inches, and broken floor ceramic molding. This damage was noted approximately 10 feet from the chute where Amoxicillin capsules were (b)(4) _—pumped openly into IBC containers (6)(4) . C) Black stains were observed on damaged wall sections where paint and drywall had been scrap
Observation 2
Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.
Specifically, Aseptic process simulations (media fills), along with the governing procedure SOP CR-02 — Aseptic Technique & Gloved Fingertip / Thumb Test—are deficient in that they do not simulate the finished product container size, number of units, or worst-case conditions that may arise during compounding activities. Media fills conducted by your firmto simulate aseptic processes utilize (b)(4) , which contain a total of (b)(4) and associated equipment. (b)(4) used by each sterile compounding technician as part of their) (b)(4) aseptic process simulation evaluation. During a review of your sterile compounding records for March 2026, a lot size of (b)(4) of Iron 20% (200 mg/ml) was noted in the compounding of Lot #V20030526 on!) (B)(4)). This batch was compounded to fulfill Rx 4 (b) (6) and shipped to your customer.on 2/11/9096. Additional hatch sizes of (b)(4) (b)(4) were also noted in compounding records from (b)(4) Additionally, Form CR-37 — Periodic Cleanroom Aseptic Evaluation — which is used to) (6)(4) qualify your sterile technicians, does not document the amount of time required to conduct the media fill using the (b)(4) . Start and stop times, along with total operationa
Observation 3
Deviation from the procedural requirements of a decree of injunction.
[FDA 483 observation · FDA]Shilpa Medicare Limited — Process validation and audit trail control gaps
FDA483
FDA issued a Form 483 with five observations to Shilpa Medicare Limited in India after an inspection ending 05/29/2026. The observations cover process validation gaps, undocumented stability chamber investigations, cleaning hold time studies, incomplete batch records and unreviewed HMI/SCADA audit trails.
Published 2026-10-22 · Inspection date 05/29/2026 · Drug Manufacturer · FEI 3018694237
Key facts · Basis: official index plus supporting sources
Observations: 5 (process validation, discrepancy investigations, hold times, batch records, computer system controls)
Audit trail: HMI/SCADA data, audit trails and alarm reports not reviewed; alarms including sterilization load cycles not backed up and overwritten
Insight · Editorial insight
Unreviewed audit trails and alarms, including sterilization load cycles, being overwritten without backup is a weighty data integrity signal. Together with a protocol-required inspection system left unqualified during process validation, it points to a gap between validation commitments and actual operations.
Check points
Periodic review and backup of HMI/SCADA audit trails and alarm data
Qualification status of inspection systems required by process validation protocols
Worst-case reassessment of CHT/DHT when new products enter shared equipment
Observation detail · 5 observations · From the source
Observation 1
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Specifically, Your Process Validation (PV) for is deficient. You failed to use the system during in-process checks in stage for all strength due to lack of qualification of the system for product as required per Process Validation Protocol (# 044-00). According to the During step, the system is to be used to challenge for rejection
Observation 2
Written records are not always made of investigations into unexplained discrepancies.
Specifically, A. On 03/01/2025 at 15:00 hour, you observed the minimum and maximum temperatures at 25.800 C and 30.400 C (Acceptance criteria: 280 C to 320 C) and the minimum and maximum relative humidity was observed at 57.30% and 79.60 % RH (Acceptance criteria 70 to 80 %. RH) for stability chamber (#QC- E088, 30C/75%) where both humidity systems failed and lead to the chamber shutdown. Although (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4)
Observation 3
You established for Clean Hold Time (CHT) and Dirty Hold Time Study (DHT) for the following shared equipment (non-dedicated) that is used to manufacture : which was not based on the worst-case molecules.
Yet, you have not performed a Clean Hold Time (CHT) and Dirty Hold Time Study (DHT) after (as worst-case molecule in 2022) and (as worst-case molecule in 2023-2024) as required per SOP # UNIT PR/SOP/0017-02 “Cleaned and Dirty Equipment Hold Time, effective date 03/08/2026” as introduction of new product at the site. According to your Production Manager and Sr. Manager QA , is considered the worst-case molecule at the site.
Observation 4
Production records do not contain complete information relating to the production and control of each batch.
Observation 5
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
Specifically, Per your Production Manager your firm does not review data, audit trails and alarm reports generated by the HMIs (GT-2708) and SCADA of your non-dedicated equipment ID #PR-E016) and (ID #MB-E030) utilized in the Micro Lab. Alarms generated for the (Production) and (Micro) including sterilization load cycles are not backed up and automatically overwritten by the system.
[FDA 483 observation · FDA]Jiangsu Hansoh Pharmaceutical Group Co Ltd. — Aseptic airflow and sterilization validation gaps
FDA483
FDA issued a Form 483 to the sterile drug site of Jiangsu Hansoh Pharmaceutical Group Co Ltd. in China after an inspection ending 04/24/2026. Observations cover sterilization and smoke study validation, aseptic technique, visual inspection qualification, environmental monitoring, cleaning and disinfection, and weight check systems.
Published 2026-10-22 · Inspection date 04/24/2026 · Sterile Drug Manufacturer · FEI 3008316144
Key facts · Basis: official index plus supporting sources
Aseptic technique: operators blocked first air during stopper addition and leaned into the RABS to retrieve forceps
Investigations: recurring gram-negative recoveries in the grade B area not investigated; retain samples not examined in complaint investigations
Insight · Editorial insight
Concurrent findings on smoke studies, media fill representativeness, BI placement and technique around the RABS signal weak design and verification evidence across the sterility assurance program. Uninvestigated recurring gram-negative recoveries and shallow complaint investigations put the quality unit's investigation function under scrutiny as well.
Check points
Turbulence assessment in smoke study videos and coverage of actual work locations
Media fills that physically reproduce interventions and distinguish operator setup qualification
Representativeness of visual inspection kits for defect types, particle sizes and container sizes
Observation detail · 7 observations · From the source
Inspectors: Sandra A Boyd · Karen A Briggs
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the sterilization process.
Specifically, A. Scientific evidence could not be provided demonstrating the source of the smoke used during your air flow visualization studies is neutrally buoyant. During your review of smoke study videos in your aseptic filling lines in workshops@gy as well as thefy line, the following discrepancies were noted: 1. The positioning of the ga ducts of the (4 RABS in relation to the grade B area has the potential to short circuit the grade B air flow, causing an upward movement ofair in the cleanroom. Smoke studies have not been performed in this area to demonstrate adequate airflow in aseptic filling lines workshops §y 2. Air flow videos are recorded with the smoke pointing directly upwards, not providing a uniform curtain of smoke in which to evaluate air currents.
Observation 2
Your firm failed to thoroughly investigate any unexplained discrepancy or failure ofa batch or any of its components to meet any of its specifications whether or not the batch has already been distributed.
Observation 3
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.
A. Inadequate aseptic technique was observed in the review of videos and while watching the aseptic filling ofo@ Injection in workshop @@ on 20Apr2026. Discrepancies include: |. Operators block first air during the addition of stoppers. This was seen in workshopsw@ ee aseptic filling lines. 2. An operator was seen having to lean his upper body inside the RABS unit to retrieve and return forceps in workshopow 3. Reaching over ioe _ vials during the execution ofan intervention. The affected vials were not removed, B. The firm’s visual inspection qualification program is inadequate to demonstrate that inspectors can reliably detect all defect types in sterile injectable products. 1. Your visual inspection qualification program lacks adequate Quality Unit over-site and control. Production personnel maintain qualification kits, administer qualification tests, make pass/fail determination with only a Quality review of the bottle condition. This arrangement fails to ensure the proper administration of qualification tests according to a written procedure as well as fails to ensure objective evaluation ofinspector performance.
Observation 4
Aseptic processing areas -ate deficient regarding the system for monitoring environmental conditions.
Specifically, the following discrepancies were noted during review of the environmental monitoring program
Observation 5
Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Discrepancies were noted during the cleaning performed on 20Apr2026 in workshop®@ _ after the manufacture of M@® Injection-USP including: A. Operators were seen kneeling on the@@ as well as reaching over and leaning on equipment during cleaning. B. Using the same cloth to clean numerous pieces of equipment, including cleaning the lower parts of the @ 2ABS followed by cleaning the inside ofbe RABI C. Only the forceps used during setup or the removal of a stuck stopper areo@ All remaining forceps, including those used in the removal of O® fallen/jammed vials are not m@ These forceps remain on the aseptic filling lines
Observation 6
Routine calibration, inspection, checking ofautomatic, mechanical, electronic equipment is not performed according to a written program designed to assure proper performance.
Control procedures are not established that describe in process controls which validate the performance ofthose manufacturing processes that may be responsible for causing variably in the characteristics of in-process materials and the drug product.
A. Your firm failed to validate the in-process inspection method to evaluateoo ofaseptically e Currently you use mm ut provided no documented evidence that this method has been validated tor y; precision, or reproducibility. e There is no documented acceptance criteria frm® ° There ig no documented training program for personnel performing inspections, including no visual training aids or competency assessments to ensure consisten technique.
FDA issued a Form 483 with two observations to Therapak Corporation after an inspection ending 02/12/2026, citing incorrect inspection sampling and complaint risk categorization not performed as required.
Published 2026-10-22 · Inspection date 02/12/2026 · Contract Manufacturer · FEI 3010882984
Key facts · Basis: official index plus supporting sources
Observation 1: receiving inspection sampling deviated from the ANSI/ASQ Z1.4-2008 plan in SOP-QA016-01, and kits made in 2025 were under-sampled
Observation 2: 8 of 8 complaints over 3 years were rated "low risk" without considering risk or severity
Insight · Editorial insight
Sample sizes on receiving checklists and DHRs that did not follow the firm's own statistical sampling procedure signal that consistency between procedures and shop-floor forms is under scrutiny. Complaints uniformly rated low risk without assessing severity or frequency show that the documented basis for risk categorization can be examined.
Check points
Alignment of receiving, in-process and final inspection sample sizes with the procedure's sampling plan
Records of severity and frequency assessment in complaint risk categorization
Whether checklists and DHR forms reflect current procedures
Observation detail · 2 observations · From the source
Inspectors: Linda Galindo
Observation 1
Analysis of data indicating the quality management system is not suitable, adequate, or effective was not used as input for improvement.
Specifically, your procedure SOP-QA016-01 Statistical Technique, dated 10/08/21, states you will use ANSI/ASQ Z1.4-2008 Sampling Procedures and Tables for Inspection By Attributes: General Inspection Level ®®, (5)X4)9 for sampling (reduced) for your receiving inspection, in-process, and final inspection ofmedical devices. In review ofyour receiving acceptance of the primary component(By (218) in device (S\N, Manufacturer Part number (S)N4)ENN (GLA) for the past 2 years, I observed that your sampling was erroneous for all records I reviewed. Most ofthe quantities received for this material come in quantities of(6)(4) tubes each, and using the above sampling plan, it would require you to sample @@tubes, notMM as noted by your "Receiving Inspection Checklist." In addition, I reviewed your sampling for your manufacturing ofthe device(SYA, Manufacturer Part number(64) (G4 that you have been manufacturing since 2020. Your DHR (GYAN an inspection sample size of ™each for lots of(6)(4) kits, which is the most common run
Observation 2
Procedures for the feedback process have not been documented.
Specifically, your procedure SOP-QA014-03 Complaint Handling and Nonconforming Events, dated 09-Feb-2026, states that complaints will be categorized for risk using factors of severity and frequency. In review ofyour complaint records for your material number (5)(4 , Manufacturer Part number CAI GIGI for the past 3 years, I observed that 8 of 8 complaints did not factor in risk or severity, yet a "low risk" designation was assigned for these complaints.
[FDA 483 observation · FDA]Blossom Pharmaceuticals — Batch record falsification, no cleaning validation
FDA483
FDA issued a Form 483 with seven observations to Blossom Pharmaceuticals, an OTC drug manufacturer in India, after an inspection ending 04/11/2025, citing falsified and non-attributable batch records, missing cleaning and process validation, and failed quality unit oversight.
Published 2026-10-22 · Inspection date 04/11/2025 · OTC Drug Manufacturer · FEI 3010806039
Key facts · Basis: official index plus supporting sources
Data integrity: supervisors completed BMR/BPR after operations instead of operators; tare weights recorded without weighing
Cleaning and validation: equipment labeled "CLEAN" had residue; no cleaning validation for shared equipment; HPLC and microbial methods not verified
Insight · Editorial insight
Supervisors filling in batch records after the fact, without operator signatures, and recording weights that were never measured signal a breakdown of attributability and contemporaneous recording across the record system, not isolated errors. Making multiple US products on shared equipment without cleaning validation shows that cross-contamination control generally depends on documented cleaning evidence.
Check points
Contemporaneous recording and signatures by the operator performing each batch step
Cleaning validation for shared equipment and control of clean status labels
Verification of raw material and finished product test methods (HPLC assay, microbial)
Observation detail · 7 observations · From the source
Inspectors: Kellia N Hicks
Observation 1
Written production and process control procedures are not followed in the execution of production and process control functions and documented at the time of performance.
Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically, your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment to prevent contamination or carryover of materials. For example, but not limited to the following: A. Your firm failed to use adequate and validated cleaning processes to prevent cross-contamination for
Observation 3
Written procedures are not established and followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
Specifically, your firm failed to maintain and ensure the accuracy, reliability, and integrity of records and signatures used to document equipment cleaning and maintenance activities in cleaning and use logs that are attributable to the individuals performing the work, accurate, complete, and contemporaneously documented.
Observation 4
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards and test procedures designed to assure that in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity.
Specifically, laboratory test methods used for raw material and finished product testing are not verified or validated to ensure accuracy, sensitivity, specificity, and reproducibility. Your firm failed to verify or validate the analytical test methods used for raw material acceptance testing. This includes, for example, assay testing of active pharmaceutical ingredients (APIs) by high- performance liquid chromatography (HPLC), which are used in the manufacture of OTC drug products. These methods have not been demonstrated to be suitable under actual conditions of use. No data was provided to support the accuracy or reproducibility of this method for its intended purpose. Additionally, none of the microbiological test methods used for finished product release testing, including total microbial enumeration testes (aerobic microbial count, total yeast and mold count), and testing for the absence of specified microorganisms, including, but not limited to, staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans have been validated or verified for any OTC drug product. Your firm failed to establish data to show these methods are appropriate for the specific product formulati
Observation 5
Buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable to facilitate cleaning, maintenance, and proper operations.
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Specifically, your Quality Unit failed to adequately exercise its authority and responsibilities, including but not limited to, ensuring data integrity, implementing effective procedures, and conducting adequate oversight to support the safety, effectiveness, and quality of the drug products you manufacture. For example, but not limited to: A. Your firm failed to perform Process Validation (PV), Cleaning Validation (CV), and/or Cleaning Verification for Product Changeover and Batch to Batch Cleaning for all US marketed products as confirmed by your Production Management and QA Manager. You utilize non-dedicated equipment to manufacture US marketed products. You established a clean hold time (CHT) ofe@ and a dirty hold time (DHT) of@@ for equipment without performing adequate studies to support the CHT and DHT. You currently manufactured approximately@@US marketed products and @@products for the rest of the world (ROW) at your facility. For example, but not limited to, US Marketed Products: we
Observation 7
Employees are not given training in the particular operations they perform as part of their function and current good manufacturing practices.
Specifically, your firm failed to maintain adequate records demonstrating that all laboratory employees had completed required training programs relevant to their job functions. 1. Your firm failed to tran@@ ofo@ %) current employees on cGMP training. There was no evidence that ALL employees conducting critical laboratory activities had received training in current Good Manufacturing Practices (cGMPs) and Good Laboratory Practices (GLPs). Additionally, your firm failed to integrate 21 CFR 211 into the cGMP training program. Your firm’s current cGMP training materials do not include specific requirements from 21 CFR 211, which provides critical guidance on Good Manufacturing Practices for drug manufacturing. This omission limits personnel understanding of essential quality standards specifically relevant to drug product production. Your firm failed to maintain adequate training records. Training records for employees were either incomplete or not maintained. Employees working in critical areas, such as thegy@ production and packaging »@%), do not have documented evidence of training in the operations they perform including proper documentation practices (BMR).
[FDA 483 observation · FDA]Lonza AG — First air blocked during aseptic operations
FDA483
FDA's 483 for Lonza AG (Visp, Switzerland), inspection ending 04/04/2025, cites a single observation that procedures to prevent microbiological contamination of sterile drug products were not established and followed. Dynamic smoke study videos showed operators covering sterile openings and blocking first air over the stopper feed area.
Published 2026-10-22 · Inspection date 04/04/2025 · Drug Product Manufacturer · FEI 3012793444
Key facts · Basis: official index plus supporting sources
Observation: procedures to prevent microbiological contamination of sterile drug products not established and followed
Detail: sterile openings and tubing ends covered during connection assembly; first air blocked during stopper addition and jammed-stopper removal
Insight · Editorial insight
The finding rests on operator aseptic behavior seen in dynamic smoke study videos rather than equipment failure, signalling that FDA uses smoke studies directly to judge operator interventions. First air blockage over indirect product-contact surfaces such as the stopper chute and bowl, and interventions like clearing jammed stoppers, look likely to stay a focus in aseptic processing inspections.
Check points
Review of smoke study videos for operator first air blockage
Whether interventions such as jammed-stopper removal are covered by aseptic procedures
Handling of sterile openings and tubing ends during aseptic connections
Observation detail · 1 observation · From the source
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Specifically, while reviewing the dynamic smoke study videos for the [8 in Manufacturing Complex| Module“GI (HL) observed the following deficiencies: a) While assembling th connection, your operator covered the sterile opening of th and both sterile ends of the]7/® tubing with 777% b) Your operator blocked first air over the exposed indirect product-contact surface of the stopper chute and bowl during stopper addition operation. Your operator was also observed to block first air over the stoppers in the| 4 during removal of ajammed stopper.
[FDA 483 observation · FDA]Apotek Production & Laboratorier AB — Aseptic validation and EM gaps
FDA483
FDA's 483 for Swedish sterile drug manufacturer Apotek Production & Laboratorier AB, inspection ending 01/29/2026, lists nine observations. They include a static-only smoke study, media fills not designed around worst-case interventions, poor operator aseptic behavior, environmental monitoring and disinfectant efficacy gaps, and manually transcribed test results.
Published 2026-10-22 · Inspection date 01/29/2026 · Sterile Drug Manufacturer · FEI 3003766921
Key facts · Basis: official index plus supporting sources
Aseptic process: smoke study only under static conditions; media fill protocol lacks worst-case conditions and maximum interventions
Other: no surface monitoring on the Grade A line, no disinfectant efficacy studies, raw test data not saved and transcribed by a single analyst
Insight · Editorial insight
Both the smoke study and the media fills failed to reflect dynamic operations and operator interventions, a sign that FDA is assessing aseptic process validation at the level of individual interventions. Because the observations also cover a partially open ampoule line without RABS and a loading area extending into Grade B, sterile sites that rely on procedures and monitoring to offset equipment design limits may want to compare against this combination of findings.
Check points
Smoke studies covering dynamic conditions and operator interventions
Worst-case conditions such as maximum interventions and their duration in media fill protocols
Rationale for environmental monitoring locations on manually handled Grade A surfaces
Observation detail · 9 observations · From the source
Inspectors: Anastasia M Shields
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
Specifically, A.During review of your firm’s airflow visualization (smoke) study, document ID VFU315T, entitled, “Rokstudie modifiering @@ *. dated 2024/07/03. conducted on the filling line used to fill the m@ @@ drug, oe the following was observed: 1.Your, airflow visualization study is deficient as it was only conducted under static conditions. The study fails to evaluate but is not limited to the following: i.aseptic filling process under dynamic conditions ii.set-up activities iii.expected and unexpected operator interventions 2.The static study performed shows air turbulence in the Grade A filling area of filling machine @@ at the level of the HEPA filter where the ceiling meets the surrounding @@ barrier. The HEPA in the ceiling is surrounded by ag@ that is approximately q@ from the edge of the HEPA filter to the Grade A barrier. Turbulence was observed around this @@ . 3.The study failed to show smoke that is uniformly supplied and distributed covering the entire airflow cascade from the HEPA filter to the working area. 4.There is no evidence to show that the smoke generated is neutrally buoyant. Smoke used for the airflow visualization study is generated by using handheld d
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
Specifically, Examples of poor aseptic behavior were observed during review of the aseptic process simulation study, media fill batchay@ and batch@@ on the ampoule lineg used to fill the gy@ drug a)@ 0) 4) 1. During line set up for both media fill batches an operator was observed setting up the@@ using their gloved hands where their hands came in direct contact with the components used to hold the m@ @@ _‘«in place on the line and components that the m@ They were observed physically manipulating multiple machine parts around the @@ and touching the upper part of the a@ with their hands when placing the g@@ —onto the machine. 2. An operator was observed using their gloved hands to secure and arrange unfilled ampoules onto the q@ @) (4) (ampoule loading area) in the Grade A filling machine.
Observation 3
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing and processing.
Specifically, Batch records do not contain documentation of all interventions performed in the Grade Aor the length of time taken to perform each intervention. Routine interventions not recorded include but are not limited to the following
Observation 5
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design and suitably located to facilitate operations for its intended use.
Specifically, 1.The m@ is located above the end of the filling line m@ at the ceiling level. HEPA filtered air is drawn up and directly off the line when a m@ on the end is removed for the duration of machine set up. @@ are located on each side of the line and extend down from the top of the line to approximately @@ above the table holding the filling line. The aseptic filling line is not equipped with RABS technology or @@ and is not fully enclosed on all sides. The front and back are partially covered with ag)@ that extends from the top of the line downward. The front g@ stops approximately @@ before the table that holds the filling line and the line is open from the end of this g@ down to the table. 2.The w@ (ampoule loading area) extends out of the Grade A into the surrounding Grade B room. @) sterilized ampoules are loaded onto the g@ protruding out of the Grade A prior
Observation 6
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
Specifically, your firm’s @@ Equipment ID @m@ does not save testing data generated from ag@ nor is it attached to any type of system that will print or save the generated raw data. The current process relies on a single analyst to manually transcribe results from the equipment display into the laboratory record without independent verification or electronic capture of raw data. Two person verification is not required. This @@ ow is used to conduct assay and impurity testing on the ew drug
Observation 7
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
Specifically, your firm has omitted the @@ °C incubation step during incubation of the plates used to conduct environmental monitoring of all classified areas and operators. No method suitability study was performed or able to be provided that demonstrates that eliminating this incubation temperature does not have a negative impact on recovery of mold and yeast in the EM samples being tested.
Observation 8
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Observation 9
Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
Specifically, there is no requirement for stratification or distinct timepoints throughout the filling process at which BET samples are to be collected. A single vial is randomly collected from each batch ofgy and is used for Bacterial Endotoxin Testing (BET) per SOP 1525, “Kontrollomfattning Steril Produktion”. There are approximately@g)@ ampoules filled in one commercial scale batch ofg@
[FDA 483 observation · FDA]Q-Med AB — Contamination control and QU oversight gaps
FDA483
FDA's 483 for Q-Med AB, a Swedish drug substance and drug product site, inspection ending 03/27/2026, lists eleven observations. They cover weak containment and personnel flow controls around upstream drug substance areas, aseptic technique lapses during filling setup, flawed environmental monitoring and media fill design, and Quality Unit control failures including use of unreleased materials and release of mislabelled batches.
Published 2026-10-22 · Inspection date 03/27/2026 · Drug Substance and Drug product Manufacturer · FEI 3003347293
Key facts · Basis: official index plus supporting sources
Contamination control: containment breaches not required to be documented; no shower after upstream work; changing rooms shared with aseptic drug product staff
Quality system: drug substance batches used before Quality Unit release; mislabelled batches approved for release; high invalid assay rates not investigated
Insight · Editorial insight
The site skipped showers and shoe changes on the assumption that safety cabinets give total containment, while not recording containment breaches, which signals that FDA is testing the assumptions underlying a contamination control strategy. Releasing mislabelled batches and leaving high invalid assay rates uninvestigated reads less as isolated lapses and more as a challenge to how the Quality Unit makes disposition decisions.
Check points
Breach records and trending that support containment assumptions in the contamination control strategy
Separation of personnel flow, changing rooms and footwear between upstream and downstream areas
Adequacy of the trigger for investigating invalid assays
Observation detail · 11 observations · From the source
Deficiencies in procedures for handling mw containment breaches and controlling personnel flow create arisk ofg@@ transfer to downstream DS and drug product (DP) manufacturing suites. A. Your procedures for managing breaches of m@ containment are inadequate. The Classo@ Microbiological Safety Cabinets (MSCs) are yourm@ containment for thegsy@ handling of )@) However, your procedures (including QMS-12492 and QMS-12331), do not require the documentation ofm@ _ failures (e.g.@@ ). This failure to record containment breaches prevents your firm from tracking, trending, or assessing the potential impact of mw on any given batch, making it impossible to ensure that containment was maintained during manufacturing. B. Your firm does not require personnel to shower after working in the upstream@@ handling suite before moving to other manufacturing areas. SOP QMS-8836 requires only a change of outer garments. Your justification for not requiring a shower, (documented in MA-38919), is based on the assumption that the MSCs provide total containment. However, your risk
Procedures designed to simulate aseptic processes are inadequate to assure the sterility of the drug product.
A. Vials that are exposed during media fill interventions are excluded/omitted from incubation; therefore, the aseptic process simulation does not adequately evaluate the sterility of the full manufacturing process (including interventions). The intervention list for media fills (QMS
Observation 5
The firm’s visual inspection is inadequate to ensure that the visual inspection process is under a state of control and that recurring deviations are effectively investigated or corrected.
A. Your firm’s procedure for 100% visual inspection categorizes rejected vials only into the following categories: Critical, Major, and Minor. Details for specific defect sub-categories (e.g., cracks, scratches, damaged caps, poor grooving) are not recorded or trended. A change control to implement specific sub-categories (record CC-482203) was not implemented until March 2026, which prevented your firm from adequately investigating and identifying the sources of all prior recurring manufacturing defects.
Specifically, A. Your cleaning log documentation is deficient because it fails to demonstrate that cleaning and disinfection are performed according to established procedures. Your practice of using a single log entry for multiple rooms is inadequate, as it does not record room-specific times or, most
Observation 7
Your firm’s quality system is inadequate because the Quality Unit does not ensure control over material status and final product disposition, resulting in the use of unreleased materials for manufacturing and the distribution of incorrectly labelled drug products.
A. Notall@@ DS batches are withheld from use until the lots have been fully released by the Quality Unit. Multiple @@ DS batches have been partially released and manufactured into DP batches prior to being released by the Quality Unit. A few examples include: e DP batches m@ manufactured for comparability studies. e DP batchesm@ manufactured for PPQ. e DP batches m@ manufactured for analytical transfer submissions tom@® B. Upon reviewing your labeling procedure it was discovered that twom@ drug product batches had labelling errors.
Observation 8
Your firm's quality unit has failed to maintain adequate oversight, written documentation, procedural adherence, and document control.
Observation 9
Components and raw materials are not adequately tested and approved prior to their use in manufacturing.
There are discrepancies between the information included in the w@ and the testing operations at the manufacturing facility.
Specifically, The reference standards used for the m@ method for the quantitative determination of m@ are not included in thea Upon review of SOPs (QMS-15037 and QMS-15190), it was discovered that special reference standards are used inthe@@ method(s) for the quantitative determination Ofe for m@ drug substance and drug product. However, the reference standards used for the we method are different from those that are described in theme
FDA issued a 483 with three observations to Steriscience Specialties Private Limited, a sterile drug manufacturer in India, after an inspection ending 11/22/2024. Observations cover smoke studies of Grade A airflow that did not reflect production interventions, missing audit trails in testing and environmental monitoring software, and shared login use without change control.
Published 2026-10-22 · Inspection date 11/22/2024 · Sterile Drug Manufacturer · FEI 3005652193
Key facts · Basis: official index plus supporting sources
Observation 1: smoke studies did not represent canister switching during commercial production, and observed turbulence was scored as acceptable airflow with no impact
Observation 3: NVPC machines accessible with a common user name 'USER' until August 2024; no change control opened when individual IDs were assigned
Insight · Editorial insight
Airflow studies that did not reproduce real production interventions, and that scored observed turbulence as having no impact, signal that FDA focused on how representative the aseptic process validation was. The parallel findings on missing audit trails in environmental monitoring software and shared accounts suggest the reliability of cleanroom data is a separate line of scrutiny.
Check points
Whether smoke studies reproduce commercial interventions and how turbulence is assessed
Audit trail enablement for integrity testing and environmental monitoring software
Change control and risk assessment of existing data when retiring shared accounts
Observation detail · 3 observations · From the source
Inspectors: Anastasia M Shields · Clinton J Lott
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
Specifically, the software m@ software, versiong@ installed ongw used for ®@ integrity testing of the m@ and the ~~ Particle Counter (NVPC) o@ Software, version m@ used for environmental monitoring in the Grade A, B, C and D areas is not equipped and/or audit trail enabled.
Observation 3
Changes to written procedures are not drafted, reviewed and approved by the appropriate organizational unit.
Specifically, your m@ NVPC machines were accessible using a common user name “USER” and password until August 2024. Per SOP, PROC SSCOR SOP GQA 1196, “Change Management”, a Change Control is to be initiated when changes are made which may have direct or indirect impact on quality and documentation of the product, system, material, process, equipment or procedures. Your firm failed to open a Change Control and conduct any associated risk assessments to existing data when individual user IDs and passwords were assigned to approved operators.
[FDA 483 observation · FDA]Biomylz Private Limited — Data integrity breaches not investigated
FDA483
FDA issued a Form 483 to Biomylz Private Limited, an OTC drug manufacturer in India (inspection date 02/09/2026), citing among other things the firm's failure to investigate after a former Plant Manager was found to have directed record destruction and false data entry.
Published 2026-10-22 · Inspection date 02/09/2026 · OTC Drug Manufacturer · FEI 3013697420
Key facts · Basis: official index plus supporting sources
Key observations: uninvestigated data integrity breaches, missing raw data, no quality agreements with contract labs, no cleaning procedures
CAPA reports for the 17 observations in the July 2, 2020 Form 483 could not be provided
Insight · Editorial insight
Knowing that records were destroyed and data falsified at a manager's direction, yet not reviewing records for products made for the American market, signals a system-wide reliability problem rather than isolated lapses. The inability to show CAPA for the previous 483 makes this worth noting when evaluating overseas OTC suppliers with repeat findings.
Check points
Scope of retrospective investigation and impact assessment after a data integrity breach
Quality agreements and qualification records for contract testing laboratories
Evidence of CAPA completion for prior inspection observations
Observation detail · 6 observations · From the source
Inspectors: Alan A. Rivera
Observation 1
Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed.
On January 22, 2026, your firm terminated the former Plant Manager due to repeated and ongoing data integrity violations, including, but not limited to, destruction of batch production records, destruction of laboratory-controlled records, and documentation of false production and laboratory data. According to your Quality Head, employees working in the production and laboratory areas were instructed by the former Plant Manager to destroy, alter, or manipulate records and felt compelled to comply due to his supervisory authority. This inadequate practice was also observed and confirmed by your Operations Manager to whom the former Plant Manager reported to. Despite these identified data integrity concerns, your firm did not initiate an investigation or conduct a comprehensive evaluation of manufacturing and laboratory records associated with OTC drug products manufactured for the U.S. market to determine the extent and impact of the data integrity breaches. In addition, your firm did not perform reconciliation of incoming raw materials, finished drug products manufactured and released, inventory records, equipment usage logbooks, laboratory test results, sample
Observation 3
Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards.
Your firm failed to maintain complete laboratory records, including raw data, for laboratory analyses - | conducted on commercial drug products. Specifically, raw data supporting laboratory test results used to release commercial batches, to validate the commercial manufacturing process, and/or in house gw w@@ System were not retained or were unavailable for review.
Observation 4
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Specifically, A. There is no assurance that laboratory testing used to determine raw material suitability and finished drug product quality is performed in accordance with applicable cGMP requirements. For example, your firm uses contracted laboratories that are not registered or inspected by the agency to perform incoming raw material and finished OTC drug product testing, including the Certificate of Analysis (CoA) used to support the release decision. In addition, no Quality Agreements have been established between your firm and the contracted laboratories to define roles, responsibilities, and oversight related to testing, data integrity, and compliance with cGMP requirements. Moreover, no documented evidence was provided, which demonstrates that the selected contracted laboratories have been inspected by your Quality Unit to assess their compliance with applicable cGMP requirements. SEE
Observation 5
Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
Specifically, your firm failed to develop and approve cleaning procedures describing in sufficient detail the methods, equipment and materials to be used for cleaning the production equipment (i-¢., gq tank, holding tank and filling line) and utensils or auxiliary equipment (e.g., transfer lines and filling hoses) used in the manufacture ofyour @@ OTC product. As per your Quality Manager, your cleaning procedures are executed q
Observation 6
Your firm failed to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state of repair.
Observation 7
Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.
Specifically, according to your procedure titled “Procedure for Collection and Storage of Control Sample”, SOP Number: QCD/009, Version: R04, Effective Date: April 07, 2025, Section 5.1.1 states, “The control sample shall be collected from each batch of finished goods manufactured and from each batch of raw material ingredient received”. However, no examination is performed at least once a year to determine if product deterioration in U.S. marketed OTC products that include oe we has occurred. v ov
FDA issued a Form 483 with four observations to Laboratorios Grifols, S.A., a drug manufacturing facility in Spain, after an inspection ending 07/26/2024. Observations cover inadequate procedures for handling sterilization cycles during autoclave malfunction, missing calculations in batch records, undocumented endotoxin reagent preparation, and insufficiently detailed cleaning procedures.
Published 2026-10-21 · Inspection date 07/26/2024 · Drug Manufacturing Facility · FEI 3009736169
Key facts · Basis: official index plus supporting sources
Lots released after autoclave cycles were stopped, transferred, or exceeded allowed time suggest that sterility assurance decisions were left to individual discretion without procedural criteria. Combined with long-running gaps in batch calculations and endotoxin reagent records, the observations point to record completeness issues spanning both production and testing.
Check points
Whether procedures define transfer, manual stop, and acceptance criteria for sterilization equipment malfunctions
Completeness of calculation steps in batch records and test reagent preparation records
Level of detail on cleaning methods, equipment, and materials for non-dedicated lines
Observation detail · 4 observations · From the source
Inspectors: Irina Gaberman
Observation 1
Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Specifically, Your standard operating procedure Hb)(4) entitled "ALARMAS CRITICAS DE AUTOCLAVES" [Autoclaves, Critical Alarms, IG] is not detailed enough to include the steps during the autoclave malfunction when the(b) (4) is allowed to be transferred to another autoclave to continue sterilization cycle, when sterilization cycle can be stopped manually and when sterilization cycle is acceptable despite increased (B) (4) stage ofthe sterilization cycle. For example: a) on November 11, 2022, the autoclave had a ina during the stage of sterilization of lo , the cycle was stopped, and was moved from autoclave to . This lot was released on February 24, 2023. b) On March 14, 2023, sterilization cycle for lob)(4) was manually stopped by the operator without any explanation documented. c) On April 25, 2023, the(b) (4) stage exceeded allowed time o , and was documented asa on the autoclave sterilization printout for lo due to autoclave malfunction. This lot was released on June 20, 2023.
Observation 2
The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing.
Specifically, uses(b) (4) | amount depending on and requires additional calculation if it is no . Calculation of(b) (4) was not documented on the batch records for all lots manufactured on lines and(4) from May 28, 2020 to July 22, 2024.
Observation 3
Laboratory records are deficient in that they do not include a complete record of all data obtained during testing.
Specifically, , your raw materials, and finished product,ss are tested for Endotoxin.(BY (4 reagent preparation 1s required for the Endotoxin test. Review of Endotoxin testing records for the raw materials and batches manufactured from May 28, 2020 to July 22, 2024 found that preparation of this solution is not documented.
Observation 4
Written procedures for cleaning and maintenance fail to include description in sufficient detail of methods, equipment and materials used.
[FDA 483 observation · FDA]Greenwich Rx — Supplement-grade API and aseptic practice lapses
FDA483
FDA issued a 483 with 14 observations to Greenwich Rx, a producer of sterile and non-sterile drug products, at the close of an inspection on 09/09/2026. Findings included dietary supplement grade API used in a sterile injection, compounding during adjacent construction, microbial recovery in the ISO 5 area, pressure reversals and weak aseptic practices and smoke studies.
Published 2026-10-21 · Inspection date 09/09/2026 · Producer of Sterile and Non Sterile Drug Products · FEI 3043120213
Key facts · Basis: official index plus supporting sources
Firm: Greenwich Rx, FEI 3043120213
Inspection date: 09/09/2026 (establishment type: Producer of Sterile and Non Sterile Drug Products)
API: dietary supplement grade glutathione used to compound Glutathione Injection 200mg/mL dispensed for patient-specific prescriptions
14 observations: compounding during construction, ISO 5 surface microbial recovery, pressure reversals, first air blocked, no dynamic smoke studies
Insight · Editorial insight
Compounding a sterile injection from dietary supplement grade API, alongside compounding next to active construction and repeated pressure reversals, signals that both material suitability and sterile environment control broke down at once. Blocked first air in the ISO 5 area and contaminated gloves and gowns observed without any dynamic smoke studies point to a weak basis for airflow and operator control in aseptic processing.
Check points
Pharmaceutical grade status of sterile product APIs and supplier CoA verification
Cleanroom differential pressure records and response to reversals
Dynamic smoke studies and first air protection during aseptic manipulation
Observation detail · 14 observations · From the source
Inspectors: Camerson E Moore
Observation 1
Use of ingredients not intended for pharmaceutical use in sterile drug production.
Specifically, your firm was found to use a reduced dietaiy supplement grade APis in the compounding of finished sterile drug product, Glutathione Injection 200mg/mL. For example the API, Glutathione (L) USP (Reduced) (Dietaiy Supplement Grade), Lot <Redacted B4>, Expiry <Redacted B4> was used in the compounding of the finished sterile drug, Glutathione Injection 200mg/mL Lot 0060061826-1, BUD 09-26-2026. This lot was dispensed to fill patient-specific prescriptions. The firm continues to receive this grade of API based on a review of supplier provided COAs for Glutathione (L) USP.
Observation 2
Your firm produced drugs while construction was underway in an adjacent area without adequate controls to prevent contamination of the production environment and product.
Specifically, A. On 8/l7/2026, during a site walk-through, I found construction with sheet rock in areas surrounding a newly constructed ISO Classified modular Cleanroom Suite <Redacted B4> occurring at the same time as compounding activities within ISO <Redacted B4> modular cleanrooms (Suites <Redacted B4> located in the same general area separated by a wall not extended to the facility ceiling. Your firm's management reported construction activities had been occurring approximately three (3) weeks prior to the start of this FDA inspection. Your firm was compounding the sterile drugs, Tirzepatide 30mg/Bl2 0.5mg/mL (2.4mL) 30mg/0.5mg mg/mL, Lot number 0011081726-1 BUD 2026-11-25, Batch size <Redacted B4> vials and Semaglutide 10mg/B12 0.5mL (1.3mL) 10mg/0.5mg, Lot number 0005081726-1, BUD 2026-11-25, Batch size <Redacted B4> vials.
Observation 3
Microbial contamination was present in the ISO 5 area and areas adjacent to production areas.
Specifically, during my review of your firm's environmental monitoring (EM) records, I found the following deficiencies: A. During a review of your fnm's 2025 <Redacted B4> EM monitor sampling of the ISO Classified Cleanroom Suite found two (2) different occurrences where I CFU was found during ISO 5 LAFC surface sampling (Acceptance Limits ISO Class 5: <Redacted B4>. These include: 1. 10/9/2025: ISO 5 <Redacted B4> Buffer Hood -1 CFU; Compounded sterile product include; a. SEMAGLUTIDE IMG, Bl2 0.5/ML, Lot 0002-100925-A, BUD 1/17/2026 b. SEMAGLUTIDE IMG, B12 0.5MG/ML, Lot 0002 -100925-A c. SEMAGLUTIDE 4MG, Bl2 0.5MG/ML, Lot 0003-100925-A d. SEMAGLUTIDE 6MG, B12 0.5MG/ML, Lot 0004-100925-A e. BPC-157 3mg/mL, Lot 019-1 00925-A f. BPC157/TB500/KPV 3/3/3MG/ML (NO COPPER), Lot 0021-100925-A, BUD 1/17/2026 g. GHK-CU l 0mg/mL, Lot 0027-100925-A, BUD 1/17/2026 h. BPC, TB500, KPV 3mg/3mg/3mg/mL, Lot 0021-100925-A 1. BPC-1 57 3mg/mL, Lot 0019-1 00925-A J. TIRZEPATIDE l 0MG, B12 0.5/ML, Lot 0007-100925-A
Observation 4
Personnel were observed conducting aseptic manipulations where the movement of "first air" in the ISO 5 area is blocked or disrupted.
Specifically, during compounding observations of your firm's technicians, I observed your firm's technicians reaching over open vials while filling and stoppering filled sterile vials using their sterile gloved hands in the processing of sterile finished drug products, Tirzepatide 30mg/B 12 0.5mg/mL (2.4mL) 30mg/0.5mg mg/mL, Lot number 0011081726-1 BUD 2026-11-25; and Semaglutide 10mg/B12 0.5mg/mL (1.3mL) 10mg/0.5mg, Lot number 0005081726-1, BUD 2026-11-25 having the potential of blocking first air within the ISO 5 LAFC. The rubber stoppers were removed from a non-sterile. <Redacted B4> bag that were originally stored in the approved supplier's sterile packaging.
Observation 5
A pattern of frequent or acute pressure reversals was observed from areas of less clean air to areas of higher air cleanliness.
Specifically, during a review of your firm's 2026 <Redacted B4> ISO Classified Cleanroom differential pressure monitoring logs approved by the firm's pharmacist for Cleanrooms Suite <Redacted B4> found differential pressure reversals that occurred in the following months for Cleanroom <Redacted B4>. a. February 2026 (18 out 22 Differential pressures equal; 1 missing data for Garbing Rooms; 1 pressure reversals) b. March 2026 (17 out of 24 Differential pressures equal; 6 pressure reversals) C. April 2026 (20 out of25 Differential pressures equal; 1 missing data for <Redacted B4> & Garbing Rooms; 1 pressure reversals) J d. May 2026 (22 out of27 Differential pressures equal; 1 missing data for Clean Room <Redacted B4> pressure reversals)
Observation 6
The facility design was observed to allow the influx of lesser quality air into a classified area containing higher quality air.
Specifically, A. Your firm was found to be using 2 separate modular ISO classified cleanrooms designed with open vents existing into non-controlled/non-classified areas of the facility. I found ISO 8 Anteroom for Suite <Redacted B4> vent appeared to contain white foreign particulates in the flow path. The vent was being held open using a yellow/black handle screwdriver, which was on the opposite side of the ISO 8 Anteroom Cleanroom for Cleanroom Suite. Your firm's Compounding Manager reported that the contract cleanroom certifier had used the screwdriver to hold open the vent during an issue with balancing the ISO 8 Anteroom differential pressure. B. I found what appeared to be white foreign particulates on the floor within your firm's ISO 8 gowning room of Cleanroom Suite along with the vent remaining in the open position directly in front of the outside shoe storage rack.
Observation 7
Personnel were observed moving quickly in a critical area or in an area immediately adjacent to a critical area likely causing disrnption ofunidirectional airflow.
Specifically, I found during aseptic processing involving stoppering and capping using sterile gloves, your firm's technicians were using a <Redacted B4> disrupting unidirectional airflow within <Redacted B4> ISO 5 LAFC units within Cleanroom Suites <Redacted B4> during the processing of sterile drug products, Tirzepatide 30mg/Bl2 0.5mg/mL (2.4mL) 30mg/0.5mg mg/mL, Lot number 0011081726-1 BUD 2026-11-25; and Semaglutide 10mg/Bl2 0.5mg/mL (1.3mL) 10mg/0.5mg, Lot number 0005081726-1, BUD 2026-11-25.
Observation 8
Personnel infrequently changed and sanitized gloves to prevent contamination.
Specifically, your firm's technician was observed pushing trash into trashcan using their sterile gloves without performing a sterile glove change afterword. The technician disinfected their gloves and returned to the ISO 5 LAFC within ISO 7 Buffer Room to continue aseptic processing activities.
Observation 9
Lack of disinfection of supplies at each transition from areas of lower quality air to areas of higher quality air.
Specifically, A. Your firm's technician was observed failing to disinfect components located within the ISO 7 Buffer Rooms <Redacted B4> prior to placing them into the ISO 5 LAFC unit. B. Your firm's technicians in both ISO 7 Buffer Rooms suites during the aseptic processing of the sterile drug products, Tirzepatide 30mg/Bl2 0.5mg/mL (2.4mL) 30mg/0.5mg mg/mL, Lot number 0011081726-1 BUD 2026-11-25; and Semaglutide 10mg/Bl2 0.5mg/mL (1.3mL) 10mg/0.5mg, Lot number 0005081726-1, BUD 2026-11-25, was observed transfering stoppered trays of vials from LAFcQ (ISO 5 filling LAFC) through the ISO 7 Buffer Room, and into ISO 5 LAFqj (ISO 5 LAFC capping and crimping) without disinfecting the trays.
Observation 10
Inadequate <Redacted B4> testing on <Redacted B4> used to sterilize drug products.
I S pecifically, during a review of your firm's <Redacted B4> test of <Redacted B4> used in the compounding of finished drug sterile products, your firm failed to use calibrated gauge(s) and equipment to ensure adequate testing and <Redacted B4> were capable of meeting their intended use.
Observation 11
Compounding with components, containers or other materials that have not been verified to assure that they do not contribute endotoxin contamination that may be objectionable given the product's intended use.
Specifically, your fnm fail to <Redacted B4> glass beakers used in the formulation of bulk non-sterile drug products that undergo sterile <Redacted B4> to render bulk product sterile. Your firm's management reported that glassware is <Redacted B4> used. It is <Redacted B4> and wiped with sterile <Redacted B4> prior to use. Your firm's cleanroom manager reported a <Redacted B4> has been purchased for the processing of glassware. I found your firm's washed glassware used in the formulation and compounding of bulk non-sterile drug products are stored on a wire shelf in a non-controlled non-classified area directly in from of the entiy door of the facility. The glassware is positioned <Redacted B4> on the rack with no covering over the opening of the glassware.
Observation 12
Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.
Specifically, your firm failed to provide adequate rational evidence in support that media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.
Observation 13
Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.
Specifically, on 8/19/2026, two (2) technicians were observed donning their sterile gowns to enter the ISO 7 Cleanroom to strut aseptic processing. Sterile gowns worn by both technicians contacted the floor while donning rendering the gowns non-sterile. Additionally, poor sterile gloving techniques were found inadequate by the technicians contacting the non-sterile side of the glove using the sterile fingers of the opposite sterile glove.
Observation 14
Smoke studies were not performed under dynamic conditions.
Specifically, A. Your firm's PIC and cleanroom manager, reported that they neither received <Redacted B4> viewed, nor approved any static or dynamic smoke studies for either Cleanroom Suites, <Redacted B4> following original certifications or recertifications since the firm began operating in June 2025 for the <Redacted B4> cleanrooms. B. Your firm's compounding manager reported that no smoke studies during media fills were performed to assess laminar air flow conditions within any of the ISO 5 LAFCs, during aseptic manipulations and interventions to determine impact on finished sterile drug products.
[FDA 483 observation · FDA]Fresenius Kabi USA, LLC — Weak visual inspection and aseptic validation
FDA483
FDA issued a Form 483 with three observations to Fresenius Kabi USA, LLC, a US sterile drug manufacturer, after an inspection ending 05/14/2026. The key issue is that the firm's own qualification studies showed its current conveyor-based vial inspection detected particulates far less often than 100% manual inspection, yet the process was not reassessed.
Published 2026-10-20 · Inspection date 05/14/2026 · Sterile Drug Manufacturer · FEI 3001833549
Key facts · Basis: official index plus supporting sources
Facility: Fresenius Kabi USA, LLC, FEI 3001833549
Observations: visual inspection process control, aseptic and sterilization validation, analytical method transfer
Detection example: stopper particulates 93.3% manual vs. 10.0% current method; fibers 70.0% vs. 13.3%
Insight · Editorial insight
The citation targets a qualification study whose findings on the limits of the current inspection method were never carried into the process. Running the study is not enough; whether its results shaped routine conditions such as conveyor speed and the defect sets used to qualify inspectors appears to be a point worth noting.
Check points
Probability of detection for automated or semi-automated inspection versus manual inspection
Inclusion of defects at the detection limit in inspector qualification sets
Comparative testing between sending and receiving labs in method transfers
Observation detail · 3 observations · OCR reading of the scanned original
The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.
Observation 1
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.
Verification of the suitability of the testing methods is deficient in that they are not performed under actual conditions of use.
Specifically, your firm does not perform comparative testing for all in-house analytical method transfer studies that compare analytical results between the transferring lab and your receiving lab to determine a successful method transfer. For example, you did not compare the results of the transferring lab with the results of your receiving lab for the transfer of the external labs in-house method ((b) (4) ) for the Determination of Impurities in (b) (4) Injection ((b) (4) ) frorr(b) (4) to FK Grand Island, executed under Protocol: NAM-MVD-FG-000111207.
[FDA 483 observation · FDA]PETNET Solutions Inc — Sterility test incubation periods not followed
FDA483
FDA issued a Form 483 to PETNET Solutions Inc, a US PET drug manufacturer, after an inspection ending 03/19/2026. The one legible observation is that sterility test samples were read and recorded before the required incubation period ended, and an environmental monitoring plate from the ISO 5 hot cell area was removed before its required incubation was complete.
Published 2026-10-20 · Inspection date 03/19/2026 · Manufacturer · FEI 3008769593
Key facts · Basis: official index plus supporting sources
Facility: PETNET Solutions Inc, FEI 3008769593
Observation legible: laboratory procedures not followed for sterility test and environmental monitoring incubation
Insight · Editorial insight
Short-lived PET drugs are released before sterility results are in, so adherence to incubation periods in the follow-up sterility test may weigh more heavily as quality evidence. Recording results early was cited as a procedural failure, suggesting that reading times may be checked against incubation end times.
Check points
Sterility test reading times versus incubation end times
Recorded duration of each incubation stage for environmental monitoring plates
Observation detail · 1 observation · OCR reading of the scanned original
The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.
Observation 1
Each laboratory used to conduct testing of finished PET drug products does not follow written procedures for the conduct of each test.
Specifically, Your firm failed to follow established incubation procedures for sterility testing and environmental monitoring. A.) Your firm's procedure, Product Testing: Sterility Test (Doc# D0001993, Revision U, effective date: 09/05/2025), specifies a (b)(4) incubation period for sterility test samples. However, sterility test samples for the following batches were inspected and results recorded before completing the required_ (DMA) incubation period (incubation periods ranged from more than (b)(4) to less than(b)(4 ): (D)(4) injection, Batch# (b)(4) (b)(4) Iniection, Batch? (b)(4) Injection, Batch# _ (B)(4) B.) Your firm's procedure, Microbiological Environmental Monitoring of the ISO 5 Area of the Hot Cell (Doc# D0012139, Revision I, effective date: 11/01/2020), requires |(B)(4) plates
[FDA 483 observation · FDA]Pharmalogic Salt Lake City, LLC — Repeated analyst errors met only with retraining
FDA483
FDA issued a Form 483 to Pharmalogic Salt Lake City, LLC, a US PET drug manufacturer, after an inspection ending 02/24/2026. The one legible observation is that chromatography testing incidents caused by operator error, such as no blank injected, recurred over several months, and each was closed with retesting and awareness training that did not prevent recurrence.
Published 2026-10-20 · Inspection date 02/24/2026 · Pet Drug Manufacturer · FEI 3029497444
Key facts · Basis: official index plus supporting sources
Facility: Pharmalogic Salt Lake City, LLC, FEI 3029497444
Observation legible: inadequate action to prevent recurrence of nonconformances and quality problems
Incidents: at least 5 missed blank injections in about 4 months, at least 3 injection errors in about 9 months
Insight · Editorial insight
The same type of operator error kept recurring while corrective action stopped at retesting and awareness training. CAPAs that end with training can be judged ineffective when recurrence continues, suggesting that systemic actions to remove the cause may be expected for repeat events.
Check points
Trend review of repeated operator error incidents
Systemic preventive actions beyond training, such as added checks or system controls
Observation detail · 1 observation · OCR reading of the scanned original
The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.
Observation 1
You did not take appropriate action to correct any identified problems to prevent recurrence of a nonconforming product or other quality problem.
Specifically, During review of the quality system related incidents, we observed the following: A. There were at least five occurrences of QC analytical chromatography testing involving operator error resulting in no blank injected during finished product testing of (b)(4) Injection in a period of approximately four months from 05/29/2025 — 10/01/2025. For each occurrence, the testing was re-performed with blank and met specification. For each occurrence, awareness training was conducted. The action taken was inadequate in preventing recurrence. In one example, a repeat incident was logged for the same operator on two consecutive days. B. There were at least three occurrences of QC analytical chromatography testing involving operator error resulting in sample injected without nroduct or no product injected during drug product testing of (b)(4) and (b)(4) Injections in a period of approximately 9 months from 02/25/2025 — 11/16/2025. For two of the incidents, the testing was re-performed and met
[FDA 483 observation · FDA]RayzeBio, Inc — Early release and weak EMPQ investigation
FDA483
FDA issued a Form 483 to RayzeBio, Inc, a US manufacturer, after an inspection ending 02/24/2026. Two observations (1 and 4) were legible: a procedure that allows sterile injectables to ship to customers before analytical testing and batch record review are complete without defining what happens if the product fails, and an inadequate investigation of CFU action limit excursions during environmental performance qualification.
Published 2026-10-20 · Inspection date 02/24/2026 · Manufacturer · FEI 3030530655
Key facts · Basis: official index plus supporting sources
Facility: RayzeBio, Inc, FEI 3030530655
Observations legible: 1 (quality unit procedures) and 4 (discrepancy investigations)
EMPQ: 14 samples above action limits, 315 CFU in total, sources not traced
Insight · Editorial insight
Allowing quarantine shipment by procedure without defined failure and recall steps was cited as a quality unit failure. For short-shelf-life products released before testing ends, whether conditional release is paired with a recall procedure looks like a point inspectors may check.
Check points
Link between release-before-testing and failure handling or recall procedures
Investigation and source tracing of action limit excursions during EMPQ
Documented justification for overdue CAPAs
Observation detail · 2 observations · From the source
Observation 1
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Specifically, A. Your firm's procedure SOP-00013 ("Batch Review and Release Process," v. 5, effective 10/31/2025) for shipping drug products under quarantine is inadequate. The procedure allows shipment of sterile injectable drug products to end customers before the completion of analytical tests and quality review of batch manufacturing records, but it does not specify the steps to be taken if the product fails to meet finished product quality specification(s). This procedure does not ensure the quality of products prior to distribution. B. Your firm lacked a procedure for recalls that details the steps to follow, within the shelf life of the products, in the case of batch failures due to analytical test failures or manufacturing deviations. C. Per SOP-00012 ("Corrective and Preventive Action (CAPA) Handling," v. 2, effective 04/14/2025), Quality Assurance (QA) is responsible for tracking CAPA quality events, and CAPA due dates can be extended during the Implementation phase with appropriate justification. A review of the firm's list of CAPAs revealed that many remain open past their due dates without justification. For example
Observation 4
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet to any of its specifications Specifically, A.
A review of the EMPQ (REC-00703, "Environmental Performance Qualification Summary Report," v0, approved 08/23/2024) showed that protocol deviations were inadequately investigated. Protocol Deviation Reports 11-16 identified 14 samples exceeding CFU action limits, totaling 315 CFUs. The Quality Unit failed to adequately investigate and implement corrective actions after identifying the CFUs, determine microorganism sources or trace them to
[FDA 483 observation · FDA]Spirit Pharmaceuticals — Packaging PQ record gaps, metal detector checks
FDA483
FDA issued a Form 483 with two observations to Spirit Pharmaceuticals, a US pharmaceutical packager and distributor, after an inspection ending 01/25/2017. The firm did not identify the lot used in bottle packaging line performance qualification, its quality unit response to repeated cloudiness and crystallization complaints on a softgel product was inadequate, and metal detector checks did not use non-ferrous challenges.
Published 2026-10-20 · Inspection date 01/25/2017 · Pharmaceutical Packager/Distributer · FEI 3011773798
Key facts · Basis: official index plus supporting sources
Facility: Spirit Pharmaceuticals, FEI 3011773798
Observations: quality unit responsibilities and procedures, routine checks of electronic equipment
Inspection date: 01/25/2017, a past inspection record released now
Insight · Editorial insight
This is a 2017 record, but the findings remain common. Untraceable lots and rejects in packaging line qualification were cited alongside how the quality unit handled recurring complaints for which the supplier claimed a root cause, suggesting that packagers and distributors may also be held to account for tracking supplier quality issues.
Check points
Traceability of lots and rejects used in packaging line PQ
Records confirming supplier root cause actions for recurring complaints
Non-ferrous test pieces in metal detector checks
Observation detail · 2 observations · OCR reading of the scanned original
The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.
Observation 1
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Specifically: 1) Review of the firm's qualification report for bottle packaging line® found that the performance qualification failed to identify the lot number ofproduct used in the qualification operations. Further, when the rejection log was examined for a recording of the lot used in the qualification, there was no record of the rejected product. Finally, review of the inventory card which was requested found that the responsible individual reportedly recorded the wrong lot number. 2) The firm has had a large number of complaints of cloudiness/ crystallization in the softgel product (b)(4) and for specific lots such as manufacturer lot (64) there was a large percentage of rejects and four customer complaints for lot (6)(4) However, although Spirit Pharmaceuticals, LLC internal communication dated April 5, 2016 states in reference to the supplier efforts that "Based on the evaluation done so far they have found the root cause that might be causing the re-crystallization and are in the process of making permissible manufacturing changes on (6)(4) and will implement the required changes to manufacturing process after evaluating pilot scale batches", review of quality system files
Observation 2
Routine checking of electronic equipment is not performed according to a written program designed to assure proper performance.
Specifically: (6)(4)) checking of the metal detectors employed on packaging lines does not employ non-ferrous metal challenges.
[FDA 483 observation · FDA]Tropical Seas, Inc. — Uninvestigated complaint and data integrity gaps
FDA483
FDA issued a Form 483 with eight observations to Tropical Seas, Inc. (inspection date 05/30/2018). Findings included an uninvestigated consumer allergic-reaction complaint, unvalidated batch record software, deficient microbial testing and inadequate process validation (a repeat observation).
Published 2026-10-20 · Inspection date 05/30/2018 · Manufacturer · FEI 1035794
Key facts · Basis: official index plus supporting sources
Observations: eight (complaint investigation, training, equipment maintenance and calibration, microbial testing, electronic records, second-person verification, process validation, in-process controls)
Repeat finding: inadequate process validation, also cited in the 2015 cGMP inspection
Insight · Editorial insight
Closing an allergic-reaction complaint without retesting the retain sample, while relying on unvalidated software that keeps no master batch record revisions, signals that investigation and data management were not working across the quality system. Because process validation was cited again after the previous inspection, the findings may read as ineffective corrective action rather than isolated lapses.
Check points
Documented rationale when a complaint is not investigated
Validation and revision history of batch record and test result software
Preservative neutralization and media growth promotion in microbial testing
Observation detail · 8 observations · From the source
Inspectors: Saundrea A Munroe
Observation 1
The written record did not include the reason an investigation was found not to be necessary when an investigation into unexplained discrepancies was not conducted.
Employees are not given training in the particular operations they perform as part of their function and written procedures required by current good manufacturing practice regulations.
Specifically, you stated on 05/24/18 that your staff ((""") is responsible for maintaining the document : : (b) (6). (b)(7S) control system and has the authority to issue product labels. You stated your staff ) has the
Observation 3
Equipment and utensils are not maintained at appropriate intervals to prevent malfunctions and contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically, 1. On 05/21/18, I observed foreign material that appeared to be rust ona clip that secures the (6) (4) scraper for a (b) (4) kettle (Kettle “. This foreign material appeared to have discolored the scraper. The clip and scraper are internal components of the kettle that come into direct contact with (b) (4) products while batching. Additionally, because there is discoloration of the scaper, there is concern that this component is displaying reactive/absorptive properties. 2. On 05/21/18, I observed a toxic chemical spray can intended to loosen metal parts, stored on the same counter next to product contact utensils designated as "clean". Due to its close proximity, clean utensils could be exposed to toxic chemicals not intended for the finished product. 3. On 05/21/18, I observed a hose designated as "clean" hanging from a tank with the hose ends resting on the floor. Hoses are used to transfer (1) (4) products from the mixers/kettles to holding containers for filling.
Observation 4
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that components and drug products conform to appropriate standards of identity, strength, quality and purity.
Specifically, 1. Finished drug product testing for aerobic microbes is deficient in that the preservatives used in each product are not neutralized or deactivated so that the test results are accurate. Preservatives used include (b) (4) and (b) (4) for Spray products and (b) (4) for all other over the counter drug products. 2. Microbial testing for aerobic microbes is deficient in that growth promotion testing is not performed on each lot ofmedia prepared to ensure the media is capable of growth. You stated for the lots of media
Observation 5
Laboratory records do not include a complete record of all data secured in the course of each test, including all graphs, charts and spectra from laboratory instrumentation, properly identified to show the specific component and drug product tested.
Specifically, your firm uses an internally developed software (b) (4) that creates master batch records and stores test results. You stated this software currently does not maintain previous revisions of master batch records for document management, nor is there a system in place to ensure that master batch records and analytical results are complete, unaltered and inclusive of all activities performed. Additionally, this software has not been validated to demonstrate its ability to ensure data accuracy and security. PRODUCTION SYSTEM
Observation 6
Each component is not added to the batch by one person and verified by a second person..
There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.
Specifically, your process validations for the production of(b) (4) products are inadequate in that they do not include an evaluation of the elements identified below: 1. A requirement for training prior to execution of the validation protocol. 2. Identification of failure modes and critical process steps 3. A method of assessment based on scientific principles 4. Pre-determined acceptance criteria that are specific, measurable and clearly defined (This is a repeat observation from the cGMP inspection performed 11/09/2015 — 11/19/2015)
Observation 8
Written procedures are not followed that describe the in-process controls and examinations to be conducted on appropriate samples of in-process materials of each batch.
Specifically, on 05/21/18, I observed your production staffperform in-process weight and torque checking during the filling of (Db) (4) Lotion, Lot ®)@). The batch record requires in-process testing to be performed (b) (4) . With the prior in-process test documented as occurring at 10:30am, the production staffproceeded to perform the next in-process interval at (b) (4) (b) (4) I observed the staff perform this check and document the time as (b) (4) . The staff changed the documentation to the correct time only after instruction from management following my inquiry. Additionally, your employees failed to initiate an investigation for
[FDA 483 observation · FDA]Catalent CTS, LLC — Water system leaks and microbial control gaps
FDA483
FDA issued a 483 with one observation to Catalent CTS, LLC (FEI 3002929455), inspection date 03/23/2026, finding that procedures to prevent objectionable microorganisms in non-sterile drug products were not established and followed. Inspectors saw multiple water system leaks with standing water and apparent filth, and a water monitoring isolate was not identified to species level as required.
Published 2026-10-20 · Inspection date 03/23/2026 · Drug Manufacturer · FEI 3002929455
Key facts · Basis: official index plus supporting sources
Observation: procedures to prevent objectionable microorganisms in non-sterile drugs not established and followed (one observation)
Details: four water system leaks; a Bacillus isolate was not speciated or investigated
Insight · Editorial insight
Leaks, standing water and apparent filth were seen on a day capsule products were made, and the firm could not document its claim that a leak was already known, which signals a gap in facility maintenance records. Leaving a water isolate unspeciated and uninvestigated shows that the basis for objectionable-organism decisions is under scrutiny even for non-sterile products.
Check points
Documentation of detection, reporting and repair of pharmaceutical water system leaks
Species-level identification of water monitoring isolates and objectionable-organism assessment
Observation detail · 1 observation · From the source
Observation 1
Appropriate written procedures, designed to prevent objectionable microorganisms in drug products not required to be sterile, are not established and followed.
[FDA 483 observation · FDA]Linde Inc — No stability program for medical gases
FDA483
FDA issued a Form 483 with one observation to Linde Inc, a US medical gas manufacturer. The firm had not established a stability program or performed stability studies for USP grade medical gases while continuing to manufacture, release and distribute them.
Published 2026-10-20 · Inspection date 03/26/2023 · Medical Gas Manufacturer · FEI 2523830
Key facts · Basis: official index plus supporting sources
Facility: Linde Inc, FEI 2523830
Observation: no written stability testing program for USP grade gases
Insight · Editorial insight
The case confirms that medical gases, as drugs, need a written program to assess their stability characteristics. Stability testing is easily skipped for gas products, so firms that make or source medical gases may want to check that stability data exist for them.
Check points
Stability testing program for medical gas products
Stability data from gas suppliers
Observation detail · 1 observation · OCR reading of the scanned original
The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.
Observation 1
here is no written testing program designed to access the stability characteristic of USP grade (b) (4) and (b) (4) gases.
Specifically, our firm has not established a stability program, nor you have performed stability studies to assess the stability characteristics of USP grade (b) (4) (b) (4)(b) (4) . & (b) (4) (b) (4) as well as (b) (4) (b) (4) (b) (4), 8(b) (4) (b) (4) | Currently you have manufactured, released and distributed approximately lots from 12/01/2025.
[FDA 483 observation · FDA]Zhejiang, Jinhua Conba Bio-Pharm. Co. Ltd. — Staff training and cross-contamination gaps
FDA483
FDA issued a Form 483 to finished drug product manufacturer Zhejiang, Jinhua Conba Bio-Pharm. Co. Ltd. after its 08/01/2023 inspection. Observations covered weak cross-contamination prevention and monitoring between workshops in the same facility, insufficient training of manufacturing staff including visual inspection, and no growth promotion testing of prepared media.
Published 2026-10-20 · Inspection date 08/01/2023 · Finished Drug Product Manufacturer · FEI 3003663281
Key facts · Basis: official index plus supporting sources
Type: Finished Drug Product Manufacturer, Form 483
Key observations: inadequate staff training, weak cross-contamination and decontamination verification, no growth promotion testing of media
Insight · Editorial insight
Making (b)(4) products alongside other drugs in the same facility while exhaust, area monitoring and decontamination verification fall short reads as a systemic weakness in cross-contamination control. The pairing of inadequate visual inspection training with missing growth promotion testing is also worth noting for the reliability of inspection and test results.
Check points
Cross-contamination risk assessment and residue monitoring of exhaust air and areas in shared facilities
Detection limits and acceptance limits of methods verifying cleaning and decontamination
Growth promotion testing on every lot of prepared media
Observation detail · 1 observation · From the source
Observation 2
eo — Employers enqopad m YWre monipachitea anf Pinieittty Qo prcdiut lack Wha Pratndny rapvived % P2ekorn Yhalir awe function Specifically , Hh.
pmfelop set arpepd M the 1007, fitted tntentdon 3 Shatle Mluden Ow Nok odepynlily Prerad xo de Uisucd infp2titon OYtin She Freez ef titirve ‘Ysur Vaticlélion booch Yyelerer Kor Qolulkon Ghore LAr Lmplopees yee viel tf Comply US ued pndipo Lion Ad ewer 7tay thi yelorady for Dorynoyses Per fprrery ysiaop inkipecdsion Ghore Yaar omptowes wore allowed do gales ys rhO)T bs Gmplls jnSpechor Q ach Wol- Furthrermetse You Olid not Porfoim Wino lntpechn UStig a KE bo~ sine 3 - You ded Visi In ‘on ° Sped US;e Bady x buck Lng
FDA issued a one-observation Form 483 to MSN Laboratories Private Limited, Unit-II after an inspection ending 03/22/2024, citing failure to keep API manufacturing buildings and facilities clean. The investigator saw apparent water staining on ceiling tiles above retain samples in both the API and the KSM/intermediate reserve sample storage rooms.
Published 2026-10-20 · Inspection date 03/22/2024 · Manufacturer · FEI 3008656542
Key facts · Basis: official index plus supporting sources
Observations: 1 — buildings and facilities for API manufacture not maintained in a clean condition
Findings: water staining and unknown residue on ceiling tiles and baseboard in the API reserve sample room; water staining on ceiling tiles in the KSM and intermediate reserve sample room
Insight · Editorial insight
Water staining directly above retain samples suggests possible leaks and can call into question the storage conditions and integrity of those samples. Since retain samples support later investigations and retesting, API and intermediate makers may want to check that reserve sample rooms get the same facility upkeep as production areas.
Check points
Routine inspection records for leaks in reserve sample room ceilings and walls
Procedure for assessing retain samples affected by leaks or contamination
Storage condition controls for KSM and intermediate retain samples
Observation detail · 1 observation · From the source
Inspectors: Daniel L Zheng
Observation 1
Your firm failed to properly maintain buildings and facilities used in the manufacture of API in a clean condition.
[FDA 483 observation · FDA]LCC Ltd. — Discarded raw test data and weak quality unit
FDA483
FDA issued a Form 483 with 11 observations to OTC drug manufacturer LCC Ltd. (FEI 3007255059) following an inspection ending 03/22/2024. Findings include discarded raw data and worksheets, untested components, unsupported expiry dating, obstructed record access, and an unqualified QA/QC manager.
Published 2026-10-20 · Inspection date 03/22/2024 · OTC Drug Manufacturer · FEI 3007255059
Key facts · Basis: official index plus supporting sources
Observations: 11, covering discarded raw data, missing USP component testing, unsupported stability, record access issues, and lack of process validation and equipment qualification
The firm, already under an Import Alert, first denied and then admitted that lots were shipped to the US market
Insight · Editorial insight
Discarding raw data after testing and handwriting "pass" for stability time points points to a systemic data integrity breakdown rather than isolated lapses. Removing a record from the inspection room and changing statements while under an Import Alert suggests that OTC contract and supplier assessments should directly verify raw data retention and quality unit independence.
Check points
Retention of raw test data and worksheets traceable to CoAs
Incoming component testing against USP monograph requirements
Separation of QA and QC roles and qualification of the release approver
Observation detail · 11 observations · From the source
Inspectors: Arsen Karapetyan · Brittny C Cargo
Observation 1
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assure that components, in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity.
Your firm manufactured and shipped OTC drug products shipped via domestic customers). During our review of product test data, we observed the following: A. During our review of final finished drug products lots stated above, when we requested the supporting raw data for most test items, your firm’s plant manager stated that the raw data and worksheets were discarded after analysts performed tests. For example, but not limited to, assay test for active ingredient |) was not always performed for every batch, with testing for one batch Hn used in lieu oftesting another batchGa? Your firm does not have any supporting raw test data or supporting incubator logbooks for microbiological testing listed on your finished product certificate of analyses; and /) test data reported does not appear to be reliable (see Observation 4). B. During our review of your stability study reports and recorded test results for ye for active ingredient [I assay test, along with other test items, were handwritten as “pass” for each stability time point; When we requested the
Observation 2
Each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality.
Specifically, A. The firm's quality unit failed to establish specifications and conduct testing of incoming raw materials, within the respective USP monographs for Limit of These raw materials are received and approved for release without testmmg for these impurity limits. For Example, on or around our firm manufactured lots of OTC dru roduc which was shipped to the US Market (with arrival on or aroun testing was not performed for components per the USP monograph, nor was it performed on semi-finished products as required to be tested by your firm. In addition, the accuracy and specificity of the test methods have not been verified or validated for these components and active ingredient |) Furthermore, your firm’s response to regulatory deficiencies with respect to4 ve included your firm contracting a third-party laboratory to perform
Observation 3
Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength, quality and purity at the time of use.
Specifically, stability studies in support of OTC drug products do not support the stated shelf life/expiry date. Specifically, your firm has not performed adequate accelerated and long-term stability studies in support of your shelf life/expiry date. During our review of your stability studyreports and recorded test| es, drug products, we observed thatyourfirm did not have the supporting raw test data for stated test results for most, if not all test items. For example, assay test, along with other test items, were handwritten as “pass” for each stability time point;
Observation 4
Records associated with drug product components, production, control and distribution and within the retention period for such records, were not made readily available for authorized inspection.
A. During the inspection, your firm provideda list of all OTC drug products manufactured and shipped to the US Market. Pi osent « were observed to be on this list, with manufactured date as Due to your firm’s current Import Alert, we made an inquiry regarding the whereabouts of these lots, and on your firm explained that they were manufactured for the US Market, however, were shipped to a business artner, with the lotslocatednie with no intention to ship to the US Market. On we observed a record which showed the end customer ofthese lots as—_ oe: however before we were able to inquire about this record, your firmtook this record out ofthe inspectional room. When we asked about the record and named the= company we had observed, your firm initially denied what we had observed, however, shortly after adinitted that the™® lots had been manufactured fora trial run with theey company and shipped through a third-party business partner to the US market, having already cleared US customs on or aroundeee stored in a warehouse ready for distribution. B. During our walk-through inspection of your firms in-process testing laboratory on 03/18/2024 located in Factorynllwe observed discarded™® tes
Observation 5
Individuals responsible for supervising the manufacture, processing, packing and holding of a drug product lack the education, training and experience to perform their assigned functions in such a manner as to assure the drug product has the safety, identity, strength, quality and purity that it purports or is represented to possess.
A. Your firm identified one individual as being both the QA Manger and QC Manager, which appears to be a conflict of interest, allegedly responsible for review of testing data and review, approval, and release of OTC drug product batches. However, this individual appeared to lack the education, training, and experience to perform assigned function for either a QA Manager or QC Manager. In fact, when we asked this individual what the acronym “cGMP” stands for through an interpreter, this individual could not provide an answer. Furthermore, we observed that testing data is not reviewed by any personnel at the firm, and production batch records are allegedly reviewed and signed off by either a QC analyst who is responsible for in-process testing operations or a production team lead.
Observation 6
Complaint records are deficient in that they do not include the findings of the investigation and follow- up.
Specifically, from 2021 to 2023, your firm received approximately 15 complaints regarding black particles in yourPo products. Your firm did not adequately perform investigations for root cause determination such as not establishing a cleaning procedure for your 7% fe on all packaging lines. Per your plant manager, the reason for not establishing a cleaning procedure was due to the "process being simple." Per your firm corrective actions for the complaints consisted ofrefresher training for your staffwith respect to assuringnee are cleaned) more frequently however no training appears to have been documented.
Observation 7
The quality control unit lacks responsibility to approve all procedures or specifications impacting on the identity, strength, quality and purity of drug products.
Your Quality Unit has not been effective in carrying-out its duties of ensuring drug products are
Observation 8
Procedures for the cleaning and maintenance of equipment are deficient regarding sufficient detail of the methods, equipment, and materials used in the cleaning and maintenance operation, and the methods of disassembly and reassembling equipment as necessary to assure proper clea...
Observation 9
Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in- process material and the drug product.
Specifically, the manufacturing process for OTC drug products operations have not been validated to show that the process operates within established parameters, can perform effectively and reproducibly to produce a drug product which is meeting its predetermined specifications and quality attributes, although the products have been shipped to the US Market.
Observation 10
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design, of adequate size and suitably located to facilitate operations for its intended use and cleaning and maintenance.
Specifically, your firm does not have written procedures for conducting equipment qualifications such as Installation Qualification (IQ), Operational Qualification (OQ), and/or Performance Qualification (P for all equipment used in the manufacture of OTC drug products ii! During the mspection, your firm personnel, including your QA/QC Manager and Plant Manager not appear to know what equipment qualification meant or what activities they entailed. During the inspection, we observed that your firm has not qualified the following equipment or systems: (1) Manufacture equipment such asom filling lines; (2) stability chambers used for storage of stability samples, observed to have no monitoring for relative humidity; and (3) your firm’sEo system, which your firm does not fully test to assure theia meets the minimum USP| *" quality i!
Observation 11
Batch production and control records do not include complete information relating to the production and control of each batch.
Specifically, your firm’s executed batch records for OTC drug products ack the following information: A. An accurate reproduction of the appropriate master production or control record for accuracy, dated, and singed. Your firm does not maintain a master batch record.
[FDA 483 observation · FDA]Gland Pharma Limited — Inadequate aseptic area cleaning and disinfection
FDA483
FDA issued a Form 483 with 3 observations to sterile drug substance manufacturer Gland Pharma Limited (FEI 3010142300) after an inspection dated 02/25/2025. It cites poor cleaning and disinfection of aseptic areas, an inadequate smoke study, and weak process controls behind particle size distribution (PSD) failures of a sterile API.
Published 2026-10-20 · Inspection date 02/25/2025 · Sterile Drug Substance Manufacturer · FEI 3010142300
Key facts · Basis: official index plus supporting sources
Cleaning: disinfectant was doused on walls in Grade A and B areas, pooling on floors that operators walked across
Process control: repeated PSD specification failures of a sterile API, with 3 of 4 proposed CAPAs not implemented
Insight · Editorial insight
Dousing disinfectant without wiping cannot assure surface contact time, which undermines the demonstrated effectiveness of Grade A and B disinfection and signals a gap in basic sterility assurance. The lack of any batch record control while the PSD root cause kept shifting suggests that process control and CAPA status at sterile API suppliers are worth checking together.
Check points
Disinfectant application method and contact time in Grade A and B areas
Whether smoke studies allow turbulence from interventions to be seen
Implementation status of CAPAs for sterile API PSD failures
Observation detail · 3 observations · From the source
Inspectors: Ashar P Parikh
Observation 1
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room to produce aseptic conditions.
Specifically, Cleaning of the aseptic areas including the Grade A and Grade B areas of the Sterile Area 8 was observed on February 21, 2025. The cleaning process observed was the cleaning which includes a spray and wipe on the surfaces with oo Several deficiencies of the cleaning process were observed including but not limited to the following: e Several times during the cleaning of the return risers, view walls, and in the LAF402, LAF407, and Grade B areas, the operators were dousing the walls with and disinfectant. TheWP and disinfect were observed to be pooling on the floor. The operators were observed walking on the wet floors and moving throughout the Grade A and B areas of the Sterile Area — e Disinfection of the area was deficient in that the disinfect was doused on the walls without the proper use of wipes or mops to ensure the disinfectant touches all required surfaces for the expected contact time. This was observed multiple times including when the operator sprayed disinfectant on the view window and it was observed to only contact part of the window. The
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
Specifically, A.The review of the most recent airflow visualization / smoke study revealed the study is inadequate as the smoke generated is very thick and concentrated in only one area. The airflow patters are difficult to visualize and to determine if there is any turbulence caused by the interventions being performed. B.Your firm does not document the number of sterile room employee shoes that are cleaned on a basis and the cleaning record does not specifically mention the use of the disinfectant [/%®
Observation 3
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Specifically, es API (sterile) batch9 ® manufactured in April 2023, failed to meet the customer specification for particle size distribution (PSD) and was rejected. The root cause was determined to be a lack of monitoring uring s As part of your investigation into the failure, additional data was generated from the subsequent batches fi 049throuh inne? The most recent batch of[8 batch 2 manufactured in May 2024 also failed the product specification for PSD. The investigation into this failure resulted in another possible root cause of the product solution becoming too concentrated due tooe There is currently no control measure for the in the batch record. Three of the four proposed CAPAs from this investigation have not yet een unplemented to date as your firm has not manufactured any additional batches ofa 8o SUNN since May 2024 Without adequate process controls for the manufacturing of this sterile drug substance, there is no
FDA issued a Form 483 with 2 observations to API manufacturer Emcure Pharmaceuticals Limited (FEI 3005782879) after an inspection dated 02/25/2025. It cites visible residues on equipment labeled clean, gaps in cleaning validation and maintenance, and training records without individual verification.
Published 2026-10-20 · Inspection date 02/25/2025 · API Manufacturer · FEI 3005782879
Key facts · Basis: official index plus supporting sources
Equipment cleaning: equipment labeled clean showed visible residues, and no cleaning validation establishes residue limits
Training records: group training completion is entered by the trainer without individual trainee signature or verification
Insight · Editorial insight
A mismatch between clean status labels and actual residues, with no basis for residue limits or hold times, signals that API cross-contamination control exists mainly on paper. Because an untrained operator performed cleaning and training records lack individual verification, API supplier assessments may want to link cleaning validation scope with operator qualification records.
Check points
Residue limits and clean hold time justification in cleaning validation
Visual inspection criteria for equipment labeled clean
How individual trainees confirm completion in training records
Observation detail · 2 observations · From the source
Observation 1
Failure to establish and follow adequate written procedures for cleaning and maintenance of equipment to prevent contamination or carryover of materials.
Failure to ensure proper documentation and verification of training records.
Specifically, your firm failed to adequately document and verify training records for personnel involved in manufacturing, equipment, and cGMP training. For example, e The current training system does not require individual trainees to electronically sign and verify their completion ofANY group training. e Training records for ALL group trainings are entered by the trainer for all attendees without individual authentication or verification. e There is no supporting documentation ensuring that each trainee received and understood the training.
FDA cited Ritsa Pharma Private Limited with one observation, at an inspection ending 09/05/2025, for not validating the reliability of component suppliers' certificates of analysis at appropriate intervals.
Published 2026-10-20 · Inspection date 09/05/2025 · Manufacturer · FEI 3025926685
Key facts · Basis: official index plus supporting sources
Observation: API container test results compared against supplier COAs without first establishing supplier reliability
Sampling: materials scooped from only part of the container, without testing across container depth for uniformity
Insight · Editorial insight
The observation signals concern over accepting incoming components on supplier COAs without the reliability validation that would justify relying on them, and over judging uniformity from samples taken in only part of a container. Sites that reduce component testing based on supplier COAs may want to review the basis and frequency of their supplier reliability checks alongside how representative their sampling locations are.
Check points
Basis and revalidation interval for supplier COA reliability
Representative sampling across container depth
Scope of identity, purity and strength testing at receipt
Observation detail · 1 observation · From the source
Inspectors: Pearl C Ozuruigbo
Observation 1
Establishment of the reliability of the component supplier's report of analyses is deficient in that the test results are not appropriately validated at appropriate intervals.
FDA issued API manufacturer HEC Pharm Co. Ltd. five observations at an inspection ending 11/21/2025, led by an inadequately validated impurity method and inadequately qualified laboratory instruments and software.
Published 2026-10-20 · Inspection date 11/21/2025 · API Manufacturer · FEI 3006259537
Key facts · Basis: official index plus supporting sources
Impurity method: an unknown peak found in the assay chromatogram during an assay OOT investigation had not been detected by the impurity test
Other observations: unqualified UHPLC-MS data-processing software, no growth promotion testing of media, unaddressed equipment leakage, inadequately qualified DCS software
Insight · Editorial insight
That an unknown peak missed by the impurity method surfaced only during an assay OOT investigation signals that the method's specificity did not adequately support release testing. With the MassLynx and DCS software qualification also cited, buyers of APIs from this site may want to look at both the impurity profile and how computerized systems are controlled.
Check points
Specificity and unknown-impurity detection of the impurity method
Completion of qualification for analytical data-processing software
Growth promotion testing of microbiological media
Observation detail · 5 observations · From the source
Inspectors: Adetutu M Gidado
Observation 1
Analytical method used for determination of impurities in API is inadequately validated.
Specifically, the impurity method used for determination or quantification of impurities nw @ Active Pharmaceutical Ingredient (API) did not detect the presence ofan unknow impurity @ @ (b) 4) in the test sample solution. On 02/20/2025, OOT-4 «) was initiated for assay OOT for () «4) batch# & @ During the investigation, an unknown peak was detected in the assay chromatogram, which had not been detected in the impurity test chromatogram.
Observation 2
Laboratory instruments are inadequately qualified for their intended use.
Specifically, the Ultra High Performance Liquid Chromatography-Mass Spectrometer (UHPLC-MS) used for determination }) (4) impurities iN w@ API has not been fully qualified for its intended use. Although, the installation, operation and performance qualification of the instrument was performed in July 2025 and the instrument has been used for method validation and release testing since August 2025, the MassLynx software used for data analysis and processing has not been qualified to ensure data integrity and compliance.
Observation 3
The culture media ®@® used for microbial enumeration and environmental monitoring is not validated or adequately validated to determine its capability to support the growth of specific microorganisms.
Specifically, growth promotion testing was not performed on the culture media used for surface microbial monitoring in the laboratories. In addition,w water was used for
Observation 4
Manufacturing equipment are not maintained to prevent malfunctions.
Specifically, on 11/17/2025 continuous leakage of liquid material was observed from the o@ used during thee @ step form @ Although the leakage was attributed to high operating, no corrective actions were taken to address the issue.
Observation 5
Manufacturing computer and or related system is not adequately qualified for their intended use.
Svecificallv. the distributed control system (DCS) software used to automate and monitor the operation the (b) @) production process system did not detect that a value was open during manufacturing, which led to partial product loss for a batch# o @
[FDA 483 observation · FDA]Lonza Bend Inc. — Recurring deviations not trended
FDA483
FDA issued Lonza Bend Inc. one observation at an inspection ending 05/19/2026 for failing to thoroughly review unexplained discrepancies and not trending deviations to prevent recurrence.
Published 2026-10-20 · Inspection date 05/19/2026 · Manufacturer · FEI 3003722743
Key facts · Basis: official index plus supporting sources
Gasket deviations: nitrile gaskets used instead of the specified type and repeated extraneous matter in nozzles and housings
Data deviations: repeated PI system data loss, missing audit trail entries and deleted batch report data
Insight · Editorial insight
Gasket-related extraneous matter and PI data loss or audit trail gaps each recurred several times without being linked through trending, signaling deviation handling that stopped at closing individual events. With documentation gaps also cited, such as the same operator cleaning and visually verifying a gasket, companies using this site for contract manufacturing may want to check its deviation trending and data integrity controls.
Check points
Trending of same-cause deviations such as gasket failures and links to prevention
Backup and audit trail continuity of process data systems
Separation of performer and verifier in cleaning and verification records
Observation detail · 1 observation · From the source
Inspectors: Ana-Maria A Plapcianu · Conor J Mccarron
Observation 1
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
FDA issued a Form 483 to Axogen Corporation, a US drug substance and drug product manufacturer, after an inspection ending 04/29/2025. Six legible observations cover uncontrolled access to AVANCE final product and printed label storage, gaps in environmental monitoring performance qualification of classified areas, no disinfectant efficacy support, too few staff qualified for potency testing, recurring pest sightings and restricted deviation initiation.
Published 2026-10-20 · Inspection date 04/29/2025 · Drug Substance and Drug product Manufacturer · FEI 3023488176
Key facts · Basis: official index plus supporting sources
Pests: 12 sightings in controlled areas since January 2025 (4 in classified areas), 5 more after corrective action
Insight · Editorial insight
Final product in unlocked freezers open to cleaning contractors was cited alongside a system where only a few trained staff can raise deviations. Basic access control and deviation reporting routes are reviewed as evidence of quality oversight, which makes them early items to check at sites whose organization and infrastructure are still growing.
Check points
Access control for final product and printed label storage
Static and dynamic conditions covered in environmental monitoring PQ
Route for floor staff to raise deviations directly
Observation detail · 6 observations · OCR reading of the scanned original
The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.
Observation 1
Procedures describing the warehousing ofAVANCE final product, printed product labels, and retain samples are not established.
Environmental monitoring program is deficient to ensure classified environments.
For example: a. Monitoring of viable and nonviable particulates under static and dynamic conditions during the environmental monitoring performance qualification (EMPQ) of ISO classified manufacturing areas was inadequate to support routine environmental monitoring. Specifically, the following monitoring was not performed: i. Microbiological surface monitoring ofISO & ISO &, and ISO& classified areas under static condition was performed (b) (4) to prevent recovery ofmicroorganisms present. ii. Monitoring ofnonviable particles in ISO' classified areas under static and dynamic conditions, and in ISO & classified areas under dynamic conditions was not performed. iii. Microbiological active air monitoring in ISO § classified areas under static and dynamic conditions, and in ISO & and ISO& classified areas under dynamic conditions was not performed. Further, passive air monitoring using microbiological settling plates in ISO & classified areas under static conditions, and ISO % and ISO & classified under static and dynamic conditions was not performed. Additionally, microbiological surface monitoring was not performed in ISO §, ISO §, and ISO & classified areas
Observation 3
Manufacturing building used in the manufacture ofAVANCE does not have the adequate controls to prevent contamination.
Laboratory controls are not adequately established and do not include scientifically sound test procedures and sampling plans designed to assure that AVANCE drug product conform to appropriate standards of identity, strength, quality, and purity.
Investigations into pest control deviations are deficient.
Specifically, twelve incidences of pest sightings were observed in controlled areas since 01 January 2025, four ofwhich were in classified areas, and no CAPAs were opened prior to 23 April 2025. Corrective actions were implemented from DEV-2024-1511, which was opened on 27 November 2024. However, the corrective actions were not effective as five pest sightings have been identified in (b) (4) since 26 March 2025.
Observation 7
Deviation management is inadequate to demonstrate quality oversight ofthe manufacturing process.
For example, the process to document and report deviations per ®®-0013 R23 “Deviation Procedure” lacks the assurance that all deviations are recorded, because only select individuals who are trained in the deviation process can initiate deviations. Deviations cannot be initiated directly by manufacturing or laboratory staff who are not trained to the deviation process even if staff may be most knowledgeable about a specific deviation. / wy Pp; / .)
[FDA 483 observation · FDA]Capricor, Inc. — Overdue deviations and NCPs, no quality agreements
FDA483
FDA issued a Form 483 to Capricor, Inc., a US drug substance and drug product manufacturer, after an inspection ending 05/30/2025. Three legible observations (2 to 4) cover weak trending of 27 missing-data deviations and overdue NCPs and CARs, no quality agreements with outside parties including release testing, and no procedures for complaints and returned product.
Published 2026-10-20 · Inspection date 05/30/2025 · Drug Substance and Drug product Manufacturer · FEI 3021247180
Key facts · Basis: official index plus supporting sources
Facility: Capricor, Inc., FEI 3021247180
Observations legible: 2 (procedures not followed), 3 (quality agreements), 4 (quality unit procedures)
Deviations: 27 missing-data deviations over 2 years without adequate trending
Insight · Editorial insight
Twenty-seven deviations of the same missing-data type over two years without trend analysis were cited together with missing quality agreements for outside release testing. For sites that rely heavily on outside testing and contractors, deviation trending and contractor quality agreements may be treated as baseline checks of the quality system.
Check points
Trending of recurring deviations and the actions it drives
Extension requests on record for overdue NCPs and CARs
Quality agreements with release testing and other contractors
Observation detail · 3 observations · OCR reading of the scanned original
The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.
Observation 2
Written procedures are not followed.
Specifically: a. According to CORP-QA-SOP-0166, ‘Deviations and CAPA Management SOP’, the trending and analysis of deviations should be performed by the quality unit to identi t issues; however, over a 2-year period, there have been 27 deviations related to missin data incidents observed on the (b) (4) which are used for in the(b) (4). b. According to -OA-SOP- ‘Deviations and CAPA Management SOP’, nonconforming products (NCPs) must be orccrricesteal an extension is issued; however, there are outstanding NCPs without extension requests. Specitically, -582, NCP-580, and NCP-86 were past due, with the oldest outstanding initiated on May 10, 2023, with no record of extension requests. NCP-535, initiated on June 03, 2024, had one extension request that was past due and no additional extension requests. c. According to CORP-QA-SOP-0166, ‘Deviations and CAPA Management SOP’, corrective action reports (CARs) must be unless an extension is issued; however, CAR-212, CAR-244, CAR-246 were past due with no record of a requested extension. d. According to CORP-QA-SOP-0109, ‘Good Documentation Practices’, individuals creating, correcting, and presenting data generated during GxP must comply with
Observation 3
Quality agreements are not established between(b) (4)racilities and (B)(4) to delineate the roles, operational activities and responsibilities of each ensure compliance with CGMP.
Specifically, no quality agreements have been established with multiple including the fe for t release esting, testing, and
Observation 4
Procedures applicable to the quality control unit in writing.
Specifically, procedures for the receiving, evaluating, and documenting complaints related t d for the handling, evaluation, and disposition ofreturned(6) (4) have not been established. Si is not maintained in a state ofgood repair. specitically,(D) (4) ws: ahserved onthe inside theIS con hsnutastring suite (ProductionoF /S/
[FDA 483 observation · FDA]Lonza Portsmouth, Inc. — CASGEVY aseptic, cleaning and GDP failures
FDA483
FDA issued a Form 483 to Lonza Portsmouth, Inc., a US cell therapy manufacturer, after an inspection ending 06/06/2025. Nine legible observations span CASGEVY manufacturing, including poor aseptic behavior found on CCTV review, missed cleaning of classified areas, documentation failures such as records found in the trash and replaced signatures, repeated pressure differential losses, and deviation data deleted on cancellation.
Published 2026-10-20 · Inspection date 06/06/2025 · Drug Product Manufacturer · FEI 3001451441
Key facts · Basis: official index plus supporting sources
Deviations: cancelled without documented justification and deleted from the electronic system
Insight · Editorial insight
FDA cited operator aseptic behavior on the basis of CCTV footage, alongside a practice of deleting deviation data from the electronic system when cancelling it. Since video can serve as evidence of aseptic practice and deviation cancellation history is reviewed, this is a case worth noting for how firms review their own CCTV and keep cancelled deviation records.
Check points
Routine review of CCTV footage of aseptic work
Recorded reasons and retained data when deviations are cancelled
Deviation handling and root cause work for repeated pressure losses
Observation detail · 9 observations · OCR reading of the scanned original
The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.
Observation 1
Aseptic processing ofCASGEVY drug product is deficient.
The following practices that are inconsistent with Good Documentation Practices were observed: a.
Your firm uses (b) (4) to instruct quality control analysts to review/ revise environmental monitoring records. On June 05, 2025, (b) (4) 2ncompassing review comments were observed on a laboratory record and in the trash can to the (b) (4) (Room (6) (4), For example, one (fb) (4) reads (b) (4) b. Five original (b) (4) were identified in the aforementioned trash. — C3 oy he authenticity of documents cannot be established. Specifically, the comment on page 48 of ofbatch records for lot indicates that spreadsheet was reprinted for clarity on December 18, 2024. The performer’s signature dated October 4, 2024, for Step 10.3 was crossed out and replaced j with the reviewer’s signature dated December 18, 2024. The original excel spreadsheet was not attached to the batch records and remains missing.
Observation 4
Heating, ventilation, and air conditioning maintenance and controls are inadequate.
For example: a. There have been repeated losses in differential pressure within the Grade Marcas for extended periods of time (e.g., July 11, 2024, August 19, 2024, October 08, 2024, October 14, 2024). These events were not deemed deviations, and no root cause orcorrective and preventive actions (CAPA) were identified. The pressure differentials within the Grade areas are completely lost. Upon retrospective evaluation in response to FDA request, your firm tabulated that a repeated (b) (4) ofthe respective fan unit led to the loss of pressure differentials. Nevertheless, you failed to holistically identify or rectify the cause ofthe (b) (4) b. Grade areas to Cell Therapy contain HEPA air supply vents adjacent to (b) (4) which lack installation of a (b) (4)
Observation 5
Areas designed to (b) (4) in a biological safety cabinet are deficient regarding characterization and mapping of the areas and operations for aseptic processing ofdrug products.
Specifically, a. Turbulent upward airflow was observed in Grade o®-ooms when operators opened (b) (4) in (b) (4) b. During operations in the BSC, turbulent airflow was observed in the prevailing Grade” environment near the operator’s (b) (4) c. Worst-case operations were not challenged during the full dynamic smoke study supporting operations in the BSC, including maximum number of (b) (4) (b) (4) |
Observation 6
Management of deviations and anomalous events is inadequate to identify root causes and appropriate corrective § actions.
Environmental monitoring and control are deficient.
For example: a. The non-viable particulate monitoring on (b) (4) exceeded the prospective allowable limits. Nonetheless, your firm deemed the results in specification. The determination that the results were in specification was based on an assignment ofan (fb) (4) _ status despite no ongoing manufacturing operations. b. Procedure USPO-1637 titled “Remedial Action for Environmental, Water, Clean Steam, and Gas Monitoring Data” stipulates (b) (4) (b) (4) Thus, your response to (b) (4) does not include the appropriate scrutiny and follow-up to address the potential problem. OBSERVATION 8 () (4) . Your firm routinely downgrades Grade suites intended for commercial CASGEVY manufacturing (b) (4) (b) (4) to.Grade environmental status for the purposes of personnel training. The procedures followed to restore Grade status are inadequate to ensure purported safety of products manufactured in (b) (4) and (b) (4) The following deficiencies were observed: a. USPO-5217 indicates that (b) (4) However, the limits applied tothe EM data collected, were set at Grade (Db) (4) limits, as opposed to (b) (4)limits as required per USPO-5217. The total particulates (per m*) data collected for (b) (4) (b)
Observation 9
Each batch of drug product purporting to be sterile and/or pyrogen-free is not adequately tested to determine conformance to such requirements.
Specifically, sterility samples ofCASGEVY drug product are stored frozen under liquid nitrogen per procedure USPO-3046| titled ' (b) (4) Analytical Testing - QC Monograph for(®) (4) Product Samples”, and shipped in liquid nitrogen prior to sterility testing.
Observation 10
Pest control program is deficient.
The pest contro] trending report for Q1 2025 indicated numerous incidences of insects (same type) in (b) (4) and Grade” storage room (6) (4) which are : (b) (4) corridor and Grade” corridor, respectively. The same insect species was reported to be persistently seen in the facility with incidences varying seasonally. No source for the insect entry has been identified, and no deviation has been initiated.
[FDA 483 observation · FDA]Genlbet Biopbarmaceuticals SA — Process control and cleaning validation gaps
FDA483
FDA issued a Form 483 to Genlbet Biopbarmaceuticals SA, a drug substance and drug product manufacturer in Portugal, after an inspection ending 01/31/2023. Four legible observations cover process control data that did not support the maximum target batch size, hold times or operating ranges, cleaning validation that did not represent hard-to-clean areas, maximum lot size or hold times, no decontamination efficacy study, and procedures that do not set how long cleaned equipment may stay exposed.
Published 2026-10-20 · Inspection date 01/31/2023 · Drug Substance/Drug Product Manufacturer · FEI 3011160795
Key facts · Basis: official index plus supporting sources
Facility: Genlbet Biopbarmaceuticals SA, FEI 3011160795
Process performance qualification batches that did not represent the approved maximum target batch size, and cleaning validation that did not reflect real post-cleaning hold times and maximum lot size, are a typical way inspectors probe process and cross-contamination controls on shared equipment. Firms may want to check that their own validation batches cover worst-case conditions: maximum batch size, hard-to-clean areas and actual hold times.
Check points
Whether PPQ batch sizes represent the maximum target batch size
Hard-to-clean areas, maximum lot size and hold times in cleaning validation
Decontaminant efficacy studies
Observation detail · 4 observations · OCR reading of the scanned original
The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.
Observation 1
There are no written procedures for production and process controls designed to assure that the| __,,, have the identity, strength, quality, and purity they purport or are represented to possess.
Specifically, there is insufficient data to support the maximum target batch size, - _ hold time, and process control parameters for the manufacture of ww . a.The|~ executed batch sizes for the process performance qualification an | sw ~~) do not represent the maximum. target batch size of vom as per the current approved master batch record, wo : b. There is insufficient data to ensure that the uniformity of the formulated _,,, containing _,,, - within the is maintained throughout the hold time and during the c. The operating ranges specified during -— manufacturing are not optimized. For example, an the manufacturing batch record, Curent operatingrangesfof ats respectively. d. There is no| detection device toensure thatthe = +~—==—————_jis freeof|.. _ contamination. e. The supplier for ene respectively), used for the = steps during the manufacturing of __,, , allows the presence ofparticles __... . A toxicological assessment was not performed to evaluate the safety of the) . - hile using which are not particulate-free.
Observation 2
Equipment cleaning processes are inadequate.
Specifically: a. The cleaning validation study dm | Cleaning Validation Summary Report) performed on we | ye |Contact equipment does not ensure removal of the| Specifically: _ was not performed to ensure that the product is removed from the difficult to clean areas. ii. _ was not assessed. iii. The cleaning validation did not include the maximum lot size of oe b, ~ hold time is not representative ofthewe |manufacturing rocess, which includes Pr that equipment are exposed to the Grade environment after cleaning) _ . c.|~ |hold time is not representative of the ,, manufacturing process, which includes a hold) - | manufacturing) ,. decontamination.
Observation 3
Decontamination is incomplete or not adequately demonstrated to ensure prevention of cross-contamination.
Specifically: a. A decontamination study was not performed to evaluate the effectiveness of _ ,,,, which is used to decontaminate) ... parts, against! so ; | we , Report on the Cleaning Validation Strategy and Results did not evaluate the material of construction of all equipment or| materialsincluding == lay sts—~s—sY
Observation 4
Written procedures for decontamination, cleaning, and maintenance of equipment are deficient regarding sufficient details to protect equipment from contamination prior to use.
For example: a. (eye) one , do not specify the duration that equipment may be exposed to the environment after cleaning. a , Cleaning Validation Summary Report, does not specify how the) - _hold time is determined. c. Protocols governing decontamination of - —_|containing equipment that - the manufacturing suites are deficient regarding sufficient details such as the locations in order to prevent contamination.
[FDA 483 observation · FDA]Kamada Ltd. — Use of unvalidated amended procedures
FDA483
FDA's inspection of drug substance and drug product manufacturer Kamada Ltd. (inspection date 03/02/2023) cited five observations, including the use of unvalidated amended procedures, facilities not in good repair, and deficiencies in aseptic filling setup.
Published 2026-10-20 · Inspection date 03/02/2023 · Drug Substance and Drug product Manufacturer · FEI 1000630279
Key facts · Basis: official index plus supporting sources
Firm: Kamada Ltd., FEI 1000630279
Process: unvalidated amended procedures used when equipment and processes fail, and unvalidated SOP versions applied to PPQ lots
Facilities: 20 power outages in the last three years, repeated water leaks into production areas, and 20 pressure differential excursion deviations
Insight · Editorial insight
Responding to equipment and process failures with unvalidated procedures that differ from the licensed process, without adequately evaluating their impact, signals a gap between change control, process validation and actual operations. Together with power outages, leaks and pressure excursions recurring after CAPAs, the effectiveness checks of CAPAs are also worth reviewing.
Check points
Change control and impact assessment records for temporary or amended procedures used during process failures
Validation status of SOP versions applied to PPQ lot manufacturing
Effectiveness verification of CAPAs for recurring facility issues such as outages, leaks and pressure excursions
Observation detail · 5 observations · From the source
Inspectors: Pete Amin · Olga Simakova
Observation 1
Adequate process validation for (b) (4) used during the (b) (4) =E step was not for(b) (4) Jr resulted in mishandling of (b) (
Observation 2
Internal SOPs, recommendations of the equipment's manufacturer and process control procedures in execution of various production and process control functions are not followed, and non -validated "amended" procedures are used when equipment and processes fail.
No data package is sent to FDA/CBER to demonstrate that safety, purity, potency, and effectiveness of product manufactured using these amended processes are equal to or greater than product manufactured by the licensed process. Specifically, a. During Cytogam manufacturing run, non -qualified (b) (4) to the (b) (4) tep during manufacturing of the lot (b) ( led to about (b) (4) and difficulties in sample collection. The impact of this unqualified amended procedure on the manufacturing process has been insufficiently evaluated. b The unvalidated fourth version of the (b) (4) in the Production of Cytogam" SOP (b) (4) was used during the manufacturing of the PPQ lots (b) (4) xhile the unvalidated fifth version of this SOP with major revisions including (b) (4) (b) (4) procedure of the (b) (4) was used to manufacture the PPQ lot (b) (4) The impact of these changes on the manufacturing process have not been validated. c. After(b) Mat the (b) ( in (b) (4) Ifailing(b) ( reach the (b) (4) (a critical parameter), the (b) (4)_MMI was approved to proceed to the next stage during manufacturing of the (b) (4) PPQ lot (Deviation MDR -43906). The impact of this amended procedure on the manufacturi
Observation 3
Facilities are not in state of good repair.
For example Beit Kama TYPE OF ESTABUSHMENT INSPECTED Drug substance and Drug Product Manufacturer a. Twenty incidents of power outages were noted in last three years caused by incidents within the company including a recent power outage noted January 2023. As of this inspection, preventive actions including (b) (4) (b) (4) are still pending. b. There were multiple incidents of water leaks (the number of leaks were 11 in 2021 and 4 in 2022) that penetrated the production areas. Several Corrective and preventive actions (CAPA) were taken to address the issue. However, two leakage incidents occurred again in January 2023. The completion of the repair of the (b) (4) (b) (4) to prevent rain penetration preventive actions are pending as of this inspection. c. There are twenty pressure differential excursion related deviations documented (last two years) in the production areas, one of the root causes was operators not closing the production areas door properly or blocking the air shutter in the vial preparation room. CAPA 46034 was open on 03/02/2023 during this inspection.
Observation 4
During observation of aseptic filling setup procedure, the followings were noted in filling suite"(room(b) ( a.
Product spill incident during PPQ "'run required an additional intervention in the critirI fi4ling areas including (b) () removal of glass bottles, cleaning the product spill, and cleaning the filling areas (2022). additional media fill study were performed in 2022, however these additional interventions was not captured as part of the several media fill study performed after this incident in 2022. b. The trash bin partially blocked the air return grill, filling suite used 03) recirculating air. c. Current routine monitoring procedure for the critical areas during aseptic filling setup does not include the monitoring during (b) (4) connection to product transfer line. Firm initiated a CAPA during last day of this inspection.
Observation 5
Failure to establish adequate written procedures for the labelling of the (b) (4) drug substance) to assure the proper labelling and to prevent mix ups of the drug substance stored in multi -product facility.
FDA issued a 483 with 8 observations to drug manufacturer Jubilant HollisterStier LLC at the close of an inspection on 06/17/2026. Core issues are inadequate investigation of 14 recurring endotoxin OOS and OOT results in a utility system, missing requalification after a system change, and failure to follow audit trail review and data reprocessing approval procedures.
Published 2026-10-20 · Inspection date 06/17/2026 · Drug Manufacturer · FEI 3010477
Key facts · Basis: official index plus supporting sources
Firm: Jubilant HollisterStier LLC, FEI 3010477
Inspection date: 06/17/2026 (establishment type: Drug Manufacturer)
8 observations: component identity testing, expired materials co-mingled, endotoxin OOS investigation, system requalification, BET sample mixing, sampling plans, test procedures not followed, data integrity procedures
Endotoxin OOS and OOT: 14 recurring results from July 2024 to January 2026, no root cause found and CAPAs ineffective
Insight · Editorial insight
Fourteen recurring endotoxin OOS and OOT results with no identified contamination source, in a system run without requalification since a storage tank and distribution loop were added in 2011, signal that investigation failures and an equipment validation gap reinforced each other. Combined with an audit trail access path that leaves no time stamp and data reprocessing without second-person review or supervisor approval, the reliability of the endotoxin test data itself is worth questioning.
Check points
Root cause investigation of recurring endotoxin OOS and OOT and CAPA effectiveness
IQ, OQ and PQ requalification and change control justification after utility system changes
Audit trail access control and second review and prior approval for data reprocessing
Observation detail · 8 observations · From the source
Inspectors: Katherine E Jacobitz · Walden H Lee · Homero W Aguilar · Bryan L Mcguckin
Observation 1
Component testing is deficient in that each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality.
Specifically, your firm does not always perform complete identification testing of raw materials (b) (4) that is used as an ingredient in the manufacture of your (b) (4) injection and (b) (4) solution (b) (4) products. For (b) (4) raw materials supplied to you by your client used in the manufacture of(b) (4) injection, (b) (4) used in (b) (4) , your firm relies solely on the client and raw material supplier's certificates of analysis (CoA) for the analysis of (b) (4) (b) (4) and (b) (4) concentrations. Your firm only performs USP spectroscopic identification testing on (b) (4) raw material supplied to you by your client. The (b) (4) received by your firm frem-yeurchent, is received in (b) (4) containers. Your
Observation 2
Written procedures are not followed for the storage of components.
Specifically, Your firm's written procedure (SOP 000497-R2, Disposing ofObsolete/Outdated Warehouse Inventory, Revision: 2, Effective Date: 30 Oct 2023) requires that materials reaching their retest or expiry date be physically segregated. On 06/08/2026 and 06/12/2026, expired components were observed co-mingled with released raw materials, with no physical separation or quarantine designation including, but not limited to: e (b) (4) API/USP, Batch: (b) (4) , Expiration Date: (b) (4) e (b) (4) USP-NF, Batch: (b) (4), Expiration Date: (b) (4) e (b) (4) , Batch: (b) (4) , Expiration Date: (b) (4) e (b) (4) Sterile Goggles, Batch: (b) (4) , Expiration Date: (b) (4) (b) (4) of(b) (4) API/USP, (Batch: (6) (4) , EXP: (b) (4) ) was used in the
Observation 3
Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
Observation 5
The sensitivity of test methods have not been established.
Laboratory controls do not include the establishment of scientifically sound and appropriate sampling plans designed to assure that components conform to appropriate standards of identity, strength, quality and purity.
Specifically, the firm does not test or monitor (6) (4) quality at intermediate (b) (4) steps, (b) (4) (b) (4) , or (b) (4) storage tank. The quality unit has not established monitoring for incoming feed (6) (4) quality across key chemical attributes, including, but not limited to, (b) (4) (b) (4) . No sampling ports or monitoring points are established downstream of(b) (4) equipment, including the (b) (4) unit. This (6) (4) supplies the (b) (4) system, which is used in the manufacture of (b) (4) drug products. The firm's current monitoring of the (6) (4) system and incoming feed (b) (4) is limited to (0) (4) sampling locations, as defined in SOP 015665, titled "EM Sampling: Utility Sampling," Revision 10
Observation 7
Established test procedures are not followed.
Observation 8
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Specifically, 1) SOP-000974 “Data Integrity for Quality Control, Rev. 3” Attachment 2, provides a general overview only, of your audit trail procedure which governs all audit trail enabled equipment. On 06/17/2026 during discussion with your QC Compliance Scientist of said audit trail protocol for HPLC (b) (4) ((b) (4) ) data, it was determined there is no procedure utilized that ensures software specific review is conducted nor that audit trails are conducted in a repeatable manner. SOP- 000974 was the only procedure noted as being utilized to conduct said audit trails. Furthermore: A. On 6/16/2026, during discussion of “(b) (4) Bacterial Endotoxin Test: (b) (4) Method”, one of your lead microbiologists stated that there were two avenues in which the audit trail for the (b) (4) could be accessed. One way, detailed by the procedure, SOP-001186 “(b) (4) Bacterial Endotoxin Test: (b) (4) Method”, revision 22, which when followed, records a time stamp for accessing the audit trail,
[Warning Letter · FDA]Zhejiang Gaorong Cosmetic Co., Ltd. — Component identity testing and QU oversight gaps
FDACGMP
FDA CDER issued a Warning Letter to OTC drug manufacturer Zhejiang Gaorong Cosmetic Co., Ltd. after a records review, citing failure to identity-test incoming components and failure to establish an adequate quality unit.
Published 2026-10-20 · Issuing office / date Center for Drug Evaluation and Research (CDER) · 10/01/2026
Key facts · Basis: official index plus supporting sources
Violation 1: no identity test for each component and supplier COA reliability not established (21 CFR 211.84(d)(1) and 211.84(d)(2))
Violation 2: adequate quality control unit not established (21 CFR 211.22(a))
Import Alert 66-40 placement on July 31, 2026
Issuing office/date: CDER · 10/01/2026
Insight · Editorial insight
FDA tied the acceptance of high-risk components on supplier COAs alone to lethal poisoning incidents, signaling that incoming identity testing is a core enforcement focus. Because incomplete batch records and missing stability support were also framed as quality unit failures, component control gaps may be worth viewing as a test of the whole quality unit.
Check points
Identity testing of every incoming component lot
Initial validation and periodic revalidation of supplier COA results
QU final review of batch records and stability data
Violation detail · 2 items · From the source
Violation 121 CFR 211.84(d)(1)
Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).
Violation 221 CFR 211.22(a)
Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).
[Warning Letter · FDA]Signature Formulations LLC — Shared-equipment cross contamination in all lots
FDACGMP
FDA CDER issued a warning letter to Signature Formulations LLC after FDA-sampled contract-manufactured drug lots all showed contamination. FDA deemed the products adulterated due to cross contamination from shared equipment and insanitary manufacturing conditions.
Published 2026-10-20 · Issuing office / date Center for Drug Evaluation and Research (CDER) · 10/01/2026
Key facts · Basis: official index plus supporting sources
Prior actions: Warning Letter 320-26-38 and a 2025 recall for the same contamination
Requests: inventory list and disposition plan, commitment to stop shared-equipment production, written response within 15 business days
Insight · Editorial insight
By calling contamination in every sampled lot a systemic failure that retrospective testing cannot fix, FDA signals that shared-equipment cross contamination must be prevented by design and segregation rather than testing. Since contamination recurred despite a prior warning letter and recall, contract manufacturers handling highly potent ingredients alongside other products may want to review their level of segregation, such as dedicated equipment, HVAC and airlocks.
Check points
Segregation level for highly potent ingredients, including dedicated equipment and HVAC
Evidence that cleaning of shared equipment removes residues
Effectiveness of CAPA after repeated contamination recalls
[Warning Letter · FDA]Baxter International Inc. — Beta-lactam cross-contamination, aseptic gaps
FDACGMP
FDA CDER issued a Warning Letter to Baxter International Inc. after inspecting its Round Lake injectable facility (Baxter Healthcare Corporation), citing CGMP violations covering cephalosporin cross-contamination, aseptic process validation, visual inspection and deviation investigations. FDA stated the drug products are adulterated.
Published 2026-10-20 · Issuing office / date Center for Drug Evaluation and Research (CDER) · 09/29/2026
Key facts · Basis: official index plus supporting sources
Issuing office/date: CDER, 09/29/2026
Inspection: March 23 to April 2, 2026, Round Lake facility
Key violations: inadequate beta-lactam separation, aseptic validation and media fill gaps, unqualified visual inspectors, invalidated sterility failure
Related action: voluntary recall of cefazolin Lot LD175708 after FDA contact
Insight · Editorial insight
Repeated cephalosporin detections despite a sealed wall and dedicated HVAC signal that FDA benchmarks beta-lactam segregation against the protection of a separate building. The invalidated sterility failure followed by lot release is worth noting, as FDA scrutinized both the scientific basis of the conclusion and the contemporaneity of the records.
Check points
Adequacy of EM sampling locations and recovery for beta-lactam containment
Scientific justification and Phase II investigation before invalidating sterility failures
Particle size in inspector challenge kits and inspection rate standards
Violation detail · 4 items · From the source
Violation 121 CFR 211.42(c)
Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups (21 CFR 211.42(c)).
Violation 221 CFR 211.113(b)
Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).
Violation 321 CFR 211.160(b)
Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).
Violation 421 CFR 211.192
Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).
[Warning Letter · FDA]SnugZ USA, Inc. — Repeat OOS retesting, weak investigations
FDACGMP
FDA CDER issued a warning letter to SnugZ USA, Inc. following an inspection from April 27 to May 1, 2026. It cites four CGMP violations, including retesting OOS samples until passing results were obtained and releasing product without investigation, missing component identity testing, and lack of quality unit oversight.
Published 2026-10-20 · Issuing office / date Center for Drug Evaluation and Research (CDER) · 09/28/2026
Key facts · Basis: official index plus supporting sources
Inspection: April 27 to May 1, 2026 (FEI 3009188709)
Repeat violations: similar CGMP violations cited at an April 1, 2022 Regulatory Meeting
Response due: within 15 business days of receipt
Insight · Editorial insight
FDA states that passing retest results alone cannot invalidate an OOS result, and it treated the practice of switching to a second microbiological instrument to obtain passing results as unsupported. The case suggests that even a site making promotional OTC products is held to the same CGMP expectations for OOS investigations, component identity testing and COA verification.
Check points
Whether SOPs require an investigation to open on the initial OOS result before any retest
Validation basis for accepting results from an alternate test instrument or method
Lot-by-lot identity testing of incoming components and periodic verification of supplier COAs
Violation detail · 4 items · From the source
Violation 121 CFR 211.192
Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).
Violation 221 CFR 211.160(b)
Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).
Violation 321 CFR 211.84(d)(1)
Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).
Violation 421 CFR 211.22
Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).
[Warning Letter · FDA]Rohto Pharmaceutical Co., Ltd. — Falsified EM and cleaning records, eye drops
FDACGMP
FDA issued a Warning Letter to Rohto Pharmaceutical Co., Ltd. after inspecting its Vietnam ophthalmic plant, citing falsified environmental, personnel monitoring and cleaning records, poor aseptic practices and inadequate particle investigations. The letter also cites the ROHTO® Cooling Eye Drops line as unapproved new drugs and misbranded.
Published 2026-10-20 · Issuing office / date Center for Drug Evaluation and Research (CDER) · 10/14/2026
Key facts · Basis: official index plus supporting sources
Issued by: Center for Drug Evaluation and Research (CDER), 10/14/2026
Data falsification: unexposed plates submitted and unperformed cleaning recorded as done; actual plate reads showed about 25 ISO 5 excursions
Particles: two batches over the visual inspection reject limit shipped to the U.S. without identifying particle source
Insight · Editorial insight
The contrast between consistently clean monitoring results and widespread growth on actual plate reads signals that sterility assurance data are only as reliable as sample custody. FDA's refusal to accept falsified EM history as a basis for product impact assessment is also relevant to how firms scope data integrity investigations.
Check points
Independent verification of EM and PM sample collection
Reconciliation of ISO 5 cleaning records against actual execution
Particle identification and release criteria when visual inspection limits are exceeded
Violation detail · 3 items · From the source
Violation 121 CFR 211.194(a) · 21 CFR 211.67(a)
Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards. Your firm also failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and/or sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.194(a) and 21 CFR 211.67(a)).
Violation 221 CFR 211.113(b) · 21 CFR 211.63
Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes. Your firm also failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.113(b) and 21 CFR 211.63).
Violation 321 CFR 211.192
Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).
[FDA 483 observation · FDA]Mylan Laboratories Limited — Altered weighing records and data integrity gaps
FDA483
FDA issued a Form 483 with six observations to Mylan Laboratories Limited, a finished drug product manufacturer in India, after an inspection ending 05/15/2026. Key issues are a lack of quality unit oversight of manufacturing record integrity, weak controls over analytical balances, and OOS results invalidated without scientific rationale.
Published 2026-10-19 · Inspection date 05/15/2026 · Finished Drug Product Manufacturer · FEI 3005587313
Key facts · Basis: official index plus supporting sources
Observations: quality unit oversight, computer system controls, OOS investigations, equipment cleaning, stability program, Field Alert Reports
Action: the firm opened an incident investigation and suspended batch manufacturing and release during the inspection
Insight · Editorial insight
Altered batch numbers and weights in BMRs, together with operator-level access to balance SQC functions, point to a systemic data integrity weakness rather than an isolated error. Standalone balances with limited audit trail memory, and their access rights, reprint and delete functions, appear to be a focus area worth noting.
Check points
User access and delete settings on in-process balances
Reconciliation of balance printouts against BMR entries
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically, Your investigations of out-of-specification (OOS) results were inadequate because they lacked scientific rationale for root cause determinations. For example, Pratik S. Upadhyay, DDC Investigator (™> uraonnav's| nretssueo
Observation 4
Equipment and utensils are not cleaned and maintained at appropriate intervals to prevent malfunctions and contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically, On May 4, 2026, we observed the following: a. The cover of the discharge chute of th (Equipment No. ESD1082) was observed to haveoo residue, and the protective cover was found to be damaged. This Pratik S. Upadhyay, DDC Investigator PRATIKS.UPADHYAY-S vaowars °°” | areissue
Observation 5
The written stability testing program is not followed.
Aw@ -Field Alert Report was not submitted within three working days of receipt of information concerning a failure of one or more distributed batches of a drug to meet the specifications established in the application.
Specifically, Your firm did not submit Field Alert Report (FAR) for the fire incident that caused the entire plant to shut down onw@ 14-Feb-2026. Your Incident investigation PR ID: 4063221 relating to the fire incident Pratik S. Upadhyay, DDC Investigator (SS ramitav's| reissue
FDA issued a Form 483 to Watson Pharma Private Limited in India after an inspection that ended 05/20/2025. Observations cite inadequate cross-contamination controls in shared equipment and areas and inadequate investigation of impurity and specification failures.
Published 2026-10-19 · Inspection date 05/20/2025 · Drug Product Manufacturer · FEI 3005719315
Key facts · Basis: official index plus supporting sources
Observation 1: shared equipment and areas reused without testing to verify freedom from residues
Observation 2: no investigation, additional testing or Field Alert Report after an impurity result above the acceptable intake limit
Insight · Editorial insight
The finding that multiple products share equipment without residue verification or monitoring plans signals a site-wide gap in cross-contamination control. Failing to investigate an over-limit impurity result or extend testing to other in-expiry batches is generally tied to batch disposition and FAR reporting duties, and is worth reviewing together.
Check points
Residue verification testing after changeover in shared equipment and areas
Investigation of over-limit impurity results and extended testing of other in-expiry batches
Criteria for filing a Field Alert Report when a specification failure is confirmed
Observation detail · 2 observations · From the source
Inspectors: Tamil Arasu · Lauren N Howard
Observation 1
Separate or defined areas to prevent contamination or mix-ups are deficient regarding the manufacturing and processing operations.
Specifically, your firm has failed to implement adequate cross-contamination controls to ensure dru products manufactured at your site are not contaminated by the residues from drug products. For example: A. Your firm has been manufacturing drugs, Tablets | mg Tablets mg, Tablets mg, Tablets mg and Tablets mg using equipment and rooms that are shared with other drug products. Sampling, dispensing, areas and equipment used forTP @ drug products are shared with approximately other US drug products. After Sampling, dispensing, drug products, you use these areas to sample, dispense and manufacture other drug products without any verification by appropriate testing that these areas, equipment, and air is free from residues ofen drug products. B. You don’t have adequate cross-contamination prevention and control plans for routine sampling & monitoring of facilities, personnel, air supply, and equipment at appropriate intervals to demonstrate|e drug products, manufactured at the site using shared facilities, equipment, and air handling systems are not being cross-contaminated with the traces ofrs
Observation 2
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specificall A. Tablet,‘Gmg strength, packaged batch numbere® wulk batch number tested over the acceptable intake limit on November 7, 2023, as part of risk assessment completed by your firm for impurity (result [4 acceptable intake limit Your firm did not perform an investigation into the high impurity result and did not perform any additional testing on the impacted batch or other‘Gmg batches still within expiry. Additionally, at the time the hi impurity result was confirmed, your firm failed to test otheruname Table mg batches still within expiry for possible high levels of impurities. Your firm failed to file a Field Alert Report (FAR) for the confirmed high result. Tablet, @mg strength is still actively manufactured at your site without performing testing fo impurities prior to release TabletGm x. packaged batch number (bulk batch number expiration dateee and has notbeen evaluated for 2 impurities. prema ST | ae |
[FDA 483 observation · FDA]Zen Chemicals Pvt. Ltd — Cleaning of shared equipment and lab data controls
FDA483
FDA issued a Form 483 with five observations to Zen Chemicals Pvt. Ltd, a critical API intermediate manufacturer in India, at the close of an inspection on 03/28/2023. It cited visible residue on cleaned non-dedicated equipment, uninvestigated reruns, missing audit trail and access controls on lab systems, no PQ, and inadequate cleaning training.
Published 2026-10-19 · Inspection date 03/28/2023 · Critical API Intermediate Manufacturer · FEI 3015345351
Key facts · Basis: official index plus supporting sources
Cleaning: residue and rust-like residue on product contact surfaces of cleaned non-dedicated equipment; no cleaning verification (swabbing) after changeover
Data: UV software without audit trail, a GC login shared by 4 employees, portable-drive backups overwritten each time
Insight · Editorial insight
Visible residue on equipment marked as cleaned, with no cleaning verification or hold time study, signals a systemic gap in cross-contamination control. Combined with shared logins, missing audit trails, overwritten backups and uninvestigated reruns, API makers sourcing intermediates from this site may want to revisit their confidence in its data.
Check points
Cleaning verification and hold times after changeover on non-dedicated equipment
Audit trails, individual accounts and backup retention on lab instrument software
Investigation records when analyses are rerun
Observation detail · 5 observations · From the source
Inspectors: Dipesh Shah
Observation 1
Equipment are not cleaned and sanitized to prevent contamination of the critical API intermediate product.
Specifically, your firm failed to complete a clean and ditty hold time study and to establish clean and dirty hold times fores Additionally, you failed to ensure that you are able to clean and remove the previous manufactured critical API intermediate with no carryover during changeover cleaning using non-dedicated equipment. On March 13 and 14, 2023, I observed, during the facility walkthrough, the following equipment used to manufacture U.S. marketed critical API intermediate were observed visibly dirty. This includes multiple critical API intermediate contact surfaces. All equipment noted below were in a cleaned state during my visual observation and are non-dedicated. In addition, you do not perform a cleaning verification (e.g. swabbing) of the equipment after material changeover cleaning. A. residue on the inside of th and as well as"4 and residues on the corner of the were observed on product contact surface, the inside side ofthe equipment # ZEN/MC/P-56 located in thei area. Batch to Batch cleaning was conducted on March 14, 2023.
Observation 2
No investigations are conducted to evaluate all potential root causes ofmultiple sample results.
Specifically, in reviewing your firm HPLC and GC computerized analytical data from 2021 -2023, you failed to investigate the following: A. Three (3) separate analysis were rerun on HPLC equipment # QC/INST/09. 1. The first set of samples consisted of injections which were analyzed on December 7-8, 2021 for calibration. The(___ injections were rerun due to wrong vial number. 2. The second set of samples consisted of injections and were analyzed on June 2, 2022 for stability of8s The injections were rerun due to wrong preparation of sample. 3. The third set of samples consisted o injections which were analyzed on February 5, 2023 for stability ofTy mmm? The injections were rerun due to wrong column was used for analysis. According to Assistant QC Manager, the samples were reanalyzed due to analysist error and no investigation was conducted. B. According to a QC Officer, the Gas Chromatograph (equipment # QC/INST/09) sporadically generates more files than the actual analysis that is performed. Therefore, the analyst selects theue samples that are generated from the analysis and uses the selected files as the final samples. The QC Officer . Des ots Goverment tS ou-FDA “eee
Observation 3
Appropriate controls governing computer acquired data and/or related systems have not been established to assure that changes and access to computerized software for the laboratory control system is accessed only by authorized personnel.
Specifically, Your firm failed to perform Performance Qualification (PQ) for equipment but not limited to equipment # ZEN/MC/P-56 equipment # Wi MNP equipment # ZEN/MC/P-44, (equipment According to section 7.8.4 of your SOP, QA/SOP/GEN/39, document titled, ‘Standard Operating Procedure for Qualification of Facility / Equipment’s / System’ states, that QA in coordination with user department and Engineering department shall conduct PQ.
Observation 5
Employees are not trained in cleaning procedures.
Specifically, Your firm failed to train your employees who perform cleaning, verify that cleaning is adequate and recheck and approve cleaning equipment and sign final cleaning batch to batch or product to product documentation. In reviewing employee’s training records, approximately six (6) employees were deficient in training on cleaning SOP, TR/15/05/013. During the inspection, six (6) equipment were found with product residue. This includes equipment such as the and e®
[FDA 483 observation · FDA]Micro Labs Limited — Unvalidated process ranges and weak OOS probes
FDA483
FDA issued a 483 with two observations to Micro Labs Limited after inspecting its drug product site in India (inspection date 05/30/2025). Investigators cited process ranges widened beyond validated limits without revalidation, and OOS and laboratory incident root causes not supported by scientific evidence.
Published 2026-10-19 · Inspection date 05/30/2025 · Drug Product Manufacturer · FEI 3005210225
Key facts · Basis: official index plus supporting sources
Observation 1: process ranges widened beyond those used in process validation, with no revalidation
Observation 2: OOS results invalidated and laboratory incidents closed on unsupported root causes
Insight · Editorial insight
Producing batches after widening process parameters beyond validated ranges suggests a gap between change control and process validation. Repeated invalidation of OOS results on unproven weighing or analyst errors may be read as a systemic weakness in investigations.
Check points
Revalidation triggers for process changes beyond validated ranges
Experimental evidence behind root causes used to invalidate OOS results
Consistency between laboratory incident conclusions and analytical data
Observation detail · 2 observations · From the source
Inspectors: Tamil Arasu · Lauren N Howard
Observation 1
Control procedures are not established which monitor the output and validate the performance ofthose manufacturing processes that may be responsible for causing variability in the characteristics of in- process material and the drug product.
Specifically, On April 24, 2025, your firm increased the range for thedrug) PP staze and increased the range for the stage in the manufactur ng, which is used to produce Capsules @mg ng. The new ranges exceeded what was used during process validation, completed on August 24, 2021. The table below outlines the changes made for stages.
Observation 2
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
FDA issued a Form 483 with seven observations to Berkshire Sterile Manufacturing, a US sterile drug product manufacturer, after an inspection ending 10/21/2024. Key issues are an opening between the Grade A filling line and a Grade D room without continuous overpressure monitoring, airflow studies that left out critical interventions, operators touching the inside of a formulation tank liner, and weak glove monitoring.
Published 2026-10-19 · Inspection date 10/21/2024 · Drug Product · FEI 3012144557
Key facts · Basis: official index plus supporting sources
Training: 9-22% of SOP training overdue by department in 2023
Insight · Editorial insight
An opening between the Grade A filling chamber and a Grade D room was cited together with interventions, such as removing a sterile cover during setup, that the airflow studies never simulated. When assessing contamination routes in aseptic filling, whether permitted interventions like setup and changeovers were simulated, not just routine operations, appears open to review.
Check points
Continuous pressure monitoring at openings between grades
Setup and changeover interventions in airflow visualization studies
Contact time and two-handed glove use in glove monitoring
Observation detail · 7 observations · OCR reading of the scanned original
The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.
Observation 1
Procedures designed to prevent microbial contamination of drug products purporting to be sterile are not established, written, or followed.
Specifically, ; (e) (4) ; (b) (4) ; : 1. A mousehole in the is used to connect the filling line (Grade A) to the Pe drug product bag held in Clean Rooma Grade D), opening th? to the outside environment. Sufficient air supply and overpressure are not monitored on a continuous basis at this location to ensure that is maintained. In addition, the movement of the tubing in and out of the mousehole also represents a risk of microbial contamination from the surrounding Grade D room into the (Py filling chamber. 2. “Ine sterile cover around the ™ is removed prior to the” installation in its resting position. Possible contact between the unprotected and surfaces gloves, tubing, and equipment) or possible blockage of first air above the unprotected {Pye doses a risk. 3. The Airflow Visualization Studies (AVS) of the Aseptic Processing Area are incomplete. a. The removal ofthe sterile cover around the” during setup was not simulated. b. The simulation for the replacement ofthePe a permitted critical intervention during filling, did not include the detachment oftubing from the! 0 and the attachment oftubing to the “ c. The simulation for the change of the filling assembly, a permitted critica
Observation 2
The!” formulation process is not adequately controlled or designed to minimize the contamination risk of upstream drug product manufacturing steps.
Specifically, (b) (4) (b) (4) (b) (4) : of the bulk drug substance (BDS) are performed as < orocess in one of ? formulation rooms (Clean Rooms ans in the Grade C area. During lot fa on October 15, 2024,” ®Bps bottles werele ® ina?” sterile liner placed in a tank with 2” ® centimeter diameter in Clean Room” The following risks have been identified with the current process: 1. While placing the sterile” liner in the tank, the operator touched the interior of the liner within the tank with gloved hands. There is no assurance that the product was not poured over the area touched by the operator during 2. While facing the tank, the operator was observed sanitizing his hands with a disinfectant spray in the direction of the liner and tank. There is no barrier over the tank to prevent the ingress of particles and contaminants. 3. The storage conditions of the tank used for formulation pose a risk. The tanks used to hold the liner are stored in an area of the facility that is not controlled. During a walkthrough of this area, two tanks were observed without a lid. The tanks were stored next to a barrel that was not clean. The tanks may be reused; one larger tank that was not covered had 20
Observation 3
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically, 1. Glove monitoring is not adequate. For example, on October 16, 2024, during filling line setup and filling activities in Clean Room” some” gloves were used ambidextrously (the same glove used with both the left and right hands of the operators). During environmental monitoring ofthe” the gloves that were used ambidextrously were not monitored (finger dab) ambidextrously. In addition, the environmental monitoring of gloves did not allow sufficient contact time. The QC Micro operator was observed touching the contact plate with each digit and immediately removing it after approximately a second; each digit was not gently rolled on the contact plate. 2. There is” viable passive settling plate in the filling chamber ofthe!” The location of the settling plate for viable passive monitoring is above the working surface and located” “ above the” ® table where vials are filled. 3. Insufficient instructions are provided to the QC Micro operator in SOP-QCM-030, Environmental Monitoring oftheak and Formulation Rooms at Berkshire Sterile Manufacturing, Revision 21, August 7, 2024, to perform post-fill monitoring ofthe4 The QC Micro operator was observed sampling thefps during po
Observation 4
The program for the visual inspection (VJ) of sterile injectable drug products does not provide adequate assurance that finished products manufactured at the facility possess their purported quality attributes, including that they are free from particulate matter and critical defects.
Observation 5
Standard operating procedures and protocols are not followed, established, or adequate.
Written records of investigations into unexplained discrepancies do not always include appropriate documentation, conclusions, and follow-up.
Specifically, e Deviation DEV-2024-0126 was initiated on June 26, 2024, for the presence of metal like particles between the stopper and the vial in three units of clinical batch” The particles were identified as damagedpe parts and metal particulates found under thepS Based on the risk ofthe adverse impact on product quality, the Material Review Board determined the material
Observation 7
The facility is not adequately maintained.
Specifically, as observed in unclassified areas, 1. An oil spill was observed next to a bottle ofta and its funnel. 2. Corrosion was observed on the” pump in the Dock2 area. 3. Insulation in the walls near Dock 2 was tom. Insulation was visible in the area above the” 4, Panels that line the facility walls were dislodged near Dock 2. 5. Asmall hole was observed in the wall of the facility. 6. The wall in Clean Room “ ee Room) has multiple corners which are not smooth and showa small accumulation of debris by the eae
[FDA 483 observation · FDA]Perrigo New York, Inc. — Room pressure control and cross-contamination gaps
FDA483
FDA issued a Form 483 to Perrigo New York, Inc. after an inspection of its multiproduct drug manufacturing facility ending 05/08/2026. Observations cover unmonitored pressure differentials between open-process compounding suites and the common corridor, operators leaving suites in soiled gowning, uncovered clean equipment, and damaged epoxy floors.
Published 2026-10-19 · Inspection date 05/08/2026 · Drug Manufacturer · FEI 2450054
Key facts · Basis: official index plus supporting sources
Air pressure: no monitoring of pressure differential between open-process compounding suites and the common corridor, and no continuous monitoring or documented daily checks of HVAC air handling units
Contamination control: operators adding raw materials left the suite without decontamination or degowning, and no gowning or degowning procedures existed
Insight · Editorial insight
Uncontrolled room pressures in open-process suites combined with operators entering the corridor in soiled gowning suggest that cross-contamination pathways were open through both airflow and personnel movement in a multiproduct facility. Together with uncovered clean equipment near damaged floors and a dislodged ceiling tile, this is worth reading as a facility-wide control issue rather than isolated lapses.
Check points
Continuous pressure differential monitoring between open-process suites and corridors
Decontamination and degowning procedures before leaving compounding suites
Covered storage of equipment in clean status
Observation detail · 3 observations · From the source
Inspectors: Edmund F Mrak
Observation 1
Equipment for adequate control over air pressure is not provided when appropriate for the manufacture, processing, packing or holding of a drug product.
[FDA 483 observation · FDA]Centrient Pharmaceuticals India Private Limited — Inadequate cleaning of shared API equipment
FDA483
FDA issued a 483 with 3 observations to Centrient Pharmaceuticals India Private Limited (FEI 3004497364), an API manufacturer inspected starting 01/19/2026. The lead observation cites thick residue build-up on non-dedicated equipment used without batch-to-batch cleaning, creating cross-contamination risk.
Published 2026-10-19 · Inspection date 01/19/2026 · API Manufacturer · FEI 3004497364
Key facts · Basis: official index plus supporting sources
Firm: Centrient Pharmaceuticals India Private Limited, FEI 3004497364
Observation 1: non-dedicated equipment not appropriately cleaned in 27+ years; residues and API found on equipment marked as cleaned
Observations 2 and 3: foreign particles from bags and worn equipment; exterior door handles left out of environmental monitoring, a repeat from 2022
Insight · Editorial insight
The combination of no batch-to-batch cleaning requirement, an unjustified extension of cleaning frequency and flawed swabbing suggests FDA treated the cleaning validation program as a whole as deficient. Buyers sourcing APIs from multi-product sites may want to note that inspectors directly tested whether cleaned-status labels matched actual equipment cleanliness.
Check points
Batch-to-batch cleaning requirements and justification for cleaning intervals on shared equipment
Suitability of swab recovery methods, including swab type, blank preparation and technique
Preventive maintenance records for wear and particle generation on product-contact surfaces
Observation detail · 3 observations · From the source
Inspectors: Pratik S. Upadhyay
Observation 1
Failure to clean equipment and utensils to prevent contamination or carry-over of a material that would alter the quality of the intermediates and Active Pharmaceutical Ingredient beyond the official or other established specifications.
Failure of production operations to prevent contamination of intermediate and API by other materials.
PRATIKS. pranks. uPaDHYAY-s SEE Pratik S. Upadhyay
Observation 3
Failure to have the procedures and processes necessary to ensure the API and intermediates manufactured at your facility meet established specifications for quality and purity.
Specifically, Your firm's procedure SOP No. 001480: SOPfor Environmental Monitoring ofww Content, Revision No. 12, Effective Date: 07/09/2025, is deficient. Your firm failed to monitor critical entry points; outside/exterior door handles from the external environment into the manufacturing facilities. (This is repeat observation from June-July 2022 inspection)
[FDA 483 observation · FDA]Almon Healthcare Private Limited — QA document shredding and data control gaps
FDA483
FDA issued a Form 483 with 11 observations to Almon Healthcare Private Limited, an API manufacturer in India, after an inspection ending 02/13/2026. Observations cover undocumented destruction of quality records, weak computerized system access controls, cleanroom gaps and lack of identity testing on raw materials.
Published 2026-10-19 · Inspection date 02/13/2026 · API Manufacturer · FEI 3030509366
Key facts · Basis: official index plus supporting sources
Observations: 11 (quality unit, method validation, data controls, facilities and cleaning, raw material identity testing)
Data control: an analyst logged into OpenLabs HPLC software with another analyst's username and password
Insight · Editorial insight
Quality documents shredded without a destruction log and shared HPLC credentials point to systemic data integrity weaknesses rather than isolated lapses. Companies sourcing APIs from this site may want to weigh how the identity testing, stability-indicating method and cleaning validation findings affect supply quality.
Check points
Records of GMP document destruction (when, what, who signed)
Individual accounts and segregated privileges in analytical software
Batch-by-batch identity testing of incoming raw materials
Observation detail · 11 observations · From the source
Observation 1
Failure of your quality unit to exercise its responsibility to ensure the active pharmaceutical ingredient (API) and intermediates manufactured at your facility are in compliance with CGMP.
a. Your Quality unit lacked adequate control over the shredder used in the QA document control room. On February 9, 2026, a shredder was found three-fourths full of shredded quality related documents. One partially recognizable fragment contained a batch manufacturing record number (“No hyn *). Furthermore, your QA unit completely deviated from SOP "Document destruction procedure SOP/QA/043" by failing to maintain a logbook documenting when and what quality documentation was destroyed and the name and signature of the person who destroyed the GMP documents. b. There is no QA oversight on batch issuance record to document who requested, received, returned and accepted the batch record. For example, QA issued a batch manufacturing record (BMR) for Ow on January 22, 2026, with no documentation for requested, received and returned by sign and date. However, QA has the completed BMR that was signed and released by QC and QA signature to proceed to the next stage. c. Your QA does not review microbial specification results as part of batch manufacturing release. Your firm manufactured @@ (batch M@ ow and tested finished products for analytical and microbiological testing; however, batch r
Observation 2
Your firm failed to use validated and stability-indicating test procedures.
Your firm failed to use stability indicating methods to test active pharmaceutical ingredients LLL A batches shipped to the US market when assigning retest dates ofjy) The stability indicating aspects of in-house methods used for7 and the compendial method for jm == ~~—————«USP. were not evaluated through method validation and forced degradation studies to ensure no chromatographic co-elution of impurity peaks with the active peak. The following batches were on stability studies: Batch No. Manufacturing date Stability study start date
Observation 3
Failure to ensure that all specifications are scientifically sound and appropriate to ensure that your raw materials and API conform to established standards of quality and purity.
a. Your firm failed to conduct method validation for the in-house method and verification for compendial methods for the following KSM and APIs.
Observation 4
Your firm failed to exercise sufficient controls over computerized systems to prevent unauthorized access or changes to data and failure to have adequate controls to prevent omission of data.
a. HPLC and GC data from instruments GC HS QC/001, HPLC QC/002, QC/024 and QC/0025 covering January 2024 to June 2025 saved on standalone computer were backed up only once in June 2025 to an external hard drive without assurance ofcorrect data was saved and backed up. Additionally, the firm has not established a process to retrieve and verify the reliability ofthe backed-up HPLC and IR data saved from June 2025 till February 2026 in the server.
Observation 5
Failure to properly maintain buildings and facilities used in the manufacture of intermediates and API.
a. Your firm failed to maintain cleanroom conditions that prevent contamination from the outside ENVIFONMENL Ey @ processing roonge@ contains g@ O01 and ge 001 for processing all APIs including @@ for the US market. During the | walkthrough of the facility on February 10, 2026, the following gaps were_observed around the wow QO1: approximatelygy@ gap between the@m@ bottom and the floor.gy@ gap on the top right-hand corner between thee a and wall, and ww wm — 2ap at the topside middle of thegy@ — towards the ceiling. These gaps create free airflow from outside the facility into the clean room with potential for contaminants and dust particles to enter. According to the Executive QA, @@ -()01 was installed in August 2025 and the facility, manufactured and shipped ww batches of ow to the US market. Your firm-initiated change control CC/PR/25/008 to install the g @ -in the ——T
Observation 6
Failure to clean equipment and utensils to prevent contamination or carry-over of a material that would alter the quality of the intermediates and API.
a. Your firm uses a owt No usage or cleaning logbook exists for this is used in the manufacturing of different APIs including for the US market. b. On February 9, 2026, a 002) on the loor showed apparent particle deposits along lid, gasket substance was observed draining and deposited at the bottom despite the status board indi “empty and cleaned” and the usage logbook showing batch-to-batch cleaned on February 2. 2026. c. On February 9, 2026, BEyyy 103 is room yg Showed apparent rust andoa particle deposits on the exterior of th and particle deposits inside the ww on theBy) bottom. Usage log showed the last batch to batch cleaning occurred on Pebruary 4, 2026. ~ |
Observation 7
Failure to test the identity of each batch of incoming production material and appropriately qualify suppliers to rely upon their Certificate of Analysis.
Your firm failed to perform identity testing on raw materials accepting them based solely on supplier COAs. Your QA Executive confirmed that the supplier for intentionally mislabels and shipsGe containers as Gy because your firm lacks ¢ license. No identity lesting has been performed on jm batches received since 2024. Your firm used this untested
Observation 8
Failure to monitor thebe system to ensure that water is of appropriate quality.
Your firm lacks both preventive maintenance and sanitization programs for the By) water system, failing to ensure appropriate water quality for AP! manufacturing and cleaning equipment/utensils that directly come in contact with APIs. Water testing is limited to &g collection from the gm waletgg and y@ collection at production point-of-use locations, with testing conducted against in-house specifications including| MO
Observation 9
Pailure to adequately validate written procedures for the cleaning and maintenance of equipment.
Your firm has not performed cleaning validation studies for non-dedicated manufacturing equipment including Your firm manufacture APIs including APIs, for the US market. ENPLOYEE(S)
Observation 10
Failure to retain sufficient quantities of reserve sample to conduct analyses.
Your firm failed to collect enough API reserve samples to conducigyg, full specification analyses. Your firm collects only sample, which is adequate for conducting by analytical test and microbiological test There is no scientific justification for collecting only pe sample for cach lot of API. Your firm also sent ay, of batches clain samples to contract testing laboratory for analysis.
Observation 11
Failure to store stability samples in containers that simulate the market container.
Your quality control unit does not perform testing or release ofcontainer bags used for stability samples to establish retest dates for APIs including FI YY ee oo. for the US market. Your Executive QA confirmed that the firm uses §@ bays as they container for API stability studies, which do not simulate thegyg bags used for commercial packaging. i LMPLOYEE(S)
[FDA 483 observation · FDA]Divi's Laboratories Ltd. (Unit II) — No written API equipment cleaning procedure
FDA483
In an inspection of Divi's Laboratories Ltd. (Unit II) ending 07/19/2024, FDA issued one observation that written procedures were not established for cleaning equipment used in API manufacture. The cleaning SOP did not include provisions to clean or visually inspect the area concerned.
Published 2026-10-19 · Inspection date 07/19/2024 · API Manufacturer · FEI 3004149463
Key facts · Basis: official index plus supporting sources
Observation: one — no written equipment cleaning procedure (SOP lacks area cleaning and visual inspection provisions)
Insight · Editorial insight
This signals that FDA may treat a cleaning SOP that omits specific areas or visual inspection as no established procedure at all. API sites may want to recheck that their cleaning SOPs cover every piece of equipment and area from a cross-contamination standpoint.
Check points
Gaps in equipment and area coverage of cleaning SOPs
Provisions and records for post-cleaning visual inspection
Observation detail · 1 observation · From the source
Inspectors: Khoa Nathan V Tran · Andrew Le
Observation 1
Written procedures are not established for the cleaning of equipment used in the manufacture API.
[FDA 483 observation · FDA]Greer Laboratories, Inc. — Environmental monitoring and QA release control
FDA483
FDA issued a Form 483 with five observations to manufacturer Greer Laboratories, Inc. (FEI 1011574) after an inspection ending 12/18/2024, covering environmental monitoring, production and process control procedures, equipment maintenance, building upkeep, and quality unit handling of deviations and OOS results.
Published 2026-10-19 · Inspection date 12/18/2024 · Manufacturer · FEI 1011574
Key facts · Basis: official index plus supporting sources
Observations: five (environmental monitoring, production procedures, equipment cleaning and maintenance, building repair, quality unit responsibilities)
Preventive maintenance: 174 work orders overdue by 1 to 120 days
Insight · Editorial insight
Skipping environmental samples after final processing in ISO-classified areas and placing sampling sites where they miss operator activity signals that the monitoring design may not represent real contamination risk. Product being releasable in the system before full QA batch record review, alongside late deviation and OOS closure, points to weak timing of quality unit controls overall.
Check points
Whether environmental monitoring timing and locations represent operator activity
Whether product can be released in the system before full batch record review
Justification of and adherence to deviation and OOS opening and closure timelines
Observation detail · 5 observations · From the source
Inspectors: Laurel A Beer · Peng Zhou
Observation 1
processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically, on December 16, 2024 __m ____—*i vials in ISO vue suitebuilding 4, was observed with the following deficiencies: ia NO ows sample was taken from the) ,, _—_—jafter completing the final process that would capture all activity that tookee during the|- | L=I SOP-LAB-0122, Environmental Monitoring in » anufacturin and Support Areas, rev. 07, eff. 04Nov2024, states on page 5, sec. 7.2, that ISO - areas must be monitored while is occurring but are not required when manufacturing operations have been completed for the day. On 16Dec2024, an environmental monitoring technici ed taking a na sample from the |_,,, | at station|- while the| gs jechinician was actively working. However, no} iw | sample was taken at this same station upon completion of the final) ». rocessing activities, prior to the! ,,, technician cleaning the_ with an = as she performed her so b. The environmental monitoring sampling sites used to monitor the __ activity on the - in os are insufficient in thatthey are) la tti tsti‘sSSCSY ~ activity and are potentially blocked from filling activities due to the setup of materials and equipment on the ,,, during oye | SOP-LAB-0122, EnvironmentalMonitoring in ‘a Man
Observation 2
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Specifically, during a review of standard operating procedures (SOP) and interviews with subject matter experts, the following deficiencies in SOPs were observed: a. Your license requires the ~ | allergenic extract to bel aww through a series of mixed -_ of | sit to clarify and reduce bioburden,) ,,,, ss Instructions on how to determine how many __,,, are needed and whic
Observation 3
Written procedures are not followed for the cleaning and maintenance of equipment, including[~ | used in them—_e =.
|of a drug product. Specifically, A. From January 10", 2023, to November 30", 2024, 174 equipment preventative maintenance work orders were overdue, ranging from 1 to 120 days. Examples of overdue work orders include the following: Completion Date Days Elapsed April 30", 2024 August 28", 2024 April 8", 2024 July 10", 2024 — a December 22", 2023 | January 16", 2024 (b)(4) December 31°, 2023 | January 16", 2024 fo October 18", 2024 —_| October 31°, 2024
Observation 4
Buildings used in the manufacturing and holding of a drug product are not maintained in a good state of repair.
Specifically, A. On December 13th, 2024, one located in the wa leading to the we and) aw the labeling of Sterile Diluent and ‘as Vials xs was observed to be improperly seated, leaving the area exposed. B. On December 17th, 2024, a wi was observed in sed for the transport of me iin Building’-|Work Order #62431 was created on June 26th, 2024 to initiate the repair and it was not observed to be completed on December 17th, 2024.
Observation 5
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Specifically, a. Deviations are not always closed in a timely manner and the timeframe to open a deviation from the date discovered is not properly justified. US-SOP-QA-0004, Deviation Management System, rev. 03, eff 21Jun2024, allows | vou to initiate a deviation in your vn This means there is the potential for, = sfto ona before a deviation is opened after it has been discovered. Additionally, the SOP allows for = to close a deviation. From 10/01/2022 to 12/10/2024, approximately 49% of 346 deviations were closed sas of which were classified as critical or major. b. Out of specifications (OOS) for chemistry are not always closed in a timely manner. SOP-LAB- 0053, Procedure for Handling Out ofSpecification Laboratory Testing, rev. 10, eff. 20Aug2024, allows for a ” timeframe during which to close chemistry related OOSs and no closure date extensions are allowed. From 10/01/2022 to 12/10/2024, 35 out of 133 OOSs were closed after wa — 18 of which remained open longer than /_,,,,
[FDA 483 observation · FDA]Kansas State Veterinary Diagnostic Laboratory — Expired calibration of potency test equipment
FDA483
FDA's inspection of Kansas State Veterinary Diagnostic Laboratory, a contract lab performing drug product potency and release testing (inspection date 06/20/2025), produced four observations, including expired calibration of a timer and fluorescent microscope, records missing lot and sample information, and failure to follow the RFFIT procedure.
Published 2026-10-19 · Inspection date 06/20/2025 · Contract Laboratory · FEI 3018083890
Key facts · Basis: official index plus supporting sources
Potency testing performed with a timer and fluorescent microscope whose calibration had expired, without checking calibration status before use, signals that the reliability of potency results used for release may be called into question. Test records also lacked tested lot numbers and sample receipt details, so sponsors using contract labs may want to see how result-to-lot traceability is secured.
Check points
Calibration validity and pre-use checks for potency test equipment
Tested lot numbers and sample receipt dates in test records
Contract lab adherence to written test procedures
Observation detail · 4 observations · From the source
Inspectors: Shafig Ahadi
Observation 1
Routine calibration of mechanical and electronic equipment is not performed according to a written program designed to assure proper performance.
Specifically, this facility performed potency tests and release tests for (b) (4) Drug Product - (b) (4) indicated for p (b) (4) (b) (4) when given (b) (4) or possibly ®) (4) A. Timer, model (b) (4) is used to calculate time between! (D) (4) (b) (4) as required per the firm's procedures for (b) (4) Drug Product potency testing. Calibration of the timer, (1b) (4) __ is required (B) (4) and expired as of 13 January 2025. Your firm did not calibrate equipment used to conduct potency testing of a drug product according to the written procedure. B. (b) (4) - Fluorescent Microscope, equipment ID: (b) (4) is used for examination of (b) (4) to determine the number of virus-infected cells per well and create potency test result reports for (B) (4) Drug Product. Calibration of the Fluorescent Microscope, equipment ID: (b) (4) is expired as of 3 June 2025. Your firm did not calibrate the Fluorescent Microscope used to conduct potency testing of a drug product according to the written procedure.
Observation 2
Batch production and control records do not include complete information relating to the production and control of each batch.
. (b) (4) Specifically, you performed potency tests for (B) (4) Drug Product. A total of | lots were tested between (b) (4) Set test records do not include drug product lot numbers tested for potency. A set test record consists ofup to (b) (4) For example, your firm tested and released Set #_ (1D) (4) test date (1b) (4) for (b) (4) Drug Product (DP). The batch production record does not include drug product lot numbers tested.
Observation 3
Laboratory records do not include a description of the sample received for testing, the lot number or other distinctive code of the sample and the date the sample was received for testing.
Specifically, your firm performed potency tests for (B) (4) Drug Product. A description of the samples received for testing, including identification, quantity, lot number or other distinctive code, and the date samples were received for testing, is not documented. For example, the standard (b) (4) lot no. (b) (4) used to conduct the potency testing for (b) (4) Drug Product does not have a sample received date or date of testing.
Observation 4
Written production and process control procedures are not followed in the execution of production and process control functions.
[FDA 483 observation · FDA]Grand River Aseptic Manufacturing Inc — Fill validation did not simulate all process steps
FDA483
FDA issued a Form 483 to Grand River Aseptic Manufacturing Inc, a US aseptic manufacturer, after an inspection ending 09/19/2024. The one legible observation is that the fill validation study performed on syringe filling line 3 did not simulate all manufacturing processing steps.
Published 2026-10-19 · Inspection date 09/19/2024 · Manufacturer · FEI 3008716173
Key facts · Basis: official index plus supporting sources
Facility: Grand River Aseptic Manufacturing Inc, FEI 3008716173
Observation legible: scope of process simulation in fill validation
Insight · Editorial insight
The case shows that aseptic fill validation is expected to simulate every actual manufacturing step. Aseptic fillers may want to check that each line's media fill design covers all real process steps and interventions.
Check points
Media fill design compared against actual process steps
Interventions covered in each line's media fill
Observation detail · 1 observation · OCR reading of the scanned original
The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.
Observation 1
The - fill validation study that was performed on the syringe filling line 3 did not simulate all manufacturing processing steps for the 004
[FDA 483 observation · FDA]Corixa Corporation — Environmental monitoring media not qualified
FDA483
FDA issued a Form 483 with one observation to Corixa Corporation, a US drug manufacturer, after an inspection ending 03/12/2026. The aseptic area environmental monitoring procedure requires incubation at 20-25°C and 30-35°C, but the settle and contact plates used had not been qualified for use at 20-25°C.
Published 2026-10-19 · Inspection date 03/12/2026 · Drug Manufacturer · FEI 3007726770
Key facts · Basis: official index plus supporting sources
Facility: Corixa Corporation, FEI 3007726770
Observation: environmental monitoring system in aseptic processing areas
Insight · Editorial insight
The procedure set dual-temperature incubation without confirming the media's recovery at that temperature, and several revisions of the procedure never addressed it. Firms may want to check that their environmental monitoring media are qualified for each incubation condition actually used.
Check points
Qualification of environmental monitoring media at each incubation temperature
Recovery test records for settle and contact plates
Observation detail · 1 observation · OCR reading of the scanned original
The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.
Observation 1
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
[FDA 483 observation · FDA]Corixa Corporation d.b.a. GlaxoSmithKline — Prior-batch materials left after line clearance
FDA483
FDA observed at Corixa Corporation d.b.a. GlaxoSmithKline, in an inspection ending 03/04/2022, that labels, syringes and vials from previous batches were repeatedly found on a packaging line after line clearance. It also cited an investigation into a vision system failure that did not assess the potentially affected shippers.
Published 2026-10-19 · Inspection date 03/04/2022 · Drug Manufacturer · FEI 30077266770
Key facts · Basis: official index plus supporting sources
Observation 1: prior-batch labels, unlabeled syringes and vials found after line clearance under SOP 9000006564v31, missed by multiple clearances
Observation 2: investigation of a 10/26/2021 vision system end of run challenge failure did not assess impacted shippers
Insight · Editorial insight
Rogue labels and syringes surviving several line clearances suggest the clearance procedure is not reaching blind spots such as equipment undersides and areas below control panels. Attributing a vision system failure to a camera malfunction without assessing already packed shippers shows an investigation that stopped at root cause rather than product impact.
Check points
Coverage of equipment undersides and blind spots in line clearance
Product impact assessment of packed goods after inspection equipment failures
Trend review of recurring line clearance deviations
Observation detail · 1 observation · From the source
Observation 1
Inspection ofthe packaging facilities are deficient after use to assure that materials not suitable for subsequent operations have been removed.
A. Line clearance is performed bymH qualified operators after labeling and packaging operations are completed for each batch to verify absence ofmaterials from previous packaging run, per SOP 9000006564v31, entitled “Packaging Line Clearance”. However, deviations have been generated due to the findings ofproduct labels, unlabeled syringes and vials from previous batches thatwere packaged on Line(5) (4) packaging line) after line clearance operations have been completed. In some instances, multiple line clearances were completed, and the materials were not detected. Specifically, i. Notification 200885400 —A packaging operator found a rogue label fromsc sic Line | jon 09/13/2021 shift), following production of (0)(4)batch(6) (4)and before line clearance. The batch was labeled on 09/07/2021. Five (5) line clearances were performed on lineMbetween before the label was discovered. ii.Notification 200887572 — On, 09/25/2021, a rogue syringe from batch AR ves found on the bottom ofa picce ofequipment on line eg packingbatch e syringe was discovered during theMin on 09/25/2021 and the line clearance for batch was completed on 09/24/2021. iii. Notification 200890975 — On 10/12/2021, an unl
[FDA 483 observation · FDA]Eugia Pharma Specialities Limited — Aseptic intervention and EM control gaps
FDA483
FDA issued a nine-observation 483 dated 11/14/2025 to Eugia Pharma Specialities Limited, a sterile drug product manufacturer in India. Observations cover unmonitored critical aseptic interventions, smoke studies not representative of commercial operations, environmental monitoring and cleaning-sequence gaps, and assay method reliability.
Published 2026-10-19 · Inspection date 11/14/2025 · Sterile Drug Product Manufacturer · FEI 3009883410
Key facts · Basis: official index plus supporting sources
Aseptic interventions: critical aseptic connections not visible to viewing windows or CCTV; operator arms observed blocking Grade A laminar airflow
Other: Grade B non-viable particle monitoring only once per batch, recurring HPLC assay OOS results, sole reliance on vendor COA for a sterile material
Insight · Editorial insight
Most of the nine observations concentrate on operator interventions in the Grade A zone and how they are monitored and validated, putting the aseptic assurance design itself in question. The finding that smoke studies did not reflect actual commercial intervention movements illustrates the risk when validation data diverges from shop-floor practice.
Check points
CCTV and viewing-window coverage of critical aseptic interventions
Match between airflow visualization studies and actual intervention movements
Frequency of non-viable particle monitoring during aseptic operations
Observation detail · 9 observations · From the source
Inspectors: Angelica Hernandez
Observation 1
The responsibilities and procedures applicable to the Quality Unit are not fully followed.
Aseptic processing operations are not adequately designed to provide sufficient visual monitoring ofcritical interventions and aseptic manipulations to ensure compliance with current good manufacturing practice (CGMP) requirements. For example, during inspection of aseptic filling lines (4 . it was observed that multiple corrective interventions })4) cannot be monitored through existing viewing windows or closed-circuit television (CCTV) camera systems. The CCTV system serves as the primary method for Quality Assurance personnel to review filling operations and identify potential breaches in aseptic practices. Interventions include: 1, On filling line ,,,,, critical aseptic connections are not visible to monitoring systems, specifically the aseptic connection of the manifold to the, tank and)... tubing connections for the ~— component. These connections represent the most critical control point in the process as they establish the pathway from the product-containing tank to the yy used for finished vial filling. —_fagoren
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Specifically, During aseptic filling operations, procedure EP2-PRD-SOP-002, “Personnel Behavior in Aseptic Area” and line specific intervention procedures were not followed: A. Aseptic filling on filling line §gy ‘Injection batch &o 1, On October 16, 2025, during line assembly and filling for ROW) batch wow Injection,@ gram/vial), operators performed @ay checks and challenge tests in the Grade A area. During the @@ checks, the operator's arms and upper torso were observed reaching over the line, blocking laminar airflow. The
Observation 3
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
Specifically, airflow visualization (smoke studies) of Grade A laminar flow do not demonstrate there is appropriate air laminarity during commercial operations: A. aren Line Airflow Study wen Protocol #E2-MIS-VSP-0195, effective March 28, 2024, is not representative of actual commercial production conditions: 1. Manifold Connection Intervention Discrepancies: CCTV review of Interventioryyy) (Connecting Manifold to), | Tank and Fixing4 Tubing through wen for batch ae (filled November 5, 2025) showed the operator sanitized their hands twice before finger dab monitoring. The intervention includes connecting the manifold to the, tank containing the product, then yyy tubes connecting ()))) to the manifold are connected. Finger dabs occur after the 5iy tube connection, not after manifold connection to the ,,,, _ tank. Multiple activities during this intervention showed the operator's entire forearm inside and directly over the connections. Similar activities were observed during line assembly for batch yyy however these activities were not simulated in airflow visualization study E2-MIS-VSP-0195. 2. Transfer and Removal of Sterilized Equipment: During Intervention }})\ (Transfer of Steri
Observation 4
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
A. Aseptic processing operations conducted in filling line yy) are deficient in design and controls to prevent microbiological contamination of sterile drug products. On November 05, 2025, we evaluated the filling operation in wea LIN FOI Sen Injection g; Batch yyy (USA market). During the batch filling operation, we observed the manufacturing operator performing corrective Intervention Code,,/,, Lubrication ofy)4 intervention) multiple times. During this intervention, the manufacturing operator )@ to lubricate them. According to your VP Operations, this intervention is carried outan a since they should ensure they have smooth movement during the filling process. The distance between they) and the conveyor where the empty vials are exposed is approximately [yyy ns Intervention }\), has a maximum allowable frequency of @ times and duration of NMT (yy This referenced validated frequency suggest that the operation repeatedly must reach into the ISO 5 (Grade A) filling line area indicating the filling process relies on multiple operators’ interventions inside the aseptic zone. B. There is no assurance that the current flow of personnel within the vial filling Lineyy) is designed to pre
Observation 5
Aseptic processing areas deficient regarding system for monitoring environmental conditions.
Your environmental monitoring program is inadequate in assessing and monitoring all the potential critica] surfaces, conditions and equipment in your aseptic processing areas. A. Non-viable particle count (NVPC) g@ monitoring in Grade B areas is performed only once during product batch activity as per step @@ of procedure EP2-PLA-SOP-0] 2-08, “Environmental Monitoring” Version: 08, Effective Date: 14-Jun-2025. On November 5, 2025, during the manufacturing orm ‘Injection ® 8, filling linegy@ Batch: wa (USA market), the microbiologist performed the NVPC monitoring approximately @ay before completion ofthe batch filling activity. Failure to perform sequential 9@ NVPC monitoring during an aseptic batch activity does not ensure that the Grade B environment will remain under control for the entire duration of the aseptic filling activity. Additionally, your firm does not perform continuous NVPC monitoring of the gq) laminar airflow (LAF) unit used when transferring g@) stoppers from the sterile material receiving area to the aseptic filling lines for @@ As per procedure EP2-PLA-SOP-012-08, “Environmental Monitoring”, Version: 08, Effective Date: 14-Jun-2025, step g)@) NWPC monitoring ofg
Observation 6
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
There is no assurance that your laboratory test methods have been validated or demonstrated to be suitable for their intended use to consistently produce accurate and reliable results. For example, repeated Out-of-Specification (OOS) results have been observed during the HPLC assay analyses of a Crude and sterile materials. Although low sample injection volume was identified as the root cause, the recurrence of these events indicates insufficient analytical method controls to ensure assay reliability.
Observation 7
Establishment of the reliability of the component supplier's report of analyses is deficient in that the test results are not appropriately validated at appropriate intervals.
Specifically, your firm relies exclusively on the vendor's Certificate of Analysis (COA) to ensure the sterility of (AA used on filling, line My for ee) Following an initial analysis conducted in March 2024, your firm has purchased over aw bottles of sterile yyy) acrossyyyy) separate shipments without conducting any re-validation ofthe vendor's sterility test results. This practice means your firm has been accepting sterile ))4, for critical aseptic manufacturing operations without independent verification of sterility for an extended period, encompassing
Observation 8
Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
Specifically, A. Operators conducting ay for in-process testing on filling line fa filling) lack training and qualification, Operators are trained by reading procedures without hands-on experience using @) Additionally, your firm does not maintain ) with reference standards to train and qualify operators’ ability to gay This deficiency compromises the consistency and reliability of4) detection during manufacturing operations. B. Standard Operating Procedure EP2-PFB-SOP-038-02 "In-Process Checks During Batch Operation" fails to establish adequate control procedures for @@ assessment. While firm management states that in- PrOCessy, oy is performed to evaluate @ a made from @@ the procedure and associated 4ay ‘ae Verification Record" focus solely on ga wa detection. The procedure does not establish methodology, acceptance criteria, or documentation requirements for 4 evaluation. Additionally, while the procedure defines corrective actions for wa identification, it fails to specify actions to be taken when ga are encountered during) testing. C. The pe Verification Record @¢ provides inadequate documentation for critical quality attributes. The form only captures & identification (Yes/N
Observation 9
Equipment and utensils are not cleaned, sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Your firm’s cleaning and sanitization practice performed on filling line 9 @ are inadequate to follow the cleaning and sanitization sequence from top to bottom of your filling line. For example, on November 04, 2025, your operators failed to follow a top to bottom cleaning approach during the post cleaning and sanitizing activities forw@ ‘Injection USP @e/vial, Batch: @@ (USA). Your operators began cleaning from the we located in Grade A area and subsequently proceeding towards the filling zone without first cleaning and sanitizing the @@ LAF that is located above the filling line. This deficiency does not ensure directional flow ofthe cleaning activities to prevent a potential cross contamination between uncleaned and cleaned zones. Furthermore, when reviewing the cleaning process for @gy ‘Injection USP® 2/vial, Batch:= (USA market), your operator was observed placing an uncleaned @gy stand (used for Environmental Monitoring activities) directly onto the conveyor belt that had been previously cleaned. This inadequate practice was also noted during the sanitization process of the filling line. A v4 s \r4 it wl
[FDA 483 observation · FDA]Loba biotech GmbH — Validation, deviation and CAPA control gaps
FDA483
FDA issued a 483 dated 11/11/2025 to Loba biotech GmbH, a drug substance manufacturer in Austria. Observations cover master batch records not reflecting the process, an unresolved CAPA, sterilization and hold-time validation gaps, facility design and maintenance, missing procedures, deviation management and training oversight.
Published 2026-10-19 · Inspection date 11/11/2025 · Drug Substance Manufacturer · FEI 3002807485
Key facts · Basis: official index plus supporting sources
CAPA: residue on a vessel's product contact surface identified on 2 October 2024, CAPA initiated 26 March 2025, still unresolved on 3 October 2025 while manufacturing continued
Validation and procedures: sterilization validation of anti-foam and inoculation media lacked biological indicator assessment; SOPs silent on gloved hands touching work surfaces and finger dab technique
Insight · Editorial insight
Continuing to manufacture for about a year with a known vessel residue suggests CAPAs are opened but not effectively closed. Findings spanning sterilization validation, deviations and training point to the need to assess the whole quality system when qualifying a drug substance supplier.
Check points
Timeliness of long-open CAPAs and assessment of interim manufacturing impact
Inclusion of biological indicators in sterilization validation
Root cause and CAPA for recurring deviations grouped as umbrella deviations
Observation detail · 7 observations · From the source
Observation 1
The Master Batch Record for®® does not reflect the manufacturing process.
Specifically, You failed to record process control activities during the manufacturing of DS Batchew The changes made for the process parameters for the preparation of ») (4) used for theme were not properly documented in the Master Batch Kecord for the specified batches. Batches o@ were released. Quality assurance of the batch release process is deficient.
Observation 2
You failed to take adequate corrective action preventative action (CAPA) for a manufacturing system, resolution of an aberrant condition in a timely manner.
Specifically, On 3 October 2025, observed for theo@ by system sight glass was a®® residue on the bottom product contact surface of the vessel. You identified on 2 October 2024 the observed attribute and initiated a CAPA 26 March 2025 for corrective action, with theme residue an unresolved condition. You continue to manufacture under an aberrant state.
Observation 3
Validations in support of@@ drug substance manufacture are deficient.
Specifically, a. You ®@_ sterilize the liquid anti-foam and inoculation media ino@ manufacture byo@ with the initial validation and reoccurring revalidation failing to provide a biological assessment (by biological indicator)
Observation 4
Equipment, facilities and a utility system in support ofm@ drug substance manufacture are not adequately maintained or are deficient in design.
Specifically, a. The ®@ material sampling area is a room, a corridor, Grade D space between the material receiving area and the GMP warehouse that includes @@ sampling booths. There is nom@ with the ceiling observed with gaps leading to interstitial space. o@ Sampling Areaw@was observed with a ceiling HEPA, light fixture seal dislodged from its mounting. The area is of inadequate design for raw material sampling. wr? o@ ‘ , b. You identified that your lines per manufactures recommendation should be replaced @@ There is no procedure or other mechanism for the replacement ofthe o@ lines and there is no procedure for inspection of the product contact surface at any time interval for deterioration.
Specifically, a. On 06 November 2025, observed for the simulated fill ofo@ drug substance was the fill technicians gloved hands resting on the laminar flow clean bench, a sanitized surface. You identified that the fill technician sanitized gloved hands should not touch the work surface during manufacturing, with the good aseptic practice instructed during training. SOP-07-0024, Working in Laminar Flow Workbenches, v00, Effective 11 February 2025 is silent for said requirement. b. On 06 November 2025, observed for the simulated fill ofo@ drug substance was personnel environmental monitoring that included finger dabs from each gloved hand, with only a slight touch of each finger to the media plate. Job aid, JA-06-0004, Environmental Monitoring in LAFS, Rev 02, Effective date 21 April 2025 is silent for rolling each finger across the media that provides an optimum assessment of glove quality, bioburden. c. On 27 November 2024, a tolerance limit violation event (TLV 2024/003) was identified, associated with the preparation of a sample solution a day before for RP-HPLC analysis forg@ resulting in the out of specification results. There is no time specified in the HPLC _ o@ _identity_pur
Observation 6
Quality oversight of deviation management is inadequate.
Specifically, a. You failed to open a deviation for the lack ofdocumentation forma in the master batch record for Batch according to your SOP-01-0004 Deviation Management, Rev 04, Effective date 30 October 2025. b. Deviations occurred due to different root-causes for a recipe used ingy@ manufacture foie)@ classified as an ‘umbrella deviation’ in deviation # AB 862/357-recipesw@ You classify frequently occurring
Observation 7
Supervisory oversight on the training ofthe employees is inadequate.
Specifically, a. Investigations ofthe out ofspecification results (OOS-2025-065 and OOS-2025-076) led to critical changes for the preparation ofo@ for limit ofthem@ 2omponents and » range. No re-training is documented for the operators who prepared the ®@ after the changes were introduced in the process. b. On 27 March 2025, an invalid test investigation (IT12025/045) was performed for using an unqualified HPLC (LQE03 14), for which a barrier sign label m@® was placed but not clearly visible to prevent using the instrument. No retraining was documented for the operator who ran the HPLC, without checking the qualification/validated state of the equipment. Any additional step taken to block the use of the unqualified equipment is unknown. y} a
[Regulatory news · EMA]Guidance on good manufacturing practice and good distributio… — GMP and GDP questions and answers
EMAGMP News
EMA published answers to frequently asked questions on GMP and GDP, discussed and agreed by the GMP/GDP Inspectors Working Group, covering human and veterinary medicines.
Published 2026-10-21 · Issuing authority EMA · Topic Guidance on good manufacturing practice and good distribution practice: Question…
Key facts · Basis: official index plus supporting sources
Published: 2026-10-21
Scope: human and veterinary medicines
Agreed by: GMP/GDP Inspectors Working Group
Insight · Editorial insight
Because the answers are agreed by the inspectors working group, this Q&A may serve as a reference point for how GMP and GDP provisions are read during EU inspections. Manufacturers and distributors supplying the EU may want to compare their procedures with the relevant answers.
Check points
Comparison of in-house procedures with the EMA GMP/GDP Q&A
[WHO · WHO]Alivira Animal Health (API) — API site found WHO GMP compliant
WHOWHO
WHO inspected the Alivira Animal Health API manufacturing site in Andhra Pradesh, India, and found it operating at an acceptable level of compliance with WHO GMP guidelines for APIs. Deficiencies observed during the inspection were addressed by the company to a satisfactory level before the WHOPIR was published.
Inspection date 2026-06-23 · Outcome Acceptable · Valid for 3 years · Issuing authority WHO
Key facts · Basis: official index plus supporting sources
Inspection date: 2026-06-23
Outcome: acceptable level of compliance with WHO GMP guidelines for active pharmaceutical ingredients
Validity: the WHOPIR remains valid for 3 years provided any inspection in that period is positive
The report closes with a compliant outcome after deficiencies were resolved before publication, which buyers sourcing APIs from this site may treat as supporting evidence in supplier qualification. Its description of a paper-based PQMS alongside SAP-based blocking of OOS-related materials suggests inspectors look at consistency between paper and electronic status controls.
Check points
Whether the WHOPIR outcome is reflected in supplier qualification files for this API source
Alignment of electronic Blocked status and physical labels for OOS-related materials
Consistency of the KSM list with the registered route of synthesis
Inspection report detail · From the source · WHO · Item 14
Inspection outcome
Original · WHOPIR
Based on the areas inspected, the people met and the documents reviewed, and considering the findings of the inspection, including the observations listed in the Inspection Report of Alivira Animal Health, located at Plot No: 104 to 109, Part of 112 & 113, Visakha Pharma City, JNPC- SEZ, Parawada Mandal, Anakapalli-531019, Andhra Pradesh, India, was considered to be operating at an acceptable level of compliance with WHO good manufacturing practices for active pharmaceutical ingredients guidelines. The deficiencies observed during the inspection, as listed in the full report, were addressed by Alivira Animal Health to a satisfactory level before the publication of the WHOPIR. This WHOPIR will remain valid for 3 years, provided that the outcome of any inspection conducted during this period is positive.
1. Quality management
Original · WHOPIR
Pharmaceutical Quality Management System (PQMS) The site had established a Pharmaceutical Quality Management System for the manufacture of APIs in accordance with GMP principles. The PQMS was supported by a paper-based documentation system that defined responsibilities for key quality processes, including change management, CAPA, management review, and process performance and product quality monitoring. The Quality Policy emphasized continual improvement through qualified personnel, controlled inputs, compliant facilities, and adherence to applicable regulatory requirements. …
2. Personnel
Original · WHOPIR
Personnel qualification The site employed a total of 450 personnel across Production, Quality Assurance, Quality Control, Warehouse, Engineering, EHS, HRA, and other support functions. The organizational structure covering Quality Assurance, Quality Control, Production, and related functions was described in the SMF and provided in the respective Attachment 3. The responsibilities of personnel involved in the manufacture of intermediates and APIs were defined in their respective job descriptions. …
3. Buildings and facilities
Original · WHOPIR
The facility consisted of separate units for the Warehouse, Production Block 1, Production Block 2, R&D Block, Quality Control, Quality Assurance, Engineering Services, Personnel, and Security. Production Block 1 comprised three manufacturing modules for intermediate production and eight cleanrooms, while Production Block 2 was dedicated to intermediate manufacturing. An additional cleanroom was located on the second floor of the Warehouse within the Finished Goods Store. The flow of personnel and materials throughout the facility was designed to prevent mix-ups and cross-contamination. …
4. Process equipment
Original · WHOPIR
The site was equipped with production equipment suitable for the manufacture of APIs and intermediates. Product-contact surfaces of key equipment were stated to be constructed of SS316 stainless steel or borosilicate glass. The manufacturing facility included glass-lined and stainless steel reactors, stainless steel centrifuges, vacuum tray dryers, fluid bed dryers, agitated Nutsche filter dryers, rotary cone vacuum dryers, multi mills, sifters, micronizers, storage and measuring tanks, receivers, Nutsche filters, spark filters, leaf filters and pumps fitted with flame-proof motors for liquid …
5. Documentation and records
Original · WHOPIR
Document preparation, revision, approval, issuance, and distribution were governed by documented procedures that defined responsibilities and document control processes. Documents were prepared by the relevant departments, reviewed by departmental heads, and approved by QA. Controlled master copies were maintained by QA and distributed only to authorized personnel. Revisions were managed through the change control system, with superseded versions withdrawn, recorded, destroyed, and archived as obsolete documents. Document retention periods were defined as the product shelf life plus one year. …
6. Materials management
Original · WHOPIR
Receipt, identification, quarantine, storage, handling, sampling, testing, approval, and rejection of materials were managed in accordance with the applicable SOP. The management of retest and rejected materials, as well as storage and control of materials, were governed by the respective SOPs. A supplier qualification system was established for the evaluation and approval of suppliers of critical materials. Materials were procured against approved specifications from suppliers qualified and approved by the Quality Unit. …
7. Production and in-process controls
Original · WHOPIR
The list of KSMs included in the submitted dossier was consistent with the described route of synthesis. The most recent batch manufacturing record was randomly selected for review during the inspection. Although this batch had not been supplied to WHO, it had been manufactured using the same process and route of synthesis as the WHO-designated product. The most recent WHO batch had been manufactured and dispatched on 23/11/2023. Production operation Raw materials used in the manufacture of intermediates and APIs were weighed or measured in accordance with approved procedures. …
8. Packaging and identification labelling of APIs and intermediates
Original · WHOPIR
General Material identification and labelling were implemented as part of the site’s controls for production, warehousing, sampling, testing, and release activities. Upon receipt of raw materials in the warehouse, a material status label was affixed to each container. Following completion of manufacturing operations, intermediates and finished products were packaged, identified, and labelled before a test request was submitted to QC for sampling. …
9. Laboratory controls
Original · WHOPIR
The QCL comprised an instrumental laboratory, wet chemistry laboratory, and reserve sample room located on the ground floor of the Administration Building. The stability laboratory and microbiology laboratory were located in an adjacent building. Laboratory areas were designed and organized according to their intended functions, with activities separated to prevent mix-ups, cross-contamination, and interference between analytical operations. Laboratory operations were physically separated from manufacturing activities. …
10. Validation
Original · WHOPIR
Validation documentation The following validation documentation was reviewed: - Validation Master Plan. - Validation Plan (Process and Cleaning) for the year 2026. Validation and qualification activities covered critical systems, manufacturing processes, cleaning procedures, analytical methods, and computerized systems. These activities were implemented to ensure that the systems consistently performed as intended and that the data generated and managed throughout their lifecycle remained reliable, accurate, and complete. …
11. Change control
Original · WHOPIR
Change control was established as part of the site Quality Management System and was governed by the SOP for Handling Change Management. The procedure covered the identification, documentation, assessment, review, approval, implementation, and closure of changes related to raw materials, specifications, analytical methods, facilities, utilities, equipment (including computer hardware), manufacturing processes, labelling and packaging materials, and computer software. QA was responsible for the oversight of changes that could affect the quality of intermediates or APIs. …
12. Rejection and re-use of materials
Original · WHOPIR
Rejection No API batches had been rejected since the last WHO assessment. A register was maintained to document rejection activities where applicable. The management of retest and rejected materials was governed by the SOP for Handling of Retest and Rejected Material Management. The procedure covered the handling of retest and rejected raw materials, packaging materials, intermediates, in-process materials, and finished products in both warehouse and production areas. Materials associated with OOS results were assigned a “Blocked” status by QC in the SAP system and labelled accordingly. …
13. Complaints and recalls
Original · WHOPIR
Complaints All quality-related complaints, whether received orally or in writing, were handled in accordance with the respective SOP. The investigation of a randomly selected complaint was reviewed. The complaint. The complaint was confirmed following investigation, and appropriate corrective and preventive actions were initiated. …
The list of Approved External Agencies was available. Written quality agreements or contracts were established between the contract giver and the contract acceptor, clearly defining the GMP responsibilities and quality obligations of each party. The agreements also provided the contract giver with the right to audit the contract acceptor's facilities to verify compliance with GMP requirements. The respective documents were reviewed and discussed during the inspection. Miscellaneous Samples taken N/A Assessment of the site master file Site Master File was provided in advance and reviewed. …
[WHO · WHO]MSN Life Sciences (Unit II - Chandampet) — Acceptable WHO GMP compliance for API site
WHOWHO
WHO inspected the API manufacturing site of MSN Life Sciences Unit-II in Chandampet, Telangana, and found it operating at an acceptable level of compliance with WHO GMP guidelines. Non-compliances observed were addressed satisfactorily by the manufacturer before the WHOPIR was published.
Inspection date 2026-03-02 · Outcome Acceptable · Valid for 3 years · Issuing authority WHO
Key facts · Basis: official index plus supporting sources
Inspection date: 2026-03-02
Outcome: acceptable level of compliance with WHO GMP guidelines
APIs in scope: process validation for Darunavir and Bedaquiline reviewed; Bedaquiline Fumarate in production during inspection
WHOPIR validity: three years, provided later inspections are positive
Insight · Editorial insight
A positive outcome despite synthesis, purification and packaging in non-dedicated facilities shared with other chemical products signals that the site's cross-contamination controls and cleaning validation were accepted. Buyers of Darunavir or Bedaquiline API from this site may find the WHOPIR useful as supporting evidence in supplier qualification.
Check points
Cross-contamination controls and cleaning validation scope in shared non-dedicated facilities
Whether WHOPIR validity is reflected in API supplier qualification
Alignment of imported API with the market-specific quality specification
Inspection report detail · From the source · WHO · Item 15
Inspection outcome
Original · WHOPIR
Based on the areas inspected, the people met and the documents reviewed, and considering the findings of the inspection, including the observations listed in the Inspection Report, MSN Life Sciences Private Limited Unit-II located at Sy. No: Parts of 454, 455, 457, 458 & 459, Chandampet (Village), Shankarampet-R (Mandal), Medak District, Telangana, 502255 was considered to be operating at an acceptable level of compliance with WHO GMP Guidelines. All the non-compliances observed during the inspection that were listed in the full report as well as those reflected in the WHOPIR, were addressed by the manufacturer, to a satisfactory level, prior to the publication of the WHOPIR. This WHOPIR will remain valid for three years, provided that the outcome of any inspection conducted during this period is positive.
1. Quality management
Original · WHOPIR
A documented system for quality assurance was established, with procedures covering key quality elements in place. Operations were specified in written form and critical GMP requirements were essentially being met. The quality system allows for corporate and site QA SOPs. The procedures reviewed and discussed during the inspection were generally of an acceptable standard. Annual Product Quality Review (PQR) THE SOP for “Annual Product Quality Review” was reviewed. The schedule for preparation of APQR was in place. The following APQRs were reviewed during inspection. …
2. Personnel
Original · WHOPIR
An organigram of the company presented the corporate line structure between the MSN corporate management and MSN Unit II site management. For the activities of Unit II, the number of personnel appeared adequate for the present activities on the site. The key personnel of the various departments and staff met during the inspection appeared to possess adequate educational credentials and experience in their jobs. The Site Head took the full operational responsibility of Site Unit II. It was observed that production and quality assurance functions operated independently. …
3. Buildings and facilities
Original · WHOPIR
Production blocks The premises at MSN Unit II site were documented in SMF. There were 12 production blocks in operation. Several new production blocks were under construction at the time of inspection. The synthesis, purification, and packaging of the three APIs took place in non-dedicated facilities, shared with other chemical products. Quality Control The QC laboratories were located in QC /QA building and included chemical analysis, instrumental analysis, stability chambers, control samples storage areas and microbiology laboratory. …
4. Process equipment
Original · WHOPIR
Design and construction. Generally, equipment was of appropriate design and adequate size, and suitably located for its intended use, cleaning, sanitization and maintenance. Equipment and permanently installed processing lines used during the production of an intermediates or API were appropriately identified, calibration due date was specified on each equipment as well as cleaning status and cleaning certificate. Equipment maintenance and cleaning Equipment cleaning and release for use were managed in accordance with approved procedures. …
5. Documentation and records
Original · WHOPIR
Documents related to the manufacture of intermediates or APIs were prepared, reviewed, approved, and distributed according to respective SOPs. Documents and records were controlled through both manual and electronic procedures for different type of documents. Master production instructions (master production and control records) Master production instructions were prepared, dated and approved; and contained detailed guidance on production activities. …
6. Materials management
Original · WHOPIR
The company had procedures in place to manage incoming raw materials and packaging materials, received which are coded and an in-house batch number assigned. QC sampled materials from sampling room in warehouse and recoded in sampling logbook. Different raw material, packaging material for API product were stored in different warehouses with temperature and humidity control if required. A manual system for inventory material management system was used. A secured room for rejected and returned products were in place. Supplier management Vendors were qualified according to written procedures. …
7. Production and in-process controls
Original · WHOPIR
Production operations were carried out as per approved BMRs. Raw materials were weighed and measured using appropriately accurate devices. Critical process parameters were monitored and recorded in BMRs. IPCs were performed if required. The production of Bedaquiline Fumarate was in operation at the time of inspection. The relevant production blocks were briefly inspected. Contamination and cross contamination control The SOP “Avoiding cross contamination” addressed the requirements and preventive measures for contamination control. …
8. Packaging and identification labelling of APIs and intermediates
Original · WHOPIR
Packaging materials Packaging materials were appropriately stored and subjected to quality control testing before release. Packaging and labelling operations Packaging and labelling were not in operation for Bedaquiline at the time of inspection. Line clearance in the packaging area was checked.
9. Storage and distribution
Original · WHOPIR
Warehousing procedures Adequate facilities were available for the storage of materials under appropriate conditions. Records of these conditions were maintained. Distribution procedures APIs and intermediates were released for distribution after they had been released by QA. Darunavir and Bedaquiline APIs have been released to different markets with different quality specifications.
10. Laboratory controls
Original · WHOPIR
The QC function was independent of other departments. QC laboratories were separated from production areas. The microbiology laboratory was segregated from the chemistry laboratory. Sample receiving and distribution An access-controlled area for sample receival was available. Sample register and the information for receiving and distribution were managed in LIMS following SOP “Procedure for samples handling and reporting results in LIMS”. …
11. Validation
Original · WHOPIR
Validation master plan An approved VMP was available and reviewed. The qualification and validation policy and programs were defined and documented. Process validation The SOP “Process Validation” was reviewed. Continuous PV (CPV) was addressed in the procedure. The process validation (PV) for Darunavir and Bedaquiline API were checked and found to be acceptable. Cleaning Validation The SOP “Cleaning Validation” was reviewed. Cleaning validation (CV) was performed for the intermediate stage and the final API. …
12. Change control
Original · WHOPIR
The procedures for change management were available for review. Changes were categorized into major and minor. The major changes in facility and manufacturing since last inspection were spot checked.
13. Rejection and re-use of materials
Original · WHOPIR
Rejection The company had procedures for handling rejected materials in place. Reprocessing and reworking The SOP “Reprocessing and reworking” was available. Reprocessed batch was indicated in batch number. Recovery of material The SOP “Recovery of solvents and materials” was reviewed. According to the company, recovered solvents during the manufacturing process were not used for the manufacturing of three APIs in the inspection scope.
14. Complaints and recalls
Original · WHOPIR
Complaints Product complaints were handled according to the SOP “Market complaint management” which was reviewed. The procedure was applicable to all types of complaints received from customers. According to the SOP, complaints were classified as critical, major or minor. The timeline for complaint investigation, CAPA, feedback and closure were specified in the procedure. If required, appropriate actions should be initiated for product recall. Complaint logbook 2025 was available. Recall Product recalls were handled according to the SOP “Product recall”, which was reviewed. …
Contract testing The contract laboratory used for testing of APIs in the inspection scope were documented. Contract production Production operations were not contracted out for any of the APIs that were submitted to WHO PQT.
[WHO · WHO]Hetero Labs (Unit 1 Gaddapothoram) — API site found WHO GMP compliant
WHOWHO
WHO published the public inspection report (WHOPIR) for Hetero Labs (Unit 1 Gaddapothoram), inspected on 2026-02-27. The site was considered to be operating at an acceptable level of compliance with WHO GMP Guidelines, and all non-compliances were addressed before publication.
Inspection date 2026-02-27 · Outcome Acceptable · Valid for 3 years · Issuing authority WHO
Key facts · Basis: official index plus supporting sources
Inspection date: 2026-02-27
Outcome: acceptable level of compliance with WHO GMP Guidelines
Non-compliances: addressed by the manufacturer to a satisfactory level before WHOPIR publication
Validity: three years, provided any inspection in that period is positive
Insight · Editorial insight
The report covers the full range of API GMP areas, from quality management and change control to complaints and process validation, and notes that oncology APIs are made in dedicated production blocks. Domestic manufacturers sourcing APIs from this site may find it a useful external reference for supplier qualification.
Check points
Whether the WHOPIR outcome is reflected in supplier qualification files for this firm
Information on dedicated facilities and cross-contamination control for oncology APIs
Tracking of the WHOPIR validity period and follow-up inspection outcomes
Inspection report detail · From the source · WHO · Item 15
Inspection outcome
Original · WHOPIR
Based on the areas inspected, the people met and the documents reviewed, and considering the findings of the inspection, including the observations listed in the Inspection Report, Hetero Labs Limited, Unit 1 located at Survey No 10, I.D.A, Gaddapotharam Jinnaram Mandal, Sangareddy Dist 502 319 Telangana, India was considered to be operating at an acceptable level of compliance with WHO GMP Guidelines. All the non-compliances observed during the inspection that were listed in the full report as well as those reflected in the WHOPIR, were addressed by the manufacturer, to a satisfactory level, prior to the publication of the WHOPIR. This WHOPIR will remain valid for three years, provided that the outcome of any inspection conducted during this period is positive.
1. Quality management
Original · WHOPIR
A documented system for quality assurance was established, with procedures covering key quality elements were in place. The Quality Department was divided into QA and QC and were separate from the Production Department. Operations were specified in written form and critical GMP requirements were essentially being met. Annual Product Quality Review The company had in place a procedure for performing product quality reviews. The SOP “Annual product quality review management procedure” was in place and included the purpose, scope, responsibility and procedure. The following APQRs were reviewed. …
2. Personnel
Original · WHOPIR
An organization chart was available. An adequate number of personnel was qualified by appropriate education, training and experience to perform and supervise the manufacture of intermediates and APIs. The key personnel of the various department had pharmaceutical qualification and were experienced in pharmaceutical manufacturing. Quality unit was independent from Production unit. Roles and responsibilities were described in writing. Job descriptions Responsibilities of personnel engaged in the manufacture of intermediates and APIs were specified in writing. …
3. Buildings and facilities
Original · WHOPIR
In general facilities were located, designed, and constructed to facilitate cleaning, maintenance and operations as appropriate to the type and stage of manufacture. Adequate space was provided for the orderly placement of equipment and materials. The classified areas were monitored for temperature and pressure differentials. Exposed surfaces were smooth, impervious and unbroken to minimize the shedding or accumulation of particles or microorganisms and permitted the repeated application of cleaning agents. Oncology APIs were manufactured in dedicated production Blocks. …
4. Process equipment
Original · WHOPIR
Design and construction. Generally, equipment was of appropriate design and adequate size, and suitably located for its intended use, cleaning, sanitization and maintenance. Equipment and permanently installed processing lines used during the production of an intermediates or API were appropriately identified, calibration due date was specified on each equipment as well as cleaning status and cleaning certificate. Equipment cleaning and maintenance Equipment cleaning and release for use were managed following SOP “Cleaning of equipment”. …
5. Documentation and records
Original · WHOPIR
Documents were prepared, reviewed, approved, and distributed according to the procedure “Initiation, approval, revision and distribution of procedures”. The issuance, revision, superseding and withdrawal of documents were controlled, and revision histories maintained. Documents were maintained following SOP “Archival, retrieval and destruction of documents”. Batch numbering system. The SOP “Product code and Batch numbering system” was checked. The site code was indicated in the batch number. A reprocessed/reworked batch was referenced in the batch number. …
6. Materials management
Original · WHOPIR
Written procedures describing the receipt, identification, quarantine, storage, handling, sampling, testing and approval or rejection of materials were available. Changing the source of supply of critical raw materials, if any, was managed according to the change control procedure. Supplier management Vendors were qualified according to the procedure for Supplier qualification. Warehouses (WHs) The company had warehouse areas relevant to the products in the inspection scope. They were visited during the inspection. …
7. Production and in-process controls
Original · WHOPIR
Raw materials for manufacturing of intermediate and API were weighed/measured under appropriate conditions. Critical weighing, measuring and other critical operations were witnessed. The processing status of equipment was indicated. In-process sampling was carried out. Blending batches of intermediates or APIs The SOP “Requirements for blending validation” was reviewed. The products in the scope of the inspection did not undergo this process of blending small batches to increase the batch size. …
8. Packaging and identification labelling of APIs and intermediates
Original · WHOPIR
Written procedures describing the receipt, identification, quarantine, sampling, examination and/or testing and release and handling of packaging materials were available. Packaging and labelling operations The SOP “Packaging and labelling of products” was checked. Packaging of API batches was inspected. The packaging and labelling records of the product under production were checked. The line clearance of the packaging room was checked and discussed.
9. Storage and distribution
Original · WHOPIR
Warehousing procedures Facilities were available for the storage of materials under appropriate conditions. Designated areas were available for quarantine, rejected, returned, or recalled materials. Distribution procedures APIs and intermediates were distributed to third parties after they have been released by QA. Special transport or storage conditions for an API or intermediate were stated on the labels, if required. A system was in place by which the distribution of each batch of intermediate and/or API can be readily determined to permit its recall, if needed.
10. Laboratory controls
Original · WHOPIR
The QC function was independent from other departments. QC laboratories had its independent building. The physio-chemical Laboratory was visited and seen generally in good order and clean. Microbiology laboratory was separate in a different building. Sample receiving and distribution Sample receiving and distribution managed in LIMS was spot checked during inspection. Release of starting materials and intermediates were responsible by QC. …
11. Validation
Original · WHOPIR
VMP The VMP was available. Prospective and concurrent PV were specified in the validation policy. Annual VMP was generated including the schedule for the current year. Process Validation The SOP “Process Validation” was reviewed. The procedure also covered the continuous process validation process. The procedure for continuous Process Verification was available. Equipment Qualification Before validation activities, appropriate qualification of critical equipment and ancillary systems was completed. The SOP for qualification of facilities and equipment was available. …
12. Change control
Original · WHOPIR
The SOP “Change control management procedure” was available and gave the basis for the process. Form for the change control log was part of the SOP. Changes were classified as: major or minor. Temporary changes were part of the procedure. Risk assessment was required to be performed for major changes. A standard template was attached to the procedure.
13. Re-use of materials
Original · WHOPIR
Reprocessing and reworking The SOP “Reprocessing and reworking” was available. The procedure was checked and discussed. Returns The SOP “Handling of Returned Goods” was discussed. Returned intermediates or APIs were identified as such and quarantined. The return register 2025 was checked. Recovery of material and solvents The SOP “Procedure of the usage of recovered materials in intermediate and drugs substances (API) and in house manufacturing of raw materials” was in place.
14. Complaints and recalls
Original · WHOPIR
Complaints The SOP “Handling of Customer Complaints” was reviewed. The procedure outlined the responsibilities for each department. Complaints were classified first into Critical, Major and Minor. This was further classified into two categories: quality and non-quality complaints. Quality-related complaints were recorded, investigated and managed by QA and relevant departments according to a written procedure. An Investigation team was formed and during the investigation a complaint could be re-categorised. Timelines were listed for each type of complaint was defined. …
[GMP inspection · MFDS]의료법인한라의료재단 — Contamination control and data integrity gaps
MFDSGMP inspection
MFDS published the results of a follow-up GMP inspection of a finished-product (single) manufacturing site, citing deficiencies in the quality assurance system, deviation handling and document approval records, all marked as remediated.
Published 2026-10-20 · Inspection period 2026-06-22~2026-06-24
Original text
평가 결과 지적(보완)사항(Deficiencies) 분야1) 구분2) 근거 법령 지적(보완)사항 요약 비고3) 품질경영 기타 [별표 1] 제1의2호 자사 품질보증시스템에 관한 사항 자사 기준서 반영 미흡, 자사 오염관리전략 수립 미흡, 데이터완전성 관련 카메라, 표준시계 등 관리방안 마련 필요 보완 완료 기타 [별표 1] 제3.3호 나목 기준일탈 건에 대한 미흡 사항 재검토 필요 보완 완료 기타 [별표 1] 제5.1호 나목 일부 문서에 품질(보…
Key facts · Basis: official source record kept by the collector
Type: follow-up / finished product (single)
Key findings: inadequate contamination control strategy; need for controls over cameras and reference clocks for data integrity
Other findings: deviation cases need re-review; approval dates by the QA head missing on some documents
Insight · Editorial insight
Citing both the contamination control strategy and data integrity controls for cameras and reference clocks signals that MFDS follow-up inspections are reaching system-level design documents. The missing approval dates also make the traceability of sign-off timing worth checking from an ALCOA+ perspective.
Check points
Documented contamination control strategy reflected in internal procedures
Time synchronization of clocks, cameras and other data integrity equipment
Completeness of approval dates recorded by the QA head
[GMP inspection · MFDS]영진약품(주) — No deficiencies at API site follow-up inspection
MFDSGMP inspection
MFDS published the results of a follow-up GMP inspection of a domestic API (single) manufacturing site, with no deficiencies cited.
Published 2026-10-20 · Inspection period 2026-09-04~2026-09-04
Original text
평가 결과 지적(보완)사항(Deficiencies) 없음 의 료 제 품 안 전 과
Key facts · Basis: official source record kept by the collector
Type: follow-up / API (single)
Result: no deficiencies
Publication date: 2026-10-20
Insight · Editorial insight
A one-day follow-up inspection of an API site closing with no deficiencies suggests that its GMP operations have been maintained since the previous assessment. Finished-product makers sourcing from this site may want to reflect the result in their supplier qualification records.
Check points
Whether supplier qualification records reflect the latest inspection result
How supplier requalification cycles link to MFDS inspection outcomes
MFDS suspended import of a ciclesonide nasal spray product for 3 months after the importer approved and shipped one batch before its quality testing had been approved, breaching importer compliance obligations.
Shown in the original Korean: 1 value in this table.
Original text
○ 의약품 수입자의 준수사항 등의 규정 위반
- 의약품 수입업자는「약사법」제42조제5항, 제9항 및「의약품안전규칙」제60조제2항제1호에 따라, 의약품의 품질검사를 철저히 하고 합격한 제품만을 판매하여야 하나,
- 동 업체는 ‘옴나리스나잘스프레이(미분화시클레소니드)(제조번호:128733)’의 품질검사 승인 이전에 출하승인하여 제품을 출하한 사실이 있음
※ (품질검사 승인일) 2025.11.6. / (출하 승인일) 2025.10.22.
Key facts · Basis: official source record kept by the collector
Violation: release approval and shipment before quality testing approval (batch 128733)
Basis: Pharmaceutical Affairs Act Article 42 and the MFDS safety rules on medicinal products
Insight · Editorial insight
A release approval dated ahead of the quality testing approval signals a gap where batch disposition for imported drugs ran separately from confirmation of test results. Such sequence reversals are generally associated with systems that do not enforce test approval before release, so importers may want to revisit how their release decisions are controlled.
Check points
Records comparing release approval timing against quality testing approval
Whether batches without quality testing approval are blocked from shipment
Approval sequence defined in the import release procedure
[Administrative action · MFDS]씨엠병원 — Trial site fails designation requirements
MFDSAdministrative action
MFDS imposed a first-offense one-month business suspension (2026.10.21.~2026.11.20.) on a hospital for failing to meet the requirements for designation as a clinical trial site.
Published 2026-10-21 · Action 업무정지 1개월(2026.10.21.~2026.11.20.), 1차
Shown in the original Korean: 1 value in this table.
Original text
임상시험실시기관 지정요건 미달
Key facts · Basis: official source record kept by the collector
Violation: failure to meet clinical trial site designation requirements
Action: business suspension for 1 month (2026.10.21.~2026.11.20.), first offense
Legal basis: Pharmaceutical Affairs Act Article 34-2(1)1 and Article 3 of the regulation on designation of clinical trial sites
Insight · Editorial insight
The action signals that a designated clinical trial site that no longer meets designation requirements can face a business suspension. Sponsors running or planning trials at affected sites may want to check trial schedules and site status during the suspension period.
Check points
Designation requirement status of contracted clinical trial sites
Schedule impact on trials ongoing during the suspension period
MFDS suspended clinical trial work for the relevant product at a university hospital for 3 months and ordered a change of principal investigator (1st offense) over a violation of trial subjects' informed consent procedures.
Published 2026-10-21 · Action 해당 품목 임상시험 업무정지 3개월(2026.10.21.~2027.1.20.)과 임상시험 책임자 변경(1차)
Shown in the original Korean: 1 value in this table.
Original text
임상시험 대상자의 동의 절차 위반
Key facts · Basis: official source record kept by the collector
Violation: breach of trial subject consent procedures
Action: 3-month suspension of clinical trial work for the product (2026.10.21.~2027.1.20.) plus change of principal investigator (1st offense)
Basis: Korean GCP (Pharmaceutical Affairs Act and Enforcement Rule GCP annex)
Final disposition date: 20261021
Insight · Editorial insight
Pairing a product-level trial suspension with a mandatory investigator change signals that MFDS treats consent failures as a site and investigator accountability issue. Sponsors may want to note that consent handling at a contracted site can directly halt a product's development timeline.
Check points
Completeness of signed consent records and consent timing
Scope of sponsor monitoring over site consent procedures
Handover plan for ongoing trials when an investigator changes
[Administrative action · MFDS]젬백스앤카엘 — Unreported trial plan change and IMP GMP breach
MFDSAdministrative action
MFDS issued a first warning to a pharmaceutical company for failing to report a change to a clinical trial plan and for violating manufacturing and quality control standards for investigational medicinal products.
Published 2026-10-21 · Action 경고(1차)
Shown in the original Korean: 1 value in this table.
Original text
① 임상시험계획 변경 미보고
② 임상시험용의약품 제조 및 품질관리 기준 위반
Key facts · Basis: official source record kept by the collector
Action: warning (first offense)
Violations: unreported clinical trial plan change; breach of IMP manufacturing and quality control standards
Published: 2026-10-21
Insight · Editorial insight
The pairing of an unreported protocol change with an IMP GMP breach suggests a gap between the approved trial plan and how the trial and its investigational product were actually managed. Although this is only a first warning, its designation as a first offense signals that a repeat violation could draw a heavier sanction.
Check points
Records assessing whether trial plan changes require reporting
Compliance status with IMP manufacturing and quality control standards
[Administrative action · MFDS]한국코러스(주) — Non-compliance with GMP standard procedures
MFDSAdministrative action
MFDS imposed a 1-month manufacturing suspension on a hyaluronidase API product of a manufacturer for failing to comply with its standard procedures.
Published 2026-10-15 · Action ○ 해당 품목 제조업무정지 1개월(2026.11.16.~2026.12.15.)
* (해당품목) 히알루로니다제(Hhaluronidase)[원료의약품등록 제20230704-210-J-1516호]
Shown in the original Korean: 1 value in this table.
Original text
기준서 미준수
Key facts · Basis: official source record kept by the collector
Violation type: non-compliance with standard procedures
Action: 1-month manufacturing suspension for the product (2026.11.16.~2026.12.15.)
Product: a hyaluronidase active pharmaceutical ingredient
Legal basis: Pharmaceutical Affairs Act Article 38(1) and the Rules on Safety of Pharmaceuticals Article 48(9)
Insight · Editorial insight
Non-compliance with standard procedures signals a gap between approved manufacturing and quality control procedures and actual practice, viewed as a document control issue. Since a manufacturing suspension was imposed on a single API product, API manufacturers may want to recheck that their procedures match shop-floor operations.
Check points
Alignment of manufacturing and QC procedures with actual operations
Records of training and implementation when procedures are revised
MFDS suspended manufacturing of two herbal medicine products from a manufacturer for 3 months after market-surveillance testing found benzo[a]pyrene above the 5 ppb limit.
Published 2026-10-13 · Action ○ 해당 품목 제조업무정지 3개월(2026. 11. 3. ~ 2027. 2. 2.)
- 해당 품목: ‘현진오매’, ‘현진초과'
Shown in the original Korean: 1 value in this table.
Key facts · Basis: official source record kept by the collector
Violation: herbal medicine quality test failure in market-surveillance testing by the Seoul Metropolitan Government Research Institute of Public Health and Environment
Benzo[a]pyrene results: 28 ppb and 26 ppb against a limit of 5 ppb or less
Disposition: 3-month manufacturing suspension for the products (2026. 11. 3. ~ 2027. 2. 2.)
Both products exceeded the benzo[a]pyrene limit by more than five times, which signals a raw material or processing control issue rather than a one-off deviation. Benzo[a]pyrene is generally associated with drying and heat-processing conditions, and this case shows that market-surveillance failures can lead to product-level manufacturing suspensions.
Check points
Whether benzo[a]pyrene testing is done at receipt and release of herbal materials
Records of drying and processing conditions for herbal raw materials
Re-review of test results for other batches still on the market
[Administrative action · MFDS](주)현진제약 — Herbal medicine ash content failure
MFDSAdministrative action
MFDS imposed a 3-month manufacturing suspension on two herbal medicine products from a manufacturer after market surveillance testing found ash content exceeding specifications.
Published 2026-10-13 · Action ○ 해당 품목 제조업무정지 3개월(2026. 11. 3. ~ 2027. 2. 2.)
- 해당 품목: ‘현진몰약’, ‘현진종대황’
Shown in the original Korean: 1 value in this table.
Original text
○유통한약재 품질검사 부적합(검사기관: 서울시 보건환경연구원)
① 품목: 현진몰약(제조번호: 24053-01, 제조일자/사용기한: 2024. 6. 10./ 2027. 6. 9.)
- 시험항목: 회분, 기준/결과: 15.0% 이하 / 18.8%
- 시험항목: 산불용성회분, 기준/결과: 5.0% 이하 / 14.9%
② 품목: 현진종대황(제조번호: 26158-01, 제조일자/사용기한: 2026. 2. 20./ 2029. 2. 19…
Key facts · Basis: official source record kept by the collector
Action: 3-month manufacturing suspension of the products (2026. 11. 3. ~ 2027. 2. 2.)
Myrrh product: total ash 18.8% vs limit 15.0%; acid-insoluble ash 14.9% vs limit 5.0%
Rhubarb product: total ash 16.7% vs limit 10.0%
Testing body: a Seoul municipal public health and environment research institute
Insight · Editorial insight
Excess total and acid-insoluble ash is generally associated with soil, sand or other inorganic foreign matter and with how washing and sorting are controlled. Two different products failing on the same test item suggests the incoming testing and sorting of raw herbal materials deserve a closer look.
Check points
Ash and acid-insoluble ash testing at raw material receipt
Washing and sorting controls for removing foreign matter
Release records confirming finished herbal products meet specifications
[Administrative action · MFDS](주)현진제약 — Cadmium and pesticide failures in herbal materials
MFDSAdministrative action
MFDS suspended manufacturing of two herbal medicine products for 3 months after distributed-herbal-material quality testing found a Moutan root bark product out of specification for cadmium and a Lycium fruit product out of specification for the pesticide buprofezin.
Published 2026-10-13 · Action ○ 해당 품목 제조업무정지 3개월(2026. 11. 3. ~ 2027. 2. 2.)
- 해당 품목: ‘현진목단피’, ‘현진구기자’
Shown in the original Korean: 1 value in this table.
Original text
○유통한약재 품질검사 부적합(검사기관: 서울시 보건환경연구원)
① 품목: 현진목단피(제조번호: 26049-01, 제조일자/사용기한: 2026. 2. 23./ 2029. 2. 22.)
- 시험항목: 중금속(카드뮴)
- 기준/결과: 0.3ppm 이하 / 0.7ppm
② 품목: 현진구기자(제조번호: 26027-01, 제조일자/사용기한: 2026. 5. 27./ 2029. 5. 26.)
- 시험항목: 잔류농약(뷰프로페진)…
Key facts · Basis: official source record kept by the collector
Action: 3-month manufacturing suspension for the affected products (2026. 11. 3. ~ 2027. 2. 2.)
Moutan root bark product: cadmium limit 0.3ppm or less, result 0.7ppm
Lycium fruit product: buprofezin limit 0.01mg/kg or less, result 0.04mg/kg
Testing body: a Seoul metropolitan public health and environment research institute
Insight · Editorial insight
Both failures were detected by post-market testing of distributed herbal materials, which signals that a maker's pre-release heavy metal and pesticide testing is being judged against what regulators find on the market. Cadmium and buprofezin exceedances are generally associated with the cultivation soil and pesticide history of the raw herb, so incoming raw material controls are worth reviewing alongside release testing.
Check points
Cadmium testing of incoming raw herbal materials
Whether buprofezin is in the residual pesticide test panel
Investigation of gaps between release results and market testing results
[Administrative action · MFDS]주식회사올본 — Cadmium above limit in herbal medicine
MFDSAdministrative action
MFDS imposed a 3-month manufacturing suspension on a herbal medicine product (Angelica root) from a manufacturer after a market-surveillance quality test found cadmium above the specification.
Published 2026-10-13 · Action ○ 해당 품목 제조업무정지 3개월(2026. 11. 3. ~ 2027. 2. 2.)
- 해당 품목: ‘올본당귀‘
Shown in the original Korean: 1 value in this table.
Key facts · Basis: official source record kept by the collector
Violation: failed quality test of a distributed herbal medicine (tested by the Seoul Metropolitan Institute of Public Health and Environment)
Test item: heavy metal (cadmium); limit/result: 0.3ppm or less / 0.5ppm
Action: 3-month manufacturing suspension for the product (2026. 11. 3. ~ 2027. 2. 2.)
Insight · Editorial insight
A cadmium result of 0.5ppm against a 0.3ppm limit, found in post-distribution testing, signals that heavy-metal failures can surface after release. Heavy metals in herbal materials are generally associated with cultivation soil and origin, so incoming heavy-metal testing scope for raw herbs may be worth revisiting.
Check points
Heavy-metal (cadmium) testing of raw herbal material at receipt
Heavy-metal test history by origin and supplier
Release records comparing cadmium results to the 0.3ppm limit
[Administrative action · MFDS](주)엔탭허브 — Herbal medicine cadmium limit exceeded
MFDSAdministrative action
MFDS suspended manufacturing of an herbal medicine product for 3 months after a regional health and environment research institute found its cadmium content exceeded the limit in a market quality test.
Published 2026-10-13 · Action ○ 해당 품목 제조업무정지 3개월(2026. 11. 3. ~ 2027. 2. 2.)
- 해당 품목: ‘엔탭허브오약’
Shown in the original Korean: 1 value in this table.
Key facts · Basis: official source record kept by the collector
Violation: failed quality test of a marketed herbal medicine (heavy metal: cadmium)
Limit/result: 1.0ppm or less / 1.4ppm
Action: 3-month manufacturing suspension of the product (2026. 11. 3. ~ 2027. 2. 2.)
Insight · Editorial insight
Cadmium exceedance is generally associated with the soil and growing environment of the herbal raw material, and here a market surveillance test led to a product-level manufacturing suspension. For herbal medicine manufacturers, it signals that heavy metal testing of incoming raw materials ties directly to post-release enforcement risk.
Check points
Whether cadmium testing is performed on incoming herbal raw materials
[Administrative action · MFDS](주)엔탭허브 — Benzo[a]pyrene limit exceeded in herbal medicine
MFDSAdministrative action
MFDS imposed a 3-month manufacturing suspension on a herbal medicinal material product after a market-surveillance quality test by the Seoul Metropolitan Institute of Public Health and Environment found benzo[a]pyrene above the limit.
Published 2026-10-13 · Action ○ 해당 품목 제조업무정지 3개월(2026. 11. 3. ~ 2027. 2. 2.)
- 해당 품목: ‘엔탭허브오매’
Shown in the original Korean: 1 value in this table.
Key facts · Basis: official source record kept by the collector
Action: 3-month manufacturing suspension for the product (2026. 11. 3. ~ 2027. 2. 2.)
Violation: failed quality test of a marketed herbal material (purity test for benzo[a]pyrene, limit 5ppb or less / result 12ppb)
Publication date: 2026-10-13
Insight · Editorial insight
A benzo[a]pyrene result of 12ppb against a 5ppb limit in a market sample led directly to a product-level manufacturing suspension, signaling that post-release surveillance results can by themselves trigger enforcement. Benzo[a]pyrene is generally associated with heat during drying or processing of raw herbal materials, so it is worth reviewing how this purity test is covered before release.
Check points
Whether benzo[a]pyrene purity testing is performed before release
Drying and processing information from raw herbal material suppliers
Investigation procedure for the same batch when a market test fails
MFDS suspended manufacturing of a distributed herbal medicine (peony root) product for 3 months after a Seoul public health institute's quality test found it failed the assay for albiflorin plus paeoniflorin.
Published 2026-10-13 · Action ○ 해당 품목 제조업무정지 3개월(2026. 11. 3. ~ 2027. 2. 2.)
- 해당 품목: ‘엔탭허브작약’
Shown in the original Korean: 1 value in this table.
A marker-compound content well below specification is generally associated with variability in the raw herb or content loss during storage. Because a post-market sampling assay failure led to a product-level suspension, herbal medicine makers may want to review release assay margins alongside evidence that content holds through shelf life.
Check points
Marker-compound assay at raw herb receipt
Release assay results and margin against specification
Stability evidence for marker content through shelf life
MFDS imposed a 3-month manufacturing suspension on a distributed herbal medicine product (apricot kernel) after it failed a quality test for amygdalin content.
Published 2026-10-13 · Action ○ 해당 품목 제조업무정지 3개월(2026. 11. 3. ~ 2027. 2. 2.)
- 해당 품목: ‘엔탭허브행인’
Shown in the original Korean: 1 value in this table.
Key facts · Basis: official source record kept by the collector
Reason: distributed herbal medicine quality test failure, assay (amygdalin) spec 3.0% or more vs result 2.3%
Action: 3-month manufacturing suspension of the product (2026. 11. 3. ~ 2027. 2. 2.)
Final disposition date: 20261013
Insight · Editorial insight
An amygdalin result of 2.3% against a 3.0% minimum in a product already on the market shows that marker content after release can directly trigger a suspension. Low marker content in herbal materials can generally be associated with variability in the raw botanical or changes during storage, so the basis for content stability through shelf life is worth revisiting.
Check points
Trend of amygdalin assay results for incoming apricot kernel lots
Evidence that marker content holds through the shelf life
Margin between release assay results and the specification
[Administrative action · MFDS]한미약품(주) — Late reporting of controlled drug handling records
MFDSAdministrative action
MFDS issued a warning to a narcotics manufacturer for failing to report 26 manufacturing (change) records, including a zolpidem tartrate 10mg tablet product, to the integrated narcotics management system within the reporting deadline.
Published 2026-10-23 · Action (마약류제조업자) 경고
Shown in the original Korean: 1 value in this table.
Original text
○ 「마약류 관리에 관한 법률」 제11조 및 같은 법 시행규칙 제21조에 따라 마약류취급자는 마약류의 수출입․제조․판매․양수․양도․구입․사용․폐기 등 모든 취급내역을 마약류통합관리시스템을 통해 보고기한 내 식품의약품안전처장에게 보고하여야 함에도 불구하고,
- '졸피드정(졸피뎀타르타르산염)(10mg) 등 제조(변경)’ 26건에 대하여 보고기한 내 보고하지 않은 사실이 있음.
Key facts · Basis: official source record kept by the collector
Action: warning (narcotics manufacturer)
Violation: 26 manufacturing (change) records, including a zolpidem tartrate 10mg tablet, not reported within the deadline
Legal basis: Article 11 of the Narcotics Control Act and Article 21 of its Enforcement Rule
Published: 2026-10-23
Insight · Editorial insight
The action targets not the manufacturing itself but the failure to report manufacturing records to the system on time, signaling that reporting is treated as a standalone compliance obligation. With 26 records cited at once, the lapse may reflect a process-level gap rather than a one-off miss.
Check points
Timeliness of manufacturing (change) reports to the integrated narcotics management system
Reconciliation frequency between production records and system reports
[Administrative action · MFDS]지피테라퓨틱스코리아주식회사 — API site change without variation approval
MFDSAdministrative action
MFDS imposed a fine of KRW 1,500,000 in lieu of a 1-month import suspension on an importer that changed the location of an imported drug's active ingredient manufacturer without approval and imported and sold product made with active ingredient from an unapproved site.
Published 2026-10-15 · Action ○ 수입 의약품 ‘베타딘드라이파우더스프레이’에 대한 수입업무정지 1개월 처분을 갈음한 과징금 1,500,000원 부과
Shown in the original Korean: 1 value in this table.
Original text
○ 수입 의약품 ‘베타딘드라이파우더스프레이’의 허가받은 사항 중 주성분 제조원의 소재지를 변경하면서 변경허가를 받지 아니하고, 허가받은 제조소와 다른 제조소에서 제조된 주성분을 사용하여 제조된 제품을 수입하여 판매한 사실이 있음
Key facts · Basis: official source record kept by the collector
Violation: active ingredient manufacturer location changed without a variation approval; product made with active ingredient from a non-approved site was imported and sold
Disposition: fine of 1,500,000 won in lieu of a 1-month import business suspension
Legal basis: Pharmaceutical Affairs Act Article 42(1) and Article 31(9); Rules on the Safety of Medicinal Products Article 8(1)
Final disposition date: 20261015
Insight · Editorial insight
The violation here was not a defect in the finished product but a relocation of the active ingredient manufacturer that was never reflected in the marketing authorization, signaling that a supply-chain change is itself a licensing change. For imported drugs, a foreign maker's late notice of an active ingredient site move can generally be associated with this kind of mismatch between the approved dossier and actual supply, so change-notification arrangements with overseas manufacturers are worth reviewing.
Check points
Match between approved and actual active ingredient manufacturing sites for each imported product
Advance notice clauses for active ingredient site changes in quality agreements with foreign manufacturers
Procedure to confirm variation approval before an active ingredient source change takes effect
MFDS ordered a recall of a product from a manufacturer on the grounds of a description (appearance) failure.
Published 2026-10-21 · Product 푸른무약골쇄보
Original text
성상
Key facts · Basis: official source record kept by the collector
Reason: description (appearance)
Mandatory recall: Y
Recall order date: 20261021
Insight · Editorial insight
Description is judged visually and organoleptically, so this recall suggests raw-material variability surfaced in the released product. Because the recall was mandatory, it is worth asking whether incoming description criteria and reference standards actually discriminate between acceptable and unacceptable lots.
Check points
Incoming description criteria and use of reference standards
Review records of description test results before release
[Recall / sales suspension · MFDS]에이치케이이노엔(주) — Primary packaging from another product used
MFDS💊 Small moleculeRecall
A company initiated a voluntary recall of an injection product after units were found packed using the primary packaging material of another of its own similarly named products.
Published 2026-10-21 · Product 오마프원페리주
Original text
자사 타제품(오마프플러스원페리주)의 1차 포장자재가 사용되어 포장된 제품 발견에 따른 영업자 회수
Key facts · Basis: official source record kept by the collector
Reason: primary packaging material of another in-house product used
Mandatory recall: N
Recall order date: 20261021
Insight · Editorial insight
The mix-up between primary packaging of two similarly named in-house products points to a breakdown in material identification or line clearance during packaging. Where primary packaging is key to product identity, separating storage and issuance of look-alike materials is generally associated with this kind of risk.
Check points
Segregated storage and issuance of look-alike primary packaging
Line clearance and material reconciliation records before packaging
[Recall / sales suspension · MFDS](주)다림바이오텍 — Possible mix-in of a cabergoline tablet
MFDS💊 Small moleculeRecall
A company voluntarily recalled a tablet product over concerns that tablets of another product containing cabergoline may have been mixed in.
Published 2026-10-21 · Product 엑스프리벤정
Original text
타 제품(도스티넨정0.5밀리그램(카베르골린)) 혼입 우려에 따른 영업자회수
Key facts · Basis: official source record kept by the collector
Reason: possible mix-in of another product (cabergoline tablet)
Mandatory recall: N
Recall order date: 20261021
Insight · Editorial insight
A concern that different tablets were mixed suggests a gap in changeover control on shared production or packaging lines. Since cabergoline is an active ingredient that matters if taken unintentionally, tablet identification and residual-tablet checks at changeover look like the central issue.
Check points
Residual tablet checks at product changeover
Use of visual tablet identification (imprint, color)
Scheduling and cross-mix risk assessment for shared lines
MFDS ordered a mandatory recall of a herbal product over a quality failure in its description test.
Published 2026-10-21 · Product 바른금은화
Original text
품질 부적합(성상)
Key facts · Basis: official source record kept by the collector
Reason: quality failure (description)
Mandatory recall: Y
Recall order date: 20261021
Insight · Editorial insight
For herbal products, a description failure can generally be associated with discoloration or shape changes linked to drying or storage conditions of the raw material. That it led to a mandatory recall after market release signals that changes during distribution and storage are also worth examining.
Check points
Drying and storage conditions at the raw material supplier
Stability monitoring of description over shelf life
A manufacturer began a voluntary precautionary recall of a rosuvastatin calcium 10 mg tablet product over concerns that related substances could exceed specification.
Published 2026-10-21 · Product 로수탄정10밀리그램(로수바스타틴칼슘)
Original text
유연물질 기준 초과 검출 우려에 따른 사전예방적 조치로 인한 영업자 회수
Key facts · Basis: official source record kept by the collector
Reason: precautionary voluntary recall due to concern over related substances exceeding the limit
Mandatory recall: N
Recall order date: 20261021
Insight · Editorial insight
The firm acted at the stage of a concern about exceeding the impurity limit rather than a confirmed failure, which signals a proactive reading of impurity trends. Rising related substances can generally be associated with degradation during storage or changes in the API impurity profile, so holders of rosuvastatin products may want to revisit their impurity trends.
Check points
Lot-by-lot trend analysis of related substances results for rosuvastatin products
Comparison of impurity profiles across API suppliers
A product from a domestic manufacturer was placed under a mandatory recall by MFDS for a sulfur dioxide issue.
Published 2026-10-21 · Product 현진강활
Original text
이산화황
Key facts · Basis: official source record kept by the collector
Reason: sulfur dioxide
Mandatory recall: Y
Recall order date: 20261021
Insight · Editorial insight
A mandatory recall citing sulfur dioxide signals that residual sulfur dioxide exceeded the quality standard. Sulfur dioxide residues can generally be associated with fumigation or bleaching during drying and preservation, making supplier-side treatment history a point worth examining.
Check points
Fumigation and bleaching history from raw material suppliers
Scope and frequency of incoming sulfur dioxide testing
[Recall / sales suspension · MFDS](주)현진제약 — Cadmium heavy metal recall
MFDS▫️ OtherRecall
A product from a domestic manufacturer was placed under a mandatory recall for heavy metal (cadmium).
Published 2026-10-21 · Product 현진절패모
Original text
중금속(카드뮴)
Key facts · Basis: official source record kept by the collector
Reason: heavy metal (cadmium)
Mandatory recall: Y
Recall order date: 20261021
Insight · Editorial insight
A mandatory recall over cadmium signals that heavy metal contamination at the raw material stage carried through to an out-of-limit product. Cadmium can generally be associated with cultivation soil or the growing region, making origin- and supplier-level test data a key point.
Check points
Comparison of cadmium results by origin and supplier
Whether cadmium testing is performed on every incoming lot
A product from a domestic manufacturer was placed under a mandatory recall for an identification test issue.
Published 2026-10-21 · Product 허브팜석창포
Original text
확인시험
Key facts · Basis: official source record kept by the collector
Reason: identification test
Mandatory recall: Y
Recall order date: 20261021
Insight · Editorial insight
A mandatory recall over the identification test signals that the product's identity with its labeled material itself was not confirmed, a more fundamental problem than an assay or impurity failure. Identification failures can generally be associated with material mix-ups, misidentification, or weak supplier control.
Check points
Origin verification and identification testing at material receipt
Supplier change history and material origin verification records
MFDS ordered a recall of a product from a domestic manufacturer because it failed the appearance (description) test.
Published 2026-10-21 · Product 현진산수유
Original text
성상
Key facts · Basis: official source record kept by the collector
Reason: appearance (description)
Mandatory recall: Y
Recall order date: 20261021
Insight · Editorial insight
Appearance is judged visually and by sensory checks, so a failure here can generally be associated with variability in the material itself or changes during storage. Since it led to a mandatory recall, it is worth confirming that even basic descriptive tests actually function at receipt and release.
Check points
Specificity of appearance acceptance criteria (color, odor, form)
Records of appearance testing at receipt and reference sample management
[Recall / sales suspension · MFDS]에이치케이이노엔(주) — Voluntary recall by the marketing holder
MFDS💊 Small moleculeRecall
A manufacturer started a voluntary recall of one of its chemical drug products, which was listed in the MFDS recall register.
Published 2026-10-21 · Product 오마프원페리주
Original text
자진회수
Key facts · Basis: official source record kept by the collector
Recall type: voluntary
Mandatory recall: N
Recall order date: 20261021
Insight · Editorial insight
A voluntary recall flagged N for mandatory status signals that market action began on the company's own judgment rather than a regulatory order. With many standard codes covered, how the scope was pinned down to individual pack units is worth watching.
Check points
Criteria and decision records for initiating a voluntary recall
Procedure for defining recall scope by standard code and pack unit
MFDS ordered a recall of a product from a domestic manufacturer after it failed ash, identification and assay (sum of kaurenoic acid and continentalic acid) tests.
Published 2026-10-21 · Product 현진독활
Original text
회분, 확인시험, 정량법(카우레노산 및 콘티넨탈산의 합)
Key facts · Basis: official source record kept by the collector
Reason: ash, identification test, assay (sum of kaurenoic acid and continentalic acid)
Mandatory recall: Y
Recall order date: 20261021
Insight · Editorial insight
Failing both identification and marker-compound assay signals that the material's origin or quality may not match the reference herbal standard. The added ash failure can generally be associated with foreign matter or soil contamination and sorting or washing steps, making raw-material control worth a closer look.
Check points
Whether identification testing is performed at raw-material receipt
Lot-to-lot trends in kaurenoic acid and continentalic acid assay
A manufacturer began a voluntary recall of a benfotiamine-containing product after the benfotiamine assay in its stability study fell out of specification.
Published 2026-10-20 · Product 마그액트스피드액
Original text
안정성 시험 일부 항목(벤포티아민 함량 시험) 기준일탈로 인한 영업자 회수
Key facts · Basis: official source record kept by the collector
Reason: out-of-specification result in a stability test item (benfotiamine assay)
Mandatory recall: N
Recall order date: 20261020
Insight · Editorial insight
An assay failure in post-release stability testing signals that benfotiamine content may not hold through the shelf life. Such deviations can generally be associated with ingredient interactions or packaging and storage conditions, so how the stability trend data were interpreted is worth examining.
Check points
Trend analysis and early-warning limits for benfotiamine assay on stability
Impact assessment of marketed lots after a stability OOS
Adequacy of data supporting the assigned shelf life
[Recall (Health Canada) · Health Canada]Knight Therapeutics Inc. — Particulate matter in injectable product
Health CanadaRecall
Health Canada posted a Type I recall of Knight Therapeutics Inc.'s Dantrium Intravenous (dantrolene sodium for injection) for contamination due to the presence of particulate matter.
Published 2026-10-19 · Document no. hc-82808 · Product Dantrium Intravenous (Dantrolene sodium for injection) · Type I
Original text and translation
Contamination
Key facts · Basis: official source record kept by the collector
Reason: contamination (presence of particulate matter)
Dosage form: powder for solution
Publication date: 2026-10-19
Insight · Editorial insight
Classifying particulate matter in an intravenous powder-for-solution product as Type I signals that the regulator sees a high patient risk. Particulates are generally associated with container-closure components or filling and reconstitution steps, so foreign-particle controls for powder injectables are worth revisiting.
Check points
Trends in visible and sub-visible particle results after reconstitution
Control of particles from vials, stoppers and other container components
Post-release complaints or adverse events linked to particulates
Recall detail · From the source · Health Canada
Active ingredient · 20 mg/vialDosage form · Powder For Solution
What you should do
Original · Health Canada
Consult your healthcare provider for any health concerns.Contact the recalling firm if you have any questions about the recall.Report any health product related side effects to Health Canada.Report any other health product safety complaints to Health Canada.
A company voluntarily recalled a mistletoe (Viscum album) aqueous extract injection over concerns about possible foreign matter contamination.
Published 2026-10-19 · Product 이스카도엠1밀리그램주사액[비스쿰알붐(아종:말리)수용성추출물(1→
5)로써 5밀리그램]
Original text
이물 혼입 우려에 따른 영업자 회수
Key facts · Basis: official source record kept by the collector
Reason: potential foreign matter contamination
Mandatory recall: N
Recall order date: 20261019
Insight · Editorial insight
Recalling at the 'concern' stage rather than after confirmed contamination suggests the company could not rule out the presence of foreign matter. In injection products, foreign matter is generally associated with containers, closures or the filling environment, so the root-cause scope may be broad.
Check points
Visual inspection method and defect trends for injections
Foreign-matter controls on incoming containers and closures
A manufacturer started a voluntary recall of a tablet product after the cyanocobalamin 100-fold dilution assay in its stability study fell outside specification.
Published 2026-10-16 · Product 가네진정
Original text
안정성 시험 일부 항목(시아노코발라민100배산 함량 시험) 기준일탈로 인한 영업자 회수
Key facts · Basis: official source record kept by the collector
Reason: out-of-specification result in a stability test item (cyanocobalamin 100-fold dilution assay)
Mandatory recall: N
Recall order date: 20261016
Insight · Editorial insight
An assay failure found in stability testing after release signals that the evidence supporting quality through shelf life was undermined. Loss of content for a low-dose vitamin component such as cyanocobalamin can generally be associated with the ingredient's own stability or the uniformity of the diluted raw material.
Check points
Time-point trend of cyanocobalamin assay in the stability program
Uniformity and assay results of the cyanocobalamin 100-fold dilution raw material
[Recall (Health Canada) · Health Canada]Lupin Pharma Canada Ltd. — Wrong carton mix in combination kit
Health Canada💊 Small moleculeRecall
Health Canada posted a Type II recall of an affected lot of Lupin Pharma Canada Ltd.'s Femyso mifepristone/misoprostol tablet kit, which may contain two cartons of the same component instead of one of each.
Published 2026-10-21 · Document no. hc-82831 · Product Femyso Mifepristone 200mg / Misoprostol 200 mcg tablet · Type II
Original text and translation
Packaging
Key facts · Basis: official source record kept by the collector
Reason: packaging (two green mifepristone cartons or two pink misoprostol cartons may be present)
Dosage form: kit, tablet
Publication date: 2026-10-21
Insight · Editorial insight
In a kit pairing two drugs taken in sequence, receiving duplicates of one carton can make the regimen impossible to follow, which highlights component verification in packaging. Because the cartons are colour-coded yet still got mixed, such errors are generally associated with how components are fed and checked during kit assembly.
Check points
How per-carton quantities are verified during kit assembly
Use of barcode or other automated identification beyond colour cues
Recall detail · From the source · Health Canada
Active ingredient · Mifepristone 200 mg / Misoprostol 200 mcgDosage form · Kit, Tablet
What you should do
Original · Health Canada
Verify whether your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product, or if you have any health concerns.Contact the recalling firm if you have any questions about the recall.Report any health product related side effects to Health Canada.Report any other health product safety complaints to Health Canada.
[Recall · FDA]K.C. Pharmaceuticals, Inc. — Eye drop recall over lack of sterility assurance
Evidence AFDASignal Med · T2Recall
K.C. Pharmaceuticals, Inc. recalled a batch of 8 eye drop products, including artificial tears, for the same reason: lack of assurance of sterility (Class II).
Published
2026-10-14
Document no.
D-0002-2027
Companies
K.C. Pharmaceuticals, Inc.
Product
Artificial Tears Sterile Lubricant Eye Drops (polyvinyl alcohol 0.5%, povidone 0.6%), 0.5 FL OZ (15 mL) bottles; a) Best Choice, PROUDLY DISTRIBUTED BY: VALU MERCHANDISERS, CO., 5000 KANSAS CITY, KS 66106, UPC 0 70038 47008 3; b) LEADER, DISTRIBUTED BY CARDINAL HEALTH, DUBLIN, OHIO 43017, www.myleader.com, NDC 70000-0011-1; c) Good Neighbor Pharmacy, Distributed By AmerisourceBergen, 1 West First Avenue, Conshohocken, PA 19428, NDC 24385-006-05; d) Good Sense, Distributed By: Geiss, Destin& Dunn, Inc., A Perrigo Company, Peachtree City, GA 30269, NDC 50804-110-01; e) Medic'c Choice, Sterile 0.5 fl. oz. (15 mL), Manufactured by KC Pharmaceuticals, Inc., Pomona, CA 91768, NDC 55651-008-01; f) P, DISTRIBUTED BY PUBLIX SUPER MARKETS, INC, LAKELAND, FL 33811, UPC 0 41415 00976 9; g) Quality Choice, Distributed by CDMA Inc, Novi, MI NDC 83324-189-14; h) TopCare health, DISTRIBUTED BY TOPCO ASSOCIATES LLC, ELKGROVE VILLAGE, IL 60007, UPC 0 36800 09331 7; I) Walgreens, DISTRIBUTED BY: WALGREEN CO. DEERFIELD, IL 60015, UPC 3 11917 06503 8; J) Kroger, DISTRIBUTED BY THE KROGER CO., CINCINNATI, OHIO 45202, UPC 0 11110 38600 7. 외 7품목
Class
Class II
All 8 products
Artificial Tears Sterile Lubricant Eye Drops (polyvinyl alcohol 0.5%, povidone 0.6%), 0.5 FL OZ (15 mL) bottles; a) Best Choice, PROUDLY DISTRIBUTED BY: VALU MERCHANDISERS, CO., 5000 KANSAS CITY, KS 66106, UPC 0 70038 47008 3; b) LEADER, DISTRIBUTED BY CARDINAL HEALTH, DUBLIN, OHIO 43017, www.myleader.com, NDC 70000-0011-1; c) Good Neighbor Pharmacy, Distributed By AmerisourceBergen, 1 West First Avenue, Conshohocken, PA 19428, NDC 24385-006-05; d) Good Sense, Distributed By: Geiss, Destin& Dunn, Inc., A Perrigo Company, Peachtree City, GA 30269, NDC 50804-110-01; e) Medic'c Choice, Sterile 0.5 fl. oz. (15 mL), Manufactured by KC Pharmaceuticals, Inc., Pomona, CA 91768, NDC 55651-008-01; f) P, DISTRIBUTED BY PUBLIX SUPER MARKETS, INC, LAKELAND, FL 33811, UPC 0 41415 00976 9; g) Quality Choice, Distributed by CDMA Inc, Novi, MI NDC 83324-189-14; h) TopCare health, DISTRIBUTED BY TOPCO ASSOCIATES LLC, ELKGROVE VILLAGE, IL 60007, UPC 0 36800 09331 7; I) Walgreens, DISTRIBUTED BY: WALGREEN CO. DEERFIELD, IL 60015, UPC 3 11917 06503 8; J) Kroger, DISTRIBUTED BY THE KROGER CO., CINCINNATI, OHIO 45202, UPC 0 11110 38600 7.
Sterile EYE DROPS AC (tetrahydrozoline HCl 0.05%, zinc sulfate 0.25%), 0.5 fl. oz. (15 mL) bottles; a) Equaline, DISTRIBUTED BY: UNFI, PROVIDENCE, RI 02908 UPC 0 41163 25114 4; b) Good Sense Sterile Eye Drops, Distributed By: Geiss, Destin & Dunn, Inc., A Perrigo Company, Peachtree City, GA 30269, NDC 50804-121-01; c) H.E.B A.C. Eye Drops, MADE WITH PRIDE & CARE FOR H-E-B, SAN ANTONIO, TX 78204, UPC 0 41220 43746 7; d) QC-Quality Choice, Sterile Eye drops Irritation Relief, Distributed by: CDMA, Inc., Novi, MI 48375, NDC 83324-190-14; e) TopCare health TM, DISTRIBUTED BY: TOPCO ASSOCIATES LLC, ELK GROVE VILLAGE, IL 60007, UPC 0 36800 03640 6.
Sterile EYE DROPS Advanced Relief, (dextran 70, 0.1%, polyethylene glycol 400 1% and tetrahydrozoline HCl 0.05%), 0.5 FL OZ (15 mL) bottles, Sterile; a) LEADER, DISTRIBUTED BY CARDINAL HEALTH, DUBLIN, OHIO 43017, www.myleader.com, NDC 70000-0456-1; b) Equaline, DISTRIBUTED BY: UNFI, PROVIDENCE, RI 02908 UPC 0 41163 25392 6; c) GoodSense, Distributed By: Geiss, Destin& Dunn, Inc., A Perrigo Company, Peachtree City, GA 30269, www.PerrigoDirect.com, NDC 50804-130-01; d) H.E.B A.C. Eye Drops, MADE WITH PRIDE & CARE FOR H-E-B, SAN ANTONIO, TX 78204, UPC 0 41220 43745 0; e) Medic'c Choice, Manufactured by KC Pharmaceuticals, Inc., Pomona, CA 91768, NDC 55651-025-01; f) Foster & Thrive, Distributed by: McKesson Corp., via Strategic Sourcing Services LLC, Memphis, TN 38141, NDC 70677-1158-1; g) Colirio Manzanill A+, Distributed by: PRO-MEX, P.O Box 63-0716, Miami , FL 33163, UPC: 1 84125 00018 0; h) P, DISTRIBUTED BY PUBLIX SUPER MARKETS, INC, 3300 PUBLIX CORPORATE PARKWAY, LAKELAND, FL 33811, UPC 0 41415 06776 9; I) QC-Quality Choice, Distributed by: CDMA, Inc., Novi, MI 48375, NDC 83324-191-14; J) TopCare health, DISTRIBUTED BY TOPCO ASSOCIATES LLC, ELKGROVE VILLAGE, IL 60007, UPC 0 36800 03641 3.
Eye Drops MAXIMUM, REDNESS RELIEF, Sterile, 1/2 FL OZ (0.5 ML); a) exchange select, Manufactured for your Military Exchange By: K.C Pharmaceuticals, Inc., Pomona, CA 9176, UPC: 6 14299 89636 9; b) Harris Teeter, PROUDLY DISTRIBUTED BY: HARRIS TEETER, LLC, MATTHEWS, NC 28105, UPC: 0 72036 73589 8; c) TYSON, MIKE RED EYE DROPS, Distributed by: JBRANDS Distribution, Miami, FL 33009, UPC: 7 84847 57549 4; d) up & up, Distributed by: Target Corporation, Minneapolis, MN 55403, NDC 11673-100-01; e) TopCare health, DISTRIBUTED BY TOPCO ASSOCIATES LLC, ELKGROVE VILLAGE, IL 60007, UPC 0 36800 21123 0; f) Walgreens, DISTRIBUTED BY: WALGREEN CO. 200 WILMOT RD, DEERFIELD, IL 60015, UPC 3 11917 20075 0.
Sterile Lubricant Dry Eye Relief Eye Drops, 0.5 FL OZ (15 mL); a) LEADER, DISTRIBUTED BY CARDINAL HEALTH, DUBLIN, OHIO 43017, www.myleader.com, NDC 70000-0502-1; b) Crocodile Tears, Distributed by: Crocodile Tears, Palm Beach Gardens, FL 33410, UPC: 8 67166 00000 4; c) Discount drug mart, Discount Drug Mart Food Fair, Medina, OH 44256, UPC: 0 93351 01156 6; d) exchange select, Manufactured for your Military Exchange By: K.C Pharmaceuticals, Inc., Pomona, CA 9176, UPC: 6 14299 05620 6; e) GERI CARE, Distributed by: Gericare Pharmaceuticals Corp., 1295 Towbin Ave., Lakewood, NJ 08701, NDC 57896-181-05; f) H.E.B Dry Eye, Eye Drops, MADE WITH PRIDE & CARE FOR H-E-B, SAN ANTONIO, TX 78204, UPC 0 41220 43741 2; g) Harris Teeter, PROUDLY DISTRIBUTED BY: HARRIS TEETER, LLC, MATTHEWS, NC 28105, UPC: 0 72036 71303 2; h) Foster & Thrive, Distributed by: McKesson Corp. Via Strategic Sourcing Servies LLC., Memphis, TN 38141, NDC 70677-1157-1; I) TopCare health, DISTRIBUTED BY TOPCO ASSOCIATES LLC, ELKGROVE VILLAGE, IL 60007, UPC 0 36800 36100 3.
Sterile Eye Drops, ORIGINAL, Tetrahydrozoline HCl 0.05% Redness Reliever ¿ Fast Acting Formula) Product size: 0.5 fl oz (15 mL); a) Best Choice, PROUDLY DISTRIBUTED BY: VALU MERCHANDISERS, CO., 5000 KANSAS CITY, KS 66106, UPC 0 70038 47011 3; b) Discount drug mart, Discount Drug Mart Food Fair, Medina, OH 44256, UPC: 0 93351 01157 3; c) Good Sense Sterile Eye Drops, Distributed By: Geiss, Destin & Dunn, Inc., A Perrigo Company, Peachtree City, GA 30269, NDC 50804-141-01; d) H.E.B Dry Eye, Eye Drops, MADE WITH PRIDE & CARE FOR H-E-B, SAN ANTONIO, TX 78204, UPC 0 41220 43747 4; e) Harris Teeter, PROUDLY DISTRIBUTED BY: HARRIS TEETER, LLC, MATTHEWS, NC 28105, UPC: 0 72036 71302 5; f) Circle K, Product manufactured for: Lil' Drug Store Products, Inc., Cedar Rapids, IA 52404, Proudly distributed: by Circle K Stores Inc., UPC: 1 94283 65135 8; g) Lil' DrugStore, Product manufactured for: Lil' Drug Store Products, Inc., 9300 Earhart Lane SW, Cedar Rapids, IA 52404, UPC: 3 66715 68324 3; h) QC, Quality Choice, Distributed by CDMA Inc, Novi, MI NDC 83324-340-15; i) TopCare health, DISTRIBUTED BY TOPCO ASSOCIATES LLC, ELKGROVE VILLAGE, IL 60007, UPC 0 36800 03639 0; j) Equate", DISTRIBUTED BY WALMART INC., Bentonville, AR 72716, NDC 79903-158-05; k) Walgreens, DISTRIBUTED BY: WALGREEN CO., 200 WILMOT RD, DEERFIELD, IL 60015, UPC 3 11917 20073 6; l) Kroger, DISTRIBUTED BY THE KROGER CO., CINCINNATI, OHIO 45202, UPC 0 11110 38597 0.
Sterile Eye Drops Redness Relief (Glycerin 0.25%, Naphazoline HCl 0.02% Lubricant | Redness Reliever) (Relieves Dryness, Burning and Irritations), 0.5 fl oz (15 mL); a) LEADER, DISTRIBUTED BY CARDINAL HEALTH, DUBLIN, OHIO 43017, www.myleader.com, NDC 70000-0010-1; b) Discount drug mart, Distributed by: Discount Drug Mart, 211 Commerce Drive, Medina, OH 44256, UPC: 0 93351 03411 4; c) EQUALINE, DISTRIBUTED BY: UNFI, PROVIDENCE, RI 02908 UPC 0 41163 46151 2; d) Colirio Ojo de Aguila, Distributed by Grandall Distributing Co., Inc., Glendale, CA 91204, UPC: 3 48201 01615 5; e) Clear Eyes Redness Relief, ¿ 2025 Dist. by Medtech Products Inc., Tarrytown, NY 10591, UPC 6 78112 25415 6; f) Equate", DISTRIBUTED BY WALMART INC., Bentonville, AR 72716, NDC 79903-012-01; g) Walgreens, DISTRIBUTED BY: WALGREEN CO., 200 WILMOT RD, DEERFIELD, IL 60015, UPC 3 11917 17741 0; h) Xpect Industrial Eye Relief, Distributed by: Cintas Corp., Mason, OH 45040, UPC: 130209.
Sterile High Performance Ultra Lubricating Eye Drops (Polyethylene Glycol 400, 0.4% Relieves Dry and Irritated Eyes) Product size: 0.5 fl oz (15 mL); a) LEADER, DISTRIBUTED BY CARDINAL HEALTH, DUBLIN, OHIO 43017, www.myleader.com, NDC 70000-0457-1; b) exchange select, Manufactured for your Military Exchange By: K.C Pharmaceuticals, Inc., Pomona, CA 9176, UPC: 6 1429905619 0; c) Good Sense, Distributed By: Perrigo Direct Inc., Peachtree City, GA 30269, NDC 50804-160-01; d) Walgreens, DISTRIBUTED BY: WALGREEN CO., 200 WILMOT RD, DEERFIELD, IL 60015, UPC 3 11917 20167 2.
Original text and translation · representative case
Lack of Assurance of Sterility
Key facts · Basis: official source record kept by the collector
Reason: Lack of Assurance of Sterility
Scope: 8 products recalled together for the same reason
Class: Class II
Report date: 2026-10-14
Insight · Editorial insight
For sterile ophthalmic products, lack of sterility assurance is generally associated with an aseptic process or its supporting evidence not being adequately demonstrated. The simultaneous recall of 8 products sold under many retail brands signals how one site's sterility assurance issue can spread across multiple private-label supply lines.
Check points
Currency of aseptic process validation (media fills) for eye drops
Sterility assurance evidence for contract-manufactured eye drops
Impact scope across products supplied from the same site
Recall detail · From the source · OpenFDA · Based on the representative product
This card groups 8 products into one entry. All values below refer to one representative product (including lots, quantity, and status).
Status · OngoingVoluntary: Firm initiatedFirst notified · E-Mail
Status
Recall initiated · 2026-09-11FDA classification · 2026-10-05FDA published · 2026-10-14
[Recall · FDA]BioSpectra, Inc. — Tris API recall for stability failure
FDARecall
BioSpectra, Inc. recalled its Tris/Tromethamine USP API-grade material after it failed stability specifications (Class II).
Published 2026-10-14 · Document no. D-0012-2027 · Product Biospectra Tris/Tromethamine, USP, GMP, API Grade, Manufactured at 100 Majestic… · Class II
Original text and translation
Failed stability specifications
Key facts · Basis: official source record kept by the collector
Reason: Failed stability specifications
Product: Tris/Tromethamine, USP, GMP, API Grade
Report date: 2026-10-14
Insight · Editorial insight
A stability failure at the API stage can generally be associated with retest or expiry dating that did not hold up under actual storage. Because Tris can be used as a buffer or ingredient in finished products, the issue may carry over to how downstream manufacturers control incoming raw materials.
Check points
Tris supplier and usage history of affected lots
Stability data supporting the material's retest or expiry date
Alignment of storage conditions with stability study conditions
Recall detail · From the source · OpenFDA
Status · OngoingVoluntary: Firm initiatedFirst notified · Telephone
Status
Recall initiated · 2026-07-29FDA classification · 2026-10-06FDA published · 2026-10-14
Preferred Pharmaceuticals, Inc. recalled Lidocaine Ointment USP, 5% in a 50 g jar after it failed content uniformity specifications (Class II).
Published 2026-10-14 · Document no. D-0013-2027 · Product Lidocaine Ointment USP, 5% (Generic for Xylocaine), packaged in a 50 g jar, Rx o… · Class II
Original text and translation
Failed Content Uniformity Specifications
Key facts · Basis: official source record kept by the collector
Reason: Failed Content Uniformity Specifications
Product: Lidocaine Ointment USP, 5%, 50 g jar
Manufacturer: Taro Pharmaceuticals U.S.A., Inc.
Insight · Editorial insight
Content uniformity failures in ointments are generally associated with uneven dispersion of the active ingredient during semi-solid mixing. Since the recalling firm differs from the manufacturer, the case shows how a contract manufacturer's quality issue can surface as a recall by a downstream repackager or distributor.
Check points
Uniformity validation data for ointment mixing
Quality information flow from manufacturer to repackager
Recall detail · From the source · OpenFDA
Status · OngoingVoluntary: Firm initiatedFirst notified · E-Mail
Status
Recall initiated · 2026-09-28FDA classification · 2026-10-06FDA published · 2026-10-14
Affected lots and expiry
Original · OpenFDA
Lot #: F1925G, Expiry: 4/30/2027; Lot #: E0925T, Expiry: 4/30/2027; Lot # D3025M, Expiry: 4/30/2027; Lot #: D0825D, Expiry: 4/30/2027.
[Recall · FDA]Cipla USA, Inc. — Fosfomycin granule impurity failure
FDA💊 Small moleculeRecall
Cipla USA, Inc. recalled fosfomycin tromethamine granules for oral solution, made by Cipla Ltd. in India, for failing impurities/degradation specifications (Class II).
Published 2026-10-14 · Document no. D-0014-2027 · Product Fosfomycin Tromethamine Granules for Oral Solution, (Equivalent to 3 Grams of Fo… · Class II
Original text and translation
Failed Impurities/Degradation Specifications
Key facts · Basis: official source record kept by the collector
Product: fosfomycin tromethamine granules for oral solution, single-dose sachet
Manufacturer: Cipla Ltd., Maharashtra, India
Insight · Editorial insight
Impurity or degradant failures are generally associated with degradation during shelf life or with the moisture barrier of the packaging. Seeing this in a single-dose sachet granule product puts attention on tracking degradant trends by packaging format.
Check points
Degradant stability trends for fosfomycin granules
Moisture barrier data for sachet packaging
Review of manufacturer impurity results for imported products
Recall detail · From the source · OpenFDA
Status · OngoingVoluntary: Firm initiatedFirst notified · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Status
Recall initiated · 2026-09-18FDA classification · 2026-10-06FDA published · 2026-10-14
[Recall · FDA]J&J INNOVATIVE MEDICINE — Particulate matter in injection vials
FDA🧬 BiologicsRecall
J&J INNOVATIVE MEDICINE recalled IMAAVY (nipocalimab-aahu) Injection, 300 mg/1.62 mL single-dose vials, due to the presence of particulate matter (Class II).
Published 2026-10-14 · Document no. D-0016-2027 · Product IMAAVY (nipocalimab-aahu) Injection, 300 mg /1.62 mL (185 mg/mL) per single-dose… · Class II
Original text and translation
Presence of particulate matter.
Key facts · Basis: official source record kept by the collector
Particulate matter in an intravenous product bears directly on patient safety and is generally associated with container-closure particles or aggregation within the formulation. For a high-concentration vial diluted before infusion, the finding signals attention on visual inspection and particulate testing programs.
Check points
Visual inspection criteria and inspector qualification for injectables
Trends in subvisible particulate test results
Assessment of particles from container-closure components
Recall detail · From the source · OpenFDA
Status · OngoingVoluntary: Firm initiatedFirst notified · Letter
Status
Recall initiated · 2026-09-23FDA classification · 2026-10-08FDA published · 2026-10-14
Carolina Infusion, LLC recalled a batch of 16 compounded injectable products, including tirzepatide, for the same reason: lack of assurance of sterility (Class II). The reason cites formulation with bacteriostatic water and processing equipment used in compounding.
Published
2026-10-14
Document no.
D-0017-2027
Companies
Carolina Infusion, LLC
Product
TIRZEPATIDE 26 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936; 외 15품목
Class
Class II
All 16 products
TIRZEPATIDE 26 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936;
SEMAGLUTIDE 3 MG/ML INJECTABLE, 8 x 0.1 mL syringes, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936
SEMAGLUTIDE/CYANOCOBALAMIN 3/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936
SERMORELIN ACETATE 1 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland
QUAD-MIX( PAPAV/PHENTO/ALPROS/TROP) INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936
Tri-MIX (PAPAV/PHENTO/ALPROS),30/1/20, injectable, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936,
Tri-MIX (PAPAV/PHENTO/ALPROS),30/1/10, injectable, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936,
Tri-MIX (PAPAV/PHENTO/ALPROS), 30/1/40, injectable, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936
Tri-MIX (PAPAV/PHENTO/ALPROS),30/1/60, injectable, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936
SEMAGLUTIDE/CYANOCOBALAMIN 9/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936
TIRZEPATIDE/CYANOCOBALAMIN 26/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936
TIRZEPATIDE/CYANOCOBALAMIN 64/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936
TIRZEPATIDE/CYANOCOBALAMIN 76/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936
TIRZEPATIDE/CYANOCOBALAMIN 85/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936;
Tri-MIX (PAPAV/PHENTO/ALPROS),30/2/20, injectable, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936
Tri-MIX (PAPAV/PHENTO/ALPROS),30/2/40, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936
Original text and translation · representative case
Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.
Key facts · Basis: official source record kept by the collector
Reason: Lack of Assurance of Sterility (bacteriostatic water formulation; processing equipment)
Scope: 16 products recalled together for the same reason
Class: Class II
Report date: 2026-10-14
Insight · Editorial insight
The stated reason points to both a formulation choice and processing equipment, signaling that sterility assurance can be undermined at the material and equipment levels at once. The recall of 16 products from one compounder illustrates how shared equipment or shared formulation elements can turn into a multi-product recall.
Check points
Suitability assessment of diluents such as bacteriostatic water
Cleaning and sterilization validation of compounding equipment
Cross-product impact assessment for shared equipment
Recall detail · From the source · OpenFDA · Based on the representative product
This card groups 16 products into one entry. All values below refer to one representative product (including lots, quantity, and status).
Status · OngoingVoluntary: Firm initiatedFirst notified · E-Mail
Status
Recall initiated · 2026-09-10FDA classification · 2026-10-08FDA published · 2026-10-14
Apothecary Pharma LLC recalled a batch of 2 sterile multi-dose vial products, including a tirzepatide injection, for the same reason: lack of assurance of sterility (Class II).
Original text and translation · representative case
Lack of Assurance of Sterility
Key facts · Basis: official source record kept by the collector
Reason: Lack of Assurance of Sterility
Scope: 2 products recalled together for the same reason
Class: Class II
Report date: 2026-10-14
Insight · Editorial insight
Multi-dose vials are designed for repeated puncture, so lack of sterility assurance is generally associated with the aseptic fill process or evidence of preservative effectiveness. Two different injectables from one firm being recalled for the same reason suggests an issue at the level of a shared aseptic process rather than a single product.
Check points
Aseptic fill validation for multi-dose vials
Preservative effectiveness testing evidence
Recall detail · From the source · OpenFDA · Based on the representative product
This card groups 2 products into one entry. All values below refer to one representative product (including lots, quantity, and status).
Status · OngoingVoluntary: Firm initiatedFirst notified · Letter
Status
Recall initiated · 2026-09-24FDA classification · 2026-10-08FDA published · 2026-10-14
Every Monday we email the week's new inspection records from the FDA, EMA, Health Canada and MFDS, with a short summary of the week's regulatory news. We'll also let you know when the site gains new features. Unsubscribe any time with one click.
Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.
Confirmation email sent
Click the confirmation button in the email. It's sent from GRM Solutions Brief. If you don't see it, check your spam folder.
AI Disclosure
How this content is produced, and caveats
1. Information generated by AI
Card titles, summaries, Korean translations, implications, check items, and detailed analysis are content generated automatically by generative AI from published primary official material.
2. Information provided as in the source
Figures, codes, dates, agency and company names in the fact table, quotations from the original text, source and official-document links, and findings tables (FDA Form 483 observations, MFDS routine inspection findings, and so on) are extracted mechanically from the source and are not reworded or rewritten.
3. Verification, limitations, and user notes
To improve accuracy, GRM provides evidence grades (A, B, C) and signal tiers (1–3). Evidence A means the information can be checked directly against a primary official document.
Summaries, translations, implications, check items, and detailed analysis generated by generative AI may contain mistranslations, omissions, misread context, or information that is not up to date.
This service is reference material intended to provide regulatory and quality information; it does not provide legal, regulatory, quality, or compliance advice or official interpretation.
Before using this material for decisions, quality system operation, regulatory response, or audit preparation, users must check the official source and the relevant agency's latest material themselves.
This digest is AI-generated from primary sources; interpretations are not official or legal advice — verify against the original before acting.